{"text": "The significant results described in this 12-month phase 3 study support the use of Pasireotide as a targeted therapy for ACTH - secreting tumors .", "label": "", "metadata": {}, "score": "29.890461"}
{"text": "Pasireotide is an investigational multireceptor targeting somatostatin analog ( SSA ) that binds with high affinity to four of the five somatostatin receptor subtypes ( sst 1 , 2 , 3 and 5)(5 ) .", "label": "", "metadata": {}, "score": "30.236132"}
{"text": "Pasireotide ( SOM230 ) .It is a somatostatin receptor ( SSR ) ligand with high binding affinity for multiple receptor isoforms ( SST1 - 3 and SST5 ) .", "label": "", "metadata": {}, "score": "32.808613"}
{"text": "A new molecule developed by Novartis Laboratories , namely pasireotide , is a somatostatin analog possessing strong affinity for several somatostatin receptors ( 30 to 40 times greater for sst1 and sst5 , 5 times greater for sst3 and equivalent for sst2 ) .", "label": "", "metadata": {}, "score": "33.30462"}
{"text": "Pasireotide , acting on sst5 , the most expressed receptor involved in ACTH secretion , may overcome the dependence of sst2 expression from high cortisol levels [ 161 ] .", "label": "", "metadata": {}, "score": "33.354233"}
{"text": "Because it is an investigational compound , the tolerability and efficacy profile of pasireotide has not yet been fully established .Access to this investigational compound is available only through carefully controlled and monitored clinical trials .", "label": "", "metadata": {}, "score": "33.434723"}
{"text": "In this light , pasireotide was recently approved for the medical treatment of ACTH - secreting pituitary adenomas [ 76 ] .TSH - secreting tumors are extremely rare adenomas , highly expressing sst1 , 2 and 5 , in which sst2 plays a key role in the control of TSH secretion .", "label": "", "metadata": {}, "score": "34.036957"}
{"text": "# # STR00002 # # .[0008 ] In WO02/10192 is also disclosed a synthesis for and uses of pasireotide .[0009 ] Pasireotide has been shown to have a inhibitory effect on the secretion of several hormones ( e.g. GH , GH dependent and GH independent IGF-1 secretion , ACTH , cortisol resp .", "label": "", "metadata": {}, "score": "35.78772"}
{"text": "Pasireotide is not a substrate of efflux transporter BCRP ( breast cancer resistance protein ) , influx transporter OCT1 ( organic cation transporter 1 ) , or influx transporters OATP ( organic anion - transporting polypeptide ) 1B1 , 1B3 , or 2B1 .", "label": "", "metadata": {}, "score": "36.21407"}
{"text": "638 - 645 , 2004 .View at Publisher \u00b7 View at Google Scholar .S. Petersenn , J. Schopohl , A. Barkan et al . , \" Pasireotide ( SOM230 ) demonstrates efficacy and safety in patients with acromegaly : a randomized , multicenter , phase II trial , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "36.33028"}
{"text": "Thus Pasireotide may be especially effective in these patients .The high affinity of Pasireotide for sst1 and sst3 may prove to be an advantage for the stabilisation of tumour growth .", "label": "", "metadata": {}, "score": "38.85371"}
{"text": "The effect of pasireotide on the size of the adenoma will be determined by MRI , and FSH secretion will be judged by the serum concentration .", "label": "", "metadata": {}, "score": "39.093708"}
{"text": "931 - 933 , 2010 .View at Publisher \u00b7 View at Google Scholar The purpose of this study is to determine if administration of pasireotide LAR for one year to three patients with gonadotroph adenomas and elevated serum FSH concentrations will reduce the serum follicle - stimulating hormone ( FSH ) to normal and reduce the adenoma size .", "label": "", "metadata": {}, "score": "39.678085"}
{"text": "Clinical pharmacology studies have not been performed in patients with impaired renal function .However , renal clearance has a minor contribution to the elimination of pasireotide in humans .", "label": "", "metadata": {}, "score": "39.75901"}
{"text": "It is also to assess the safety of prolonged release pasireotide .The primary objective of this study is to assess the efficacy of a preoperative prolonged release pasireotide injection in the reduction in the incidence of symptomatic , postoperative axillary lymphoceles following mastectomy - axillary node dissection .", "label": "", "metadata": {}, "score": "39.921703"}
{"text": "Pasireotide was not genotoxic in a battery of in vitro assays ( Ames mutation test in Salmonella and Escherichia coli and mutation test in human peripheral lymphocytes ) .", "label": "", "metadata": {}, "score": "39.949966"}
{"text": "New developments aim to find SRL with improved ligand - binding characteristics , as Pasireotide ( Pasireotide ) , a multireceptor ligand or chimeric ligands binding to both , sst and dopamine D2 receptors .", "label": "", "metadata": {}, "score": "40.22535"}
{"text": "Drug Interaction Studies .There was no significant drug interaction between pasireotide and metformin , nateglinide or liraglutide .13.1 Carcinogenesis , Mutagenesis , Impairment of Fertility .", "label": "", "metadata": {}, "score": "40.633"}
{"text": "Currently no medical treatment as been found that decreases the size of these adenomas , so surgery is the only treatment .The reason to think that pasireotide might affect gonadotroph adenomas is that pasireotide binds avidly to somatostatin subtype 5 receptors , and gonadotroph adenomas express these receptors .", "label": "", "metadata": {}, "score": "40.828438"}
{"text": "However , sst5 is rapidly and extensively recycled from intracellular stores back into the cell membrane .Due to its long half - life , Pasireotide can bind again to the recycled sst5 .", "label": "", "metadata": {}, "score": "41.119617"}
{"text": "The binding affinities of endogenous somatostatin and pasireotide are shown in Table 2 .Table2- Binding affinities of somatostatin ( SRIF-14 ) and pasireotide to the five human somatostatin receptor subtypes ( SSTR1 - 5 ) .", "label": "", "metadata": {}, "score": "41.455162"}
{"text": "A life - time carcinogenicity study was conducted in rats and transgenic mice .Rats were given daily subcutaneous doses of pasireotide at 0.01 , 0.05 , 0.3 mg / kg / day for 104 weeks .", "label": "", "metadata": {}, "score": "42.593754"}
{"text": "However , the negative effect on glucose metabolism was more pronounced with Pasireotide [ 141 ] .Somatoprim A recently developed somatostatin multi - receptor ligand , Somatoprim , may be at least as potent , as Octreotide , but without a negative effect on glucose metabolism .", "label": "", "metadata": {}, "score": "42.622345"}
{"text": "Pasireotide has low passive permeability and is likely to be a substrate of P - gp ( P - glycoprotein ) , but the impact of P - gp on ADME ( absorption , distribution , metabolism , excretion ) of pasireotide is expected to be low .", "label": "", "metadata": {}, "score": "42.75779"}
{"text": "In addition , diverse SST analogs may affect SST receptor trafficking in different ways , as demonstrated by the SST agonist pasireotide that either causes sst2 membrane recycling [ 63 ] or does not affect its internalization [ 64 ] , whereas octreotide mainly induces sst2 internalization .", "label": "", "metadata": {}, "score": "43.495827"}
{"text": "References .Colao , A. A 12-Month Phase III Study of Pasireotide in Cushing 's Disease .New Engl J Med .National Endocrine and Metabolic Diseases Information Service .", "label": "", "metadata": {}, "score": "44.16237"}
{"text": "Cyclosporine .Concomitant administration of cyclosporine with pasireotide may decrease the relative bioavailability of cyclosporine and , therefore , dose adjustment of cyclosporine to maintain therapeutic levels may be necessary .", "label": "", "metadata": {}, "score": "44.4402"}
{"text": "\" These data on pasireotide are the first to show a therapeutic treatment can help patients achieve biochemical control of their Cushing 's disease , while improving associated symptoms . \"", "label": "", "metadata": {}, "score": "44.499535"}
{"text": "Boscaro , M. Treatment of Pituitary - Dependent Cushing 's Disease with the Multireceptor Ligand Somatostatin Analog Pasireotide ( SOM230 ) : A Multicenter , Phase II Trial .", "label": "", "metadata": {}, "score": "44.791313"}
{"text": "There are no adequate and well - controlled studies in pregnant women .Reproduction studies have been performed in rats and rabbits which showed evidence of harm to the fetus due to pasireotide at therapeutic exposures .", "label": "", "metadata": {}, "score": "45.233"}
{"text": "[ 0024 ] It can be shown by established test models that the use of COMPOUND OF THE INVENTION , preferably pasireotide , results in an effective treatment of meningioma .", "label": "", "metadata": {}, "score": "45.317123"}
{"text": "Primary Purpose : Prevention .Official Title : .Evaluation of the Effect of Pasireotide LAR Administration in the Lymphocele Prevention After Axillary Node Dissection for Breast Cancer .", "label": "", "metadata": {}, "score": "46.061226"}
{"text": "When translated to the clinical studies in patients with advanced colorectal cancer controversial results were obtained .As far as hepatocellular cancer , proliferation was reduced by octreotide in human cell lines , [ 205 ] and by pasireotide that synergized with celecoxib to induce apoptosis in vitro and to prolong the survival of nude mice bearing hepatocarcinoma xenografts [ 206 ] .", "label": "", "metadata": {}, "score": "46.842438"}
{"text": "The trial , which represents the largest randomized study to evaluate a medical therapy in patients with Cushing 's disease , is the basis for regulatory submissions for pasireotide under way worldwide for the treatment of this condition .", "label": "", "metadata": {}, "score": "47.319443"}
{"text": "Because a medium - energy beta - emitter might have equivalent efficacy compared to high - energy emitters , and lower toxicity to non - target tissues , we have evaluated the therapeutic potential of the beta - emitting nuclide , Sm-153 , chelated to the somatostatin analog , CMDTPA - Tyr(3)-octreotate .", "label": "", "metadata": {}, "score": "47.374084"}
{"text": "Finally , sst2 activation may also lead to caspase - mediated proapoptotic effects in somatotroph tumor cells treated with octreotide , via a PTP - dependent pathway [ 136 ] , although the specific enzyme was not identified .", "label": "", "metadata": {}, "score": "47.377014"}
{"text": "Mice were given subcutaneous doses of pasireotide at 0.5 , 1.0 , 2.5 mg / kg / day for 26 weeks and did not identify any carcinogenic potential .", "label": "", "metadata": {}, "score": "47.52101"}
{"text": "1114PRTArtificial SequenceSomatostatin tetradecapeptide 1Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys 1 5 10 -- Results showed pasireotide improved key clinical manifestations of the disease , including reductions in blood pressure , cholesterol , weight and body mass index(1 ) .", "label": "", "metadata": {}, "score": "47.535866"}
{"text": "Pasireotide is eliminated mainly via hepatic clearance ( biliary excretion ) with a small contribution of the renal route .In a human ADME study 55.9 \u00b1 6.63 % of the radioactivity dose was recovered over the first 10 days post dosing , including 48.3 \u00b1 8.16 % of the radioactivity in feces and 7.63 \u00b1 2.03 % in urine .", "label": "", "metadata": {}, "score": "47.56031"}
{"text": "Among them the bispecific molecules BIM-23704 ( sst1 and 2 ) and BIM-23244 ( sst2 and 5 ) were used in several preclinical studies [ 69 , 70 ] .", "label": "", "metadata": {}, "score": "48.26778"}
{"text": "[ 0006 ] A somatostatin analog of particular interest according to the present invention has a high binding affinity to human SSTR1,2,3,5 and have been described e.g. in WO 97/01579 , the contents of which being incorporated herein by reference .", "label": "", "metadata": {}, "score": "48.512367"}
{"text": "The present invention relates to the use of a Somatostatin ( SRIF ) analog which has a high binding affinity to human SSTR1,2,3,5 , or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for the treatment of meningioma .", "label": "", "metadata": {}, "score": "48.588474"}
{"text": "The most promising analogue , peptide 2530 [ DTPA-(Pip)Gly - Pro-(PipAm)Gly - Arg - Pro - Tyr - tBuGly - Leu - OH ] was further tested in vivo in a biodistribution study using HT29 tumour - bearing nude mice .", "label": "", "metadata": {}, "score": "48.695663"}
{"text": "The structural formula is : . 12.1 Mechanism of Action .SIGNIFOR is an injectable cyclohexapeptide somatostatin analogue .Pasireotide exerts its pharmacological activity via binding to somatostatin receptors ( SSTRs ) .", "label": "", "metadata": {}, "score": "48.74636"}
{"text": "In vitro , all compounds showed high and specific binding to SS receptors in mouse pituitary AtT20 tumor cell membranes , and IC50s were in the nanomolar range .", "label": "", "metadata": {}, "score": "48.891525"}
{"text": "In a prospective open - label , multicenter trial , Feelders et al .[ 68 ] administered Pasireotide in monotherapy followed by sequential addition of cabergoline and ketoconazole if UFC remained high after 28 and 60 days of treatment , respectively .", "label": "", "metadata": {}, "score": "49.052547"}
{"text": "IGF-1 effects might be blocked by SST analogs though an indirect regulation mediated by the inhibition of GH release .In vivo studies reported that pasireotide could affect IGF-1 activity as far as cell division and inhibition of apoptosis , but coadministration of tamoxifen did not result in greater effects [ 186 , 187 ] .", "label": "", "metadata": {}, "score": "49.098907"}
{"text": "Researchers at GlaxoSmithKline conducted extensive biological studies leading to the discovery of a series of arylsulfonamide derivatives developed from high - throughput screening .The compound SB-611812 showed potent binding at the rat UT receptor ( .", "label": "", "metadata": {}, "score": "49.108845"}
{"text": "Another peptide somatostatin analogue , described by Coy et al . in 2000 , showed moderate affinity for UT receptor .This peptide , named SB-710411 , H - Cpa - c[DCys - Pal - DTrp - Lys - Val - Cys]-Cpa - NH 2 , was able to inhibit U - II - induced contraction in rat isolated thoracic aorta in a surmountable manner ( . , suggesting that it acts as a competitive antagonist .", "label": "", "metadata": {}, "score": "49.170288"}
{"text": "Somatostatin Analogs .The biological effects induced after SST receptor activation allowed their identification as relevant drug targets .However , the main limit in using native SST for in vivo therapy is the very short half - life of this peptide .", "label": "", "metadata": {}, "score": "49.413563"}
{"text": "WO2004099180 , 2004 . H. Aissoui , C. Binkert , M. Clozel et al . , \" Preparation of 1 , 2 , 3 , 4-tetrahydroisoquinolinyl ureas and related derivatives as urotensin II receptor antagonists , \" Actelion Pharmaceuticals Ltd. , PCT International Application no .", "label": "", "metadata": {}, "score": "49.463455"}
{"text": "0038 ]The pharmacological activity of a COMPOUND OF THE INVENTION , preferably pasireotide , in meningioma may , for example , also be demonstrated in clinical studies .", "label": "", "metadata": {}, "score": "49.70066"}
{"text": "Pasireotide should be used during pregnancy only if clearly needed .Dosing in rats before mating and continuing into gestation at exposures less than the human clinical exposure based on body surface area comparisons across species , resulted in adverse fertility effects including : statistically significant increased implantation loss and decreased viable fetuses , corpora lutea , and implantation sites .", "label": "", "metadata": {}, "score": "49.814426"}
{"text": "If these in vitro data are confirmed in vivo in acromegalic patients , Somatoprim will be a valuable alternative to other SRL .Chimeric Molecules Another approach has been the development of \" chimeric \" molecules .", "label": "", "metadata": {}, "score": "49.937622"}
{"text": "11 , pp .4342 - 4350 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. Ben - Shlomo and S. Melmed , \" Pasireotide - a somatostatin analog for the potential treatment of acromegaly , neuroendocrine tumors and Cushing 's disease , \" IDrugs , vol .", "label": "", "metadata": {}, "score": "49.953674"}
{"text": "Pasireotide represents a promising candidate for octreotide resistant or lanreotide low - responsive tumors [ 75 ] .Therefore , at the end of a 12-months phase III study , pasireotide has been approved for Cushing 's disease [ 76 ] , and it is currently in phase III clinical trials for acromegalic patients and phase II trials for neuroendocrine tumors ( NETs ) .", "label": "", "metadata": {}, "score": "50.069958"}
{"text": "Such compositions may be formulated in conventional manner .[ 0030 ] The COMPOUNDS OF THE INVENTION , preferably pasireotide , can , for example , be formulated as disclosed in WO05/046645 . [ 0032 ] The present pharmaceutical compositions are prepared in a manner known per se , and comprise approximately from 1 % to 100 % , preferentially from approximately 1 % to 40 % , especially from approximately 20 % to 30 % , active ingredient .", "label": "", "metadata": {}, "score": "50.10679"}
{"text": "As has been already mentioned , no tumour lacking sst2A immuno - histochemical positivity demonstrated an effect of SRL therapy [ 66 ] .Somatostatin scintigraphy does not correlate with the effects of SRL on GH [ 103 ] .", "label": "", "metadata": {}, "score": "50.4189"}
{"text": "4 , pp .645 - 654 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Boscaro , W. H. Ludlam , B. Atkinson et al . , \" Treatment of pituitary - dependent Cushing 's disease with the multireceptor ligand somatostatin analog pasireotide ( SOM230 ) : a multicenter , phase II trial , \" The Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "50.496605"}
{"text": "4 , pp .645 - 654 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Boscaro , W. H. Ludlam , B. Atkinson et al . , \" Treatment of pituitary - dependent Cushing 's disease with the multireceptor ligand somatostatin analog pasireotide ( SOM230 ) : a multicenter , phase II trial , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "50.576363"}
{"text": "5 , pp .2343 - 2350 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .S. Lesche , D. Lehmann , F. Nagel , H. A. Schmid , and S. Schulz , \" Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro , \" The Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "50.61937"}
{"text": "Overall a reduction of the tumour volume of more than 20 % was observed in 39 % of the patients during treatment with Octreotide followed by Pasireotide .", "label": "", "metadata": {}, "score": "50.7015"}
{"text": "Both inhibit the progression of the cell cycle and induce apoptosis .A recently published study , compared Octreotide and Pasireotide ( Octreotide 100 \u03bc g s.c .", "label": "", "metadata": {}, "score": "50.710293"}
{"text": "In the study , patients were randomized to receive pasireotide subcutaneous ( sc ) injection in doses of 900 micrograms or 600 micrograms twice daily .", "label": "", "metadata": {}, "score": "50.739746"}
{"text": "The method according to claim 5 wherein the pasireotide is administered during a treatment cycle of four weeks .Description : .[ 0001 ] The present invention relates to a new use of Somatostatin ( SRIF ) peptidomimetics ( also referred to as Somatostatin- or SRIF - analogs ) in the treatment of meningioma .", "label": "", "metadata": {}, "score": "50.769455"}
{"text": "12 , pp .885 - 895 , 2007 .View at Google Scholar \u00b7 View at Scopus . A. Colao , S. Petersenn , J. Newell - Price , et al . , \" A 12-month phase 3 study of pasireotide in Cushing 's disease , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "51.229088"}
{"text": "Known oversensitivity to somatostatine analogs or another component of prolonged release pasireotide or prolonged release octreotide formulations .Choosing to participate in a study is an important personal decision .", "label": "", "metadata": {}, "score": "51.301735"}
{"text": "A number of monospecific SST receptor subtype analogs were developed being either peptidomimetic compounds [ 68 ] or peptides , such as sst1-specific ( BIM-23745 and BIM-23926 )", "label": "", "metadata": {}, "score": "51.4131"}
{"text": "- II , as well as further replacement of Cys 5 by penicillamine , \u03b2 , \u03b2 -dimethylcysteine , were achieved in order to give them conformational rigidity stabilizing the putative bioactive conformation . , suggesting a sort of desensitization known to affect UT receptor - mediated responses in this preparation .", "label": "", "metadata": {}, "score": "51.554226"}
{"text": "View at Google Scholar . A. Lupp , A. Hunder , A. Petrich , F. Nagel , C. Doll , and S. Schulz , \" Reassessment of sst 5 somatostatin receptor expression in normal and neoplastic human tissues using the novel rabbit monoclonal antibody UMB-4 , \" Neuroendocrinology , vol .", "label": "", "metadata": {}, "score": "51.70598"}
{"text": "In a meta - analysis Sandret et al .confirmed the usefulness of adding Cabergoline to SRL in patients with an insufficient effect of SRL therapy .", "label": "", "metadata": {}, "score": "51.734535"}
{"text": "A phase 2 trial [ 47 ] suggested that administration of Pasireotide for a 2-week period provoked a reduction in UFC in 76 % of 29 patients affected by newly diagnosed , persistent or recurrent ACTH - dependent Cushing 's disease .", "label": "", "metadata": {}, "score": "51.891865"}
{"text": "4 , pp .843 - 849 , 2000 .View at Google Scholar .C. Bruns , I. Lewis , U. Briner , G. Meno - Tetang , and G. Weckbecker , \" SOM230 : a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor ( SRIF ) receptor binding and a unique antisecretory profile , \" European Journal of Endocrinology , vol .", "label": "", "metadata": {}, "score": "51.92698"}
{"text": "Recently , bicyclic SST - based analogs have been proposed as potential radiopeptides for SPECT / PET on NETs [ 99 ] .A recent pilot study is evaluating the clinical feasibility of imaging with the SST receptor antagonist [ 111 In]-DOTA - p .", "label": "", "metadata": {}, "score": "52.01802"}
{"text": "After weaning , body weight gains in the rat pups ( F1 generation ) exposed to pasireotide were comparable to controls , showing reversibility of this developmental delay .", "label": "", "metadata": {}, "score": "52.186806"}
{"text": "115 - 122 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. Colao , S. Petersenn , J. Newell - Price et al . , \" A 12-month phase 3 study of pasireotide in cushing 's disease , \" New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "52.201355"}
{"text": "115 - 128 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. Cuny , A. Mohamed , T. Graillon , et al . , \" Somatostatin receptor sst 2 gene transfer in human prolactinomas in vitro : impact on sensitivity to dopamine , somatostatin and dopastatin , in the control of prolactin secretion , \" Molecular and Cellular Endocrinology , vol .", "label": "", "metadata": {}, "score": "52.389565"}
{"text": "In general , the term covers all modified derivatives of the native somatostatin-14 which exhibit a somatostatin related activity , e.g. they bind to at least one of the five somatostatin receptor ( SSTR ) , preferably in the nMolar range .", "label": "", "metadata": {}, "score": "52.823826"}
{"text": "So far five different human somatostatin receptor subtypes , sst1 , sst2A , sst3 - 5 , are known .Binding of somatostatin to sst results in a G - protein - coupled activation of adenylate - cyclase .", "label": "", "metadata": {}, "score": "53.031364"}
{"text": "Validating the presence of sst2 and sst5 on adenoma tissue has been suggested to allow the prediction of clinical efficacy of SRL .However immunohistochemical application for in vitro diagnostic has been hampered due to the lack of monoclonal and specific polyclonal anti - sst2 and sst5 antibodies .", "label": "", "metadata": {}, "score": "53.096333"}
{"text": "Some of these compounds are currently in preclinical and clinical trials , other have already reached a well - established clinical application .Here a concise view is given of SST receptor expression and SST analogs tested and used as antineoplastic agents , to the intensive research which is conducted in this field .", "label": "", "metadata": {}, "score": "53.26704"}
{"text": "6 , pp .R205-R223 , 2012 .View at Google Scholar .L. J. Hofland , J. van der Hoek , R. Feelders et al . , \" The multi - ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5 , \" European Journal of Endocrinology , vol .", "label": "", "metadata": {}, "score": "53.422745"}
{"text": "Moreover , a promising therapeutic strategy recently proposed is the combination of octreotide or pasireotide and everolimus , an inhibitor of the protein kinase mammalian target of rapamycin ( mTOR ) controlling cell proliferation and survival [ 170 ] .", "label": "", "metadata": {}, "score": "53.576363"}
{"text": "Lombardi et al .treated 12 patients resistant to SRL therapy with Quinagolide 150 \u03bc g / d in a prospective , placebo - controlled trial .", "label": "", "metadata": {}, "score": "53.61257"}
{"text": "No significant difference of therapeutic efficacy was reported [ 119 , 134 , 135 ] .A publication from Baldelli et al . reported an even better result for primary therapy using Lanreotide SR [ 136 ] .", "label": "", "metadata": {}, "score": "53.650692"}
{"text": "No preview \u00b7 Article \u00b7 Oct 2001 \u00b7 European Journal of Nuclear Medicine .[ Show abstract ] [ Hide abstract ] ABSTRACT : A number of radiolabeled somatostatin analogs have been evaluated in animal tumor models for radiotherapeutic efficacy .", "label": "", "metadata": {}, "score": "53.693687"}
{"text": "No preview \u00b7 Article \u00b7 Sep 2003 \u00b7 European journal of nuclear medicine and molecular imaging .[ Show abstract ] [ Hide abstract ] ABSTRACT : The somatostatin analogue [ DOTA0,Tyr3]octreotate has a nine - fold higher affinity for the somatostatin receptor subtype 2 as compared with [ DOTA0 , Tyr3]octreotide .", "label": "", "metadata": {}, "score": "53.697807"}
{"text": "Pasireotide was shown to be metabolically stable in human liver and kidney microsomes systems .In healthy volunteers , pasireotide in its unchanged form is the predominant form found in plasma , urine , and feces .", "label": "", "metadata": {}, "score": "54.115967"}
{"text": "255 - 264 , 2011 .View at Publisher \u00b7 View at Google Scholar .T. Fischer , C. Doll , S. Jacobs , A. Kolodziej , R. Stumm , and S. Schulz , \" Reassessment of sst2 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-1 , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "54.133354"}
{"text": "The above data highlight the great efforts and developments achieved in SST receptor - targeted therapy .However further studies are needed to delve deeper the pathophysiological role of SST receptor homo- and heterodimerization , trafficking , and their cell and tissue specificity as factors that may influence SST analogs clinical responses to develop more efficacious and selective drugs .", "label": "", "metadata": {}, "score": "54.223293"}
{"text": "Wang et al . in 2008 [ 76 ] described a series of N - alkyl-5H - pyrido[4,3- b ] -indol-1-amines as UT receptor antagonists since the tricyclic compound 7 was identified in an HTS as a lead compound due to its binding affinity ( .", "label": "", "metadata": {}, "score": "54.286438"}
{"text": "In healthy volunteers , pasireotide peak plasma concentration is reached within T max 0.25 - 0.5 hour .C max and AUC are dose - proportional following administration of single and multiple doses .", "label": "", "metadata": {}, "score": "54.288918"}
{"text": "In parallel , due to the cytotoxicity of radiolabeled SST analogs , an emerging and effective treatment strategy is SST - based PRRT .Diagnostic SST radioisotopes allow the localization of SST receptor expressing tissues and identify patients for subsequent radionuclide therapy .", "label": "", "metadata": {}, "score": "54.30098"}
{"text": "Somatoprim exhibits a unique binding profile in that binds with high affinity to sst2 , 4 and 5 but not sst1 and 3 [ 78 ] .", "label": "", "metadata": {}, "score": "54.31115"}
{"text": "In accordance with this study , optimization of the piperazine moiety provided high affinity urotensin - II receptor antagonists ( more than 100-fold selectivity over the \u03ba -opioid receptor ) and , among this series , specific compounds inhibited urotensin - induced vasoconstriction in isolated rat aortic ring .", "label": "", "metadata": {}, "score": "54.387405"}
{"text": "To date , findings in molecules with high affinity to the urotensin - II system has led to discovering new ligands , peptide , and nonpeptide analogues .", "label": "", "metadata": {}, "score": "54.40674"}
{"text": "In this work , Kinney et al . also provided for a novel agonist pharmacophore model through the docking of goby UT - II into a rat UT receptor homology model .", "label": "", "metadata": {}, "score": "54.459"}
{"text": "64 - 68 , 1991 .View at Google Scholar \u00b7 View at Scopus .M. Grimaldi , T. Florio , and G. Schettini , \" Somatostatin inhibits interleukin 6 release from rat cortical type I astrocytes via the inhibition of adenylyl cyclase , \" Biochemical and Biophysical Research Communications , vol .", "label": "", "metadata": {}, "score": "54.52323"}
{"text": "5 , pp .1592 - 1599 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. Florio , S. Thellung , S. Arena et al . , \" Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non - functioning pituitary adenoma cells in vitro , \" European Journal of Endocrinology , vol .", "label": "", "metadata": {}, "score": "54.55677"}
{"text": "6 , pp . R233-R251 , 2011 .View at Google Scholar . A. Saveanu , E. Lavaque , G. Gunz et al . , \" Demonstration of enhanced potency of a chimeric somatostatin - dopamine molecule , BIM-23A387 , in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells , \" The Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "54.675858"}
{"text": "In healthy volunteers , pasireotide demonstrates approximately linear pharmacokinetics ( PK ) for a dose range from 0.0025 to 1.5 mg .In Cushing 's disease patients , pasireotide demonstrates linear dose - exposure relationship in a dose range from 0.3 to 1.2 mg .", "label": "", "metadata": {}, "score": "54.76808"}
{"text": "Thus , it was hypothesized that the simultaneous activation of different SST receptor subtypes will improve the potential of this antitumor therapeutic approach [ 218 ] .", "label": "", "metadata": {}, "score": "54.988983"}
{"text": "721 - 727 , 2004 .View at Google Scholar .P. Jaquet , G. Gunz , A. Saveanu et al . , \" BIM-23A760 , a chimeric molecule directed towards somatostatin and dopamine receptors , vs universal somatostatin receptors ligands in GH - secreting pituitary adenomas partial responders to octreotide , \" Journal of Endocrinological Investigation , vol .", "label": "", "metadata": {}, "score": "55.033787"}
{"text": "In 1972 Liuzzi et al . detected the paradox GH - reducing effect of L - Dopa in patients with acromegaly [ 147 ] .This resulted in the development of the \" first - generation \" dopamine agonist preparation , Bromocriptine , and was soon followed by \" second - generation \" dopamine agonists such as Cabergoline and Quinagolide ( a nonergot dopamine agonist ) .", "label": "", "metadata": {}, "score": "55.11682"}
{"text": "Up - to - date information about the treatment of overdose can be obtained from a certified Regional Poison Center .SIGNIFOR ( pasireotide ) injection is prepared as a sterile solution of pasireotide diaspartate in a tartaric acid buffer for administration by subcutaneous injection .", "label": "", "metadata": {}, "score": "55.16295"}
{"text": "As potent agonist with reduced conformational flexibility , Lavecchia et al . performed subsequent NMR study in DMSO on this peptide in 2005 [ 31 ] .", "label": "", "metadata": {}, "score": "55.249474"}
{"text": "Glucose Metabolism .Cardiac Electrophysiology . QTcIinterval was evaluated in a randomized , blinded , crossover study in healthy subjects investigating pasireotide doses of 0.6 mg b.i.d . and 1.95 mg b.i.d .", "label": "", "metadata": {}, "score": "55.262848"}
{"text": "As was reported previously , SB-710411 itself did not promote inositol phosphate formation but inhibited the agonistic actions of U - II in the rat aorta [ 35 ] .", "label": "", "metadata": {}, "score": "55.263824"}
{"text": "[ 0019 ] There is therefore a compelling need to develop new pharmacological approaches to effectively and safely treat meningioma patients .[ 0021 ] It can be surprisingly shown that both the efficacy and tolerability of pasireotide ( having an extended half life of 11 hours ) in patients with recurrent meningiomas is better than that observed with other treatments , including octreotide , for instance .", "label": "", "metadata": {}, "score": "55.29805"}
{"text": "258 - 263 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .I. Shimon , T. Rubinek , M. Hadani , and N. Alhadef , \" PTR-3173 ( Somatoprim ) , a novel somatostatin analog with affinity for somatostatin receptors 2 , 4 and 5 is a potent inhibitor of human GH secretion , \" Journal of Endocrinological Investigation , vol .", "label": "", "metadata": {}, "score": "55.33364"}
{"text": "477 - 486 , 2001 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .I. Shimon , T. Rubinek , M. Hadani , and N. Alhadef , \" PTR-3173 ( Somatoprim ) , a novel somatostatin analog with affinity for somatostatin receptors 2 , 4 and 5 is a potent inhibitor of human GH secretion , \" Journal of Endocrinological Investigation , vol .", "label": "", "metadata": {}, "score": "55.491096"}
{"text": "However , besides sst2 expression the ratio sst5/sst2 and combined sst and D2R targeting was recently demonstrated to have a predictive value to long - term treatment with SST analogs and improve the response rate in octreotide - resistant tumors [ 165 , 166 ] .", "label": "", "metadata": {}, "score": "55.550552"}
{"text": "WO2002047456 , 2002 .N. Bousette , J. Pottinger , W. Ramli et al . , \" Urotensin - II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease , \" Peptides , vol .", "label": "", "metadata": {}, "score": "55.61523"}
{"text": "125 - 143 , 2012 .View at Google Scholar .S. P. Rohrer , E. T. Birzin , R. T. Mosley et al . , \" Rapid identification of subtype - selective agonists of the somatostatin receptor through combinatorial chemistry , \" Science , vol .", "label": "", "metadata": {}, "score": "55.629433"}
{"text": "- II sequence with the corresponding D isomers .The role of Lys 8 was also investigated by replacing it with lipophilic amino acids and hydrophilic nonbasic amino acids that produce inactive peptides [ 33 ] .", "label": "", "metadata": {}, "score": "55.636265"}
{"text": "[ 0028 ] The present invention relates also to a commercial package comprising a COMPOUND OF THE INVENTION , preferably pasireotide , together with instructions for use thereof in the treatment of meningioma .", "label": "", "metadata": {}, "score": "55.67616"}
{"text": "On the basis of this lead compound more analogues were elaborated and compound 3 ( Figure 10 ) that , containing an aryl - substituted piperidine subunit , was found to be a more potent antagonist toward both rat and human UT receptor ( .", "label": "", "metadata": {}, "score": "55.706566"}
{"text": "Using the chicken chorioallantoic membrane model Barrie et al .demonstrated the most pronounced antiangiogenetic effect by those SRL which preferentially activate sst2 , like Octreotide or RC-160 [ 74 ] .", "label": "", "metadata": {}, "score": "55.773796"}
{"text": "N. Tarui , T. Santo , M. Mori , and H. Watanabe , \" Quinoline derivatives as vasoactive agents exhibiting orphanr eceptor GPR14 protein antagonism , \" Takeda Chemical Industries , PCT International Application no .", "label": "", "metadata": {}, "score": "55.78411"}
{"text": "Figure 1 : Schematic representation of the intracellular signaling pathways modulated by somatostatin receptors .Antiproliferative effects of somatostatin ( SST ) and its analogs ; SST and analogs binding to SST receptors activate different phosphotyrosine phosphatases ( PTPs ) SHP-1 and SHP-2 and PTP \u03b7 .", "label": "", "metadata": {}, "score": "55.868973"}
{"text": "297 - 310 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .N. Mastrodimou , F. Kiagiadaki , M. Hodjarova , E. Karagianni , and K. Thermos , \" Somatostatin receptors ( sst 2 ) regulate cGMP production in rat retina , \" Regulatory Peptides , vol .", "label": "", "metadata": {}, "score": "55.954514"}
{"text": "Among them , the first octapeptide developed was octreotide , which reaches a half - life of 90 - 120 min after subcutaneous administration , followed by lanreotide , and vapreotide , also being cyclooctapeptide SST analogs [ 1 ] .", "label": "", "metadata": {}, "score": "56.170998"}
{"text": "S27-S34 , 2000 .View at Google Scholar \u00b7 View at Scopus .T. Florio , C. Rim , R. E. Hershberger , M. Loda , and P. J. S. Stork , \" The somatostatin receptor SSTR1 is coupled to phosphotyrosine phosphatase activity in CHO - K1 cells , \" Molecular Endocrinology , vol . 8 , no .", "label": "", "metadata": {}, "score": "56.310295"}
{"text": "In a large study on 504 NET patients treated with the radiolabeled SST analog [ 177 Lu - DOTA , Tyr 3 ] -octreotate [ 90 ] , an overall survival benefit was evident when the outcome was compared with the historical data of the group .", "label": "", "metadata": {}, "score": "56.321754"}
{"text": "In endocrine tumors , PRRT with SST analogs was initially performed using [ 111 In]-coupled peptides , then replaced by DOTA stably labeled with [ 68 Ga ] , [ 90 Y ] , or [ 177 Lu].", "label": "", "metadata": {}, "score": "56.38433"}
{"text": "0004 ] Natural somatostatin binds and activates all 5 somatostatin receptors ( SSTR1 - 5 ) with nmol efficacy and thus causes its multiple physiological effects .", "label": "", "metadata": {}, "score": "56.417194"}
{"text": "[ 110 , 115 - 119 ] .In co - immunoprecipitation experiments , sst2 and SHP-1 were identified in a multiprotein complex regulated by Gi3 \u03b1 [ 125 ] .", "label": "", "metadata": {}, "score": "56.45221"}
{"text": "In a further aspect , the present invention relates to the use of a COMPOUND OF THE INVENTION , preferably pasireotide , or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for the treatment of meningioma .", "label": "", "metadata": {}, "score": "56.467384"}
{"text": "RGD ( Arg - Gly - Asp ) peptides are described to antagonise neoangiogenesis , e.g. , by binding to \u03b1v\u03b23 receptors on blood vessels .", "label": "", "metadata": {}, "score": "56.48565"}
{"text": "76 , no .6 , pp .961 - 966 , 1995 .View at Google Scholar . Y. P. Hua , X. Y. Yin , B. G. Peng et al . , \" Mechanisms and influence of octreotide - induced regulation of somatostatin receptor 2 on hepatocellular carcinoma , \" Chemotherapy , vol .", "label": "", "metadata": {}, "score": "56.610847"}
{"text": "SST-14 and SST-28 bind all SST receptors with similar high affinity although SST-28 preferentially binds to sst5 , while synthetic ligands display distinct SST - specific binding affinity ( Table 1 ) .", "label": "", "metadata": {}, "score": "56.687202"}
{"text": "[ 111 In]-DTPA - octreotide retains high affinity for sst2 and has been used for scintigraphic imaging for primary and metastatic neuroendocrine tumors ( NETs ) , improving the sensitivity of standard diagnostic modalities [ 89 ] .", "label": "", "metadata": {}, "score": "56.71824"}
{"text": "4 , pp .387 - 394 , 1998 .View at Publisher \u00b7 View at Google Scholar .J. A. Gilbert , J. P. Miell , S. M. Chambers , A. M. McGregor , and S. J. B. Aylwin , \" The nadir growth hormone after an octreotide test dose predicts the long - term efficacy of somatostatin analogue therapy in acromegaly , \" Clinical Endocrinology , vol .", "label": "", "metadata": {}, "score": "56.842678"}
{"text": "Furthermore , this receptor has much structural homology to members of the somatostatin and receptor family and it could be activated by somatostatin-14 and cortistatin at micromolar doses [ 10 ] .", "label": "", "metadata": {}, "score": "56.87346"}
{"text": "18 , pp .4973 - 4978 , 1992 .View at Google Scholar \u00b7 View at Scopus .M. Duran - Prado , M. D. Gahete , M. Hergueta - Redondo , et al . , \" The new truncated somatostatin receptor variant sst 5 TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells , \" Oncogene , vol .", "label": "", "metadata": {}, "score": "56.94143"}
{"text": "Further evidence that the 4-ureido - quinoline core , also shared with the structure of palosuran , could be taken as a promising template for antagonists turned out from several patent applications .", "label": "", "metadata": {}, "score": "57.09772"}
{"text": "1289 - 1297 , 1994 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. Florio , S. Thellung , S. Arena et al . , \" Somatostatin receptor 1 ( SSTR1)-mediated inhibition of cell proliferation correlates with the activation of the MAP kinase cascade : role of the phosphotyrosine phosphatase SHP-2 , \" Journal of Physiology Paris , vol .", "label": "", "metadata": {}, "score": "57.16262"}
{"text": "R1-R12 , 2012 .View at Google Scholar .G. Tulipano , R. Stumm , M. Pfeiffer , H. J. Kreienkamp , V. H\u00f6llt , and S. Schulz , \" Differential \u03b2 -arrestin trafficking and endosomal sorting of somatostatin receptor subtypes , \" The Journal of Biological Chemistry , vol .", "label": "", "metadata": {}, "score": "57.265526"}
{"text": "It was suggested that this resulted from cortisol stimulation of the mineralocorticoid receptor , while GRs were blocked by mifepristone .Spironolactone and potassium chloride replacement therapy can readily restore hypokalemia and blood pressure .", "label": "", "metadata": {}, "score": "57.34646"}
{"text": "This is the most currently used drug in patients with hypercortisolism .It is a synthetic antifungal drug that works principally by inhibiting the cytochrome P450 system and 17,20-lyase , which are involved in the synthesis and degradation of steroids .", "label": "", "metadata": {}, "score": "57.36474"}
{"text": "12 , pp .3261 - 3268 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. J. Behm , G. Stankus , C. P. A. Doe et al . , \" The peptidic urotensin - II receptor ligand GSK248451 possesses less intrinsic activity than the low - efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems , \" British Journal of Pharmacology , vol .", "label": "", "metadata": {}, "score": "57.421356"}
{"text": "654 - 661 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .B. Waser , R. Cescato , M. L. Tamma , H. R. Maecke , and J. C. Reubi , \" Absence of somatostatin SST 2 receptor internalization in vivo after intravenous SOM230 application in the AR42J animal tumor model , \" European Journal of Pharmacology , vol .", "label": "", "metadata": {}, "score": "57.47644"}
{"text": "You can ask your pharmacist or doctor for information about SIGNIFOR that is written for health professionals .Active ingredient : Pasireotide .Inactive ingredients : Mannitol , tartaric acid , sodium hydroxide and water for injection .", "label": "", "metadata": {}, "score": "57.514496"}
{"text": "6 , pp .968 - 976 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. P. Heaney , M. Fernando , W. H. Yong , and S. Melmed , \" Functional PPAR- \u03b3 receptor is a novel therapeutic target for ACTH - secreting pituitary adenomas , \" Nature Medicine , vol . 8 , no .", "label": "", "metadata": {}, "score": "57.5149"}
{"text": "1100 - 1106 , 2012 .View at Google Scholar .R. Cescato , S. Schulz , B. Waser et al . , \" Internalization of sst 2 , sst 3 , and sst 5 receptors : effects of somatostatin agonists and antagonists , \" Journal of Nuclear Medicine , vol .", "label": "", "metadata": {}, "score": "57.573708"}
{"text": "Furthermore , the replacement of this amino acid with the corresponding amidated Asn gives a compound that retains a full activity in all three assay systems , suggesting that in this position an amino acid negatively charged in the side chain is not required .", "label": "", "metadata": {}, "score": "57.621735"}
{"text": "Following multiple subcutaneous doses , pasireotide demonstrates linear pharmacokinetics in the dose range of 0.05 to 0.6 mg once a day in healthy volunteers , and 0.3 mg to 1.2 mg twice a day in Cushing 's disease patients .", "label": "", "metadata": {}, "score": "57.657177"}
{"text": "Subtype - selective agonists for each of SST receptors provide a direct approach to define individual role of SST receptors in the antiproliferative effects of SST [ 69 ] .", "label": "", "metadata": {}, "score": "57.742287"}
{"text": "203 - 207 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. L. Herold , D. J. Behm , P. T. Buckely , J. J. Foley , and S. A. Douglas , \" The peptidic somatostatin analogs lanreotide , BIM-23127 and BIM-23042 are urotensin - II receptor ligands , \" Pharmacologist , vol .", "label": "", "metadata": {}, "score": "57.743404"}
{"text": "M. Koutsilieris , C. S. Mitsiades , J. Bogdanos et al . , \" Combination of somatostatin analog , dexamethasone , and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases , \" Clinical Cancer Research , vol .", "label": "", "metadata": {}, "score": "57.770985"}
{"text": "6 , pp .1658 - 1662 , 1990 .View at Google Scholar \u00b7 View at Scopus . U.Pl\u00f6ckinger , A. Perez - Canto , C. Emde , R.-M. Liehr , W. Hopfenm\u00fcller , and H.-J. Quabbe , \" Effect of the somatostatin analog octreotide on gastric mucosal function and histology during 3 months of preoperative treatment in patients with acromegaly , \" European Journal of Endocrinology , vol .", "label": "", "metadata": {}, "score": "57.79761"}
{"text": "323 - 329 , 1991 .View at Google Scholar \u00b7 View at Scopus .G. Weckbecker , R. Liu , L. Tolcsvai , and C. Bruns , \" Antiproliferative effects of the somatostatin analogue octreotide ( SMS 201 - 995 ) on ZR-75 - 1 human breast cancer cells in vivo and in vitro , \" Cancer Research , vol .", "label": "", "metadata": {}, "score": "57.922615"}
{"text": "Method of treating meningioma in a subject in need thereof , comprising administering to said subject a therapeutically effective amount of pasireotide or a pharmaceutically acceptable salt thereof .", "label": "", "metadata": {}, "score": "57.95438"}
{"text": "This synthetic analogue behaved as a full agonist in the calcium functional assay in HEK293 human and rat UT cells , inducing similar maximal effects as U - II .", "label": "", "metadata": {}, "score": "57.981956"}
{"text": "219 - 224 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .L. J. Hofland , J. van der Hoek , R. Feelders et al . , \" The multi - ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5 , \" European Journal of Endocrinology , vol .", "label": "", "metadata": {}, "score": "58.06169"}
{"text": "These in vitro results were confirmed in clinical studies in which octreotide potentiated celecoxib effect in gastric carcinoma patients , increasing both necrosis and apoptosis and inhibiting angiogenesis [ 212 ] .", "label": "", "metadata": {}, "score": "58.068413"}
{"text": "175 - 186 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. C. Pagliacci , R. Tognellini , F. Grignani , and I. Nicoletti , \" Inhibition of human breast cancer cell ( MCF-7 ) growth in vitro by the somatostatin analog SMS 201 - 995 : effects on cell cycle parameters and apoptotic cell death , \" Endocrinology , vol .", "label": "", "metadata": {}, "score": "58.105053"}
{"text": "Because of the absence of specific small molecule UT receptor agonists , Croston et al . performed a functional mammalian cell - based R - SAT assay for high - throughput screening in 2002 [ 55 ] .", "label": "", "metadata": {}, "score": "58.223644"}
{"text": "These results were confirmed in non - endocrine tumor cells , natively expressing SST receptors and D2R. It was shown that these receptors can interact in the absence of agonists [ 55 ] and the treatment with the chimeric compound targeting both receptor types ( BIM-23A760 ) significantly increased the sst5/D2R and sst2/D2R dimers .", "label": "", "metadata": {}, "score": "58.224205"}
{"text": "In a phase II study , lanreotide + tamoxifen induced a 50 % of overall objective response rate , with a 12.5 % of complete responses , and similar responses were observed using the octreotide / tamoxifen association [ 189 , 190 ] .", "label": "", "metadata": {}, "score": "58.228683"}
{"text": "\"These study results demonstrate that pasireotide has the potential to be an important therapeutic option for patients living with Cushing 's disease and reinforces Novartis ' commitment to develop therapies to help address unmet medical needs , \" said Herve Hoppenot , President , Novartis Oncology .", "label": "", "metadata": {}, "score": "58.244835"}
{"text": "S41-S51 , 2012 .View at Google Scholar .S. Baldari , F. Ferrau , C. Alafaci , et al . , \" First demonstration of the effectiveness of peptide receptor radionuclide therapy ( PRRT ) with 111", "label": "", "metadata": {}, "score": "58.256172"}
{"text": "About the Study .PASPORT - CUSHINGS ( PASireotide clinical trial PORTfolio - CUSHING 'S disease ) is a prospective randomized , double - blind , Phase III study conducted at 68 sites in 18 countries .", "label": "", "metadata": {}, "score": "58.348602"}
{"text": "G. K. Stalla , J. Stalla , K. Von Werder et al . , \" Nitroimidazole derivatives inhibit anterior pituitary cell function apparently by a direct effect on the catalytic subunit of the adenylate cyclase holoenzyme , \" Endocrinology , vol .", "label": "", "metadata": {}, "score": "58.369656"}
{"text": "Octreotide ( able to bind with high affinity sst2 and 5 ) exhibited agonistic properties for sst2 but failed to activate sst5 .Finally , the recently introduced SST analogs , somatoprim ( that binds with high affinity to sst2 , 4 and 5 ) was a full agonist for both sst2 and sst5 [ 65 ] .", "label": "", "metadata": {}, "score": "58.45132"}
{"text": "In comparison to Octreotide , Pasireotide has a longer half - life ( 2 hours versus 27 hours ) [ 140 ] .This may be related to the intracellular dynamic of the sst2- and sst5-receptor - ligand complex .", "label": "", "metadata": {}, "score": "58.479267"}
{"text": "By the application of this assay to a large compound library , various 4-phenylpiperidine - benzoxazin-3-ones derivatives were identified .Compound 2 , which contained a 4-(4-chlorophenyl)piperidine subunit , was identified as moderately potent compound ( .", "label": "", "metadata": {}, "score": "58.481728"}
{"text": "271 , no .11 , pp .6129 - 6136 , 1996 .View at Google Scholar \u00b7 View at Scopus .S. Seino , \" Somatostatin receptor subtype SSTR2 mediates the inhibition of high - voltage - activated calcium channels by somatostatin and its analogue SMS 201 - 995 , \" FEBS Letters , vol .", "label": "", "metadata": {}, "score": "58.503304"}
{"text": "3B , pp .2465 - 2471 , 2003 .View at Google Scholar \u00b7 View at Scopus .R. Colucci , C. Blandizzi , N. Ghisu , T. Florio , and M. Del Tacca , \" Somatostatin inhibits colon cancer cell growth through cyclooxygenase-2 downregulation , \" British Journal of Pharmacology , vol .", "label": "", "metadata": {}, "score": "58.716637"}
{"text": "12 , pp .7099 - 7106 , 1998 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Hortala , G. Ferjoux , A. Estival et al . , \" Inhibitory role of the somatostatin receptor sst 2 on the intracrine - regulated cell proliferation induced by the 210-amino acid fibroblast growth factor-2 isoform .", "label": "", "metadata": {}, "score": "58.717773"}
{"text": "Table 2 summarizes the different pathways of SSTR subtype activation .Indirect antiproliferative effects of SST involve the inhibition of the GH / IGF - I axis through central ( sst2 , sst5 ) and peripheral ( sst2 , sst3 ) mechanisms , which via a PTP , dephosphorylate STAT5b and inhibit expression of the hepatic IGF - I [ 140 ] .", "label": "", "metadata": {}, "score": "58.734978"}
{"text": "Importantly , SST exerts antiproliferative and antiangiogenic effects on cancer cells in vitro , and on experimental tumors in vivo .Moreover , SST agonists are clinically effective as antitumor agents for pituitary adenomas and gastro - pancreatic neuroendocrine tumors .", "label": "", "metadata": {}, "score": "58.863377"}
{"text": "nM ) , and ( R)-enantiomer exhibited also good oral bioavailability in pharmacokinetics experiments .However , as piperazino - isoindolinone derivative ( Figure 11 ) , the compound 6 ( JNJ-39319202 ) showed single - digit nanomolar potencies in the rat FLIPR assay ( . nM ) .", "label": "", "metadata": {}, "score": "58.87113"}
{"text": "Newell - Price , J. The Diagnosis and Differential Diagnosis of Cushing 's Syndrome and Pseudo - Cushing 's States .Endocrine Reviews .Pedroncelli , A. Medical Treatment of Cushing 's Disease : Somatostatin Analogues and Pasireotide .", "label": "", "metadata": {}, "score": "58.89116"}
{"text": "1576 - 1582 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . H. Lahlou , N. Saint - Laurent , J. P. Est\u00e8ve et al . , \" sst 2 somatostatin receptor inhibits cell proliferation through Ras- , Rap1- , and B - Raf - dependent ERK2 activation , \" The Journal of Biological Chemistry , vol .", "label": "", "metadata": {}, "score": "58.994987"}
{"text": "We demonstrated successful scintigraphic visualisation of BN receptor - positive tumours in preclinical studies using the radiolabelled BN analogue [ ( 111)In - DTPA - Pro(1),Tyr(4)]BN .", "label": "", "metadata": {}, "score": "59.103844"}
{"text": "In particular , in CHO - K1 cells , solely expressing sst1 , SST induced cytostatic effects through a rapid activation of SHP2 and c - Src [ 33 ] .", "label": "", "metadata": {}, "score": "59.14441"}
{"text": "Breast Cancer .Breast tumors express all SST receptors at high level , sst2 being the predominant subtype [ 180 ] .Experimental studies support the efficacy of octreotide and lanreotide in the control of tumor growth in vitro and in xenograft models [ 181 - 183 ] .", "label": "", "metadata": {}, "score": "59.14554"}
{"text": "5 , pp .2555 - 2562 , 1991 .View at Google Scholar \u00b7 View at Scopus .G. Prevost , E. Foehrle , F. Thomas et al . , \" Growth of human breast cancer cell lines is inhibited by the somatostatin analog BIM23014 , \" Endocrinology , vol .", "label": "", "metadata": {}, "score": "59.16681"}
{"text": "1412 - 1417 , 2011 .View at Google Scholar .G. Pepe , R. Moncayo , E. Bombardieri , et al . , \" Somatostatin receptor SPECT , \" European Journal of Nuclear Medicine and Molecular Imaging , vol .", "label": "", "metadata": {}, "score": "59.18034"}
{"text": "Subcutaneous SRL Treatment .Octreotide and Lanreotide are cyclic peptides with a significantly prolonged half - life compared to somatostatin ( 2 hours versus 2 minutes ) .", "label": "", "metadata": {}, "score": "59.181587"}
{"text": "Thus sst2A - sst3 heterodimerisation resulted in a new receptor with enhanced sst2A - like and diminished sst3-like activity [ 67 ] .Grant and Kumar demonstrated that sst2 and sst5 form heterodimers upon subtype - specific sst2 ligand activation [ 68 ] .", "label": "", "metadata": {}, "score": "59.259155"}
{"text": "Limited clinical data are currently available about SST analogs in vivo , but SST antiangiogenic activity might be useful in refractory meningiomas as reported by The Central Nervous System National Comprehensive Cancer Network guidelines that suggests as treatment options hydroxyurea , interferon- . , or octreotide LAR [ 222 ] .", "label": "", "metadata": {}, "score": "59.289337"}
{"text": "106 - 113 , 2012 .View at Google Scholar .C. de Bruin , A. M. Pereira , R. A. Feelders et al . , \" Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas , \" The Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "59.338127"}
{"text": "An innovative chimeric molecule that acts simultaneously on SST and DA receptors was created with a view to treatment of pituitary tumors .This compound ( BIM-23A760 ) has been tested in a phase 1 and phase 2A study in 11 patients affected by acromegaly from GH - secreting pituitary adenoma , but the weak evidence of somatostatinergic activity led to the discontinuation of its development [ 69 ] .", "label": "", "metadata": {}, "score": "59.342346"}
{"text": "These findings renew interest in the potential use of dopamine agonists in Cushing 's disease .PPAR- \u03b3 Ligands .Peroxisome proliferative - activated receptor- \u03b3 ( PPAR- \u03b3 ) , a member of the nuclear receptor superfamily , functions as a transcription factor mediating ligand - dependent transcriptional regulation [ 41 ] .", "label": "", "metadata": {}, "score": "59.442078"}
{"text": "A study on primary prolactinoma cells overexpressing sst2 showed that the chimeric compound BIM-23A760 does not improve prolactin release suppression as compared to cabergoline , suggesting the predominance of dopaminergic signaling in prolactin release [ 159 ] .", "label": "", "metadata": {}, "score": "59.4589"}
{"text": "Among them TT-232 , a hepta - peptide sst4 and sst1 agonist , and J-2156 , sst4-selective compound , have shown anti - inflammatory , antinociceptive and antitumor effects [ 79 - 81 ] .", "label": "", "metadata": {}, "score": "59.46756"}
{"text": "However , when preliminary in vitro results were followed by a \" proof - of - principle \" clinical trial the results failed to show any additional effect of this chimeric molecule on GH secretion .", "label": "", "metadata": {}, "score": "59.518085"}
{"text": "6 , pp .647 - 655 , 1999 .View at Google Scholar \u00b7 View at Scopus .T. Florio , M. Morini , V. Villa et al . , \" Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen - activated protein kinase activities , \" Endocrinology , vol .", "label": "", "metadata": {}, "score": "59.54155"}
{"text": "[ 134 ] .Importantly , in glioma cell lines and primary cultures from human glioblastomas , the cytostatic activity of SST was dependent on the expression and activation of PTP \u03b7 .", "label": "", "metadata": {}, "score": "59.635887"}
{"text": "527 - 532 , 1991 .View at Google Scholar \u00b7 View at Scopus .M. S. M. Ip , K. C. B. Tan , W. C. G. Peh , and K. S. L. Lam , \" Effect of Sandostatin LAR on sleep apnoea in acromegaly : correlation with computerized tomographic cephalometry and hormonal activity , \" Clinical Endocrinology , vol .", "label": "", "metadata": {}, "score": "59.676292"}
{"text": "Specifically , the design and synthesis of selective receptor antagonists should be helpful to clarify the role of human U - II as a multifunctional peptide in mammalian pathophysiological functions .", "label": "", "metadata": {}, "score": "59.784645"}
{"text": "349 - 356 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. Albini , T. Florio , D. Giunciuglio et al . , \" Somatostatin controls Kaposi 's sarcoma tumor growth through inhibition of angiogenesis , \" The FASEB Journal , vol .", "label": "", "metadata": {}, "score": "59.80703"}
{"text": "46 , no . 1 , 2005 .View at Google Scholar \u00b7 View at Scopus . A. Imhof , P. Brunner , N. Marincek et al . , \" Response , survival , and long - term toxicity after therapy with the radiolabeled somatostatin analogue [ 90 Y - DOTA]-TOC in metastasized neuroendocrine cancers , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "59.849014"}
{"text": "SRL effects on tumour volume are independent of drug formulation .They have been observed with the subcutaneous injections of Octreotide as well as with the slow release preparations .", "label": "", "metadata": {}, "score": "59.87786"}
{"text": "considered the replacement of the disulphide bridge by a side - chain - to - side - chain lactam bridge in accordance with observations on several biologically relevant peptides , such as conotoxins , endothelin-1 , and somatostatin analogue that gave interesting results by the same modification [ 29 ] .", "label": "", "metadata": {}, "score": "59.96206"}
{"text": "In contrast , different results were obtained in the rat aorta bioassay , in which the compound behaved as a competitive antagonist , showing only in highest concentrations ( 10 \u03bc M ) a weak residual agonist activity ( 25 % compared to the maximal effect of U - II ) .", "label": "", "metadata": {}, "score": "60.02504"}
{"text": "View at Google Scholar \u00b7 View at Scopus .T. Florio , S. Arena , S. Thellung et al . , \" The activation of the phosphotyrosine phosphatase \u03b7 ( r - PTP \u03b7 ) is responsible for the somatostatin inhibition of PC CI3 thyroid cell proliferation , \" Molecular Endocrinology , vol .", "label": "", "metadata": {}, "score": "60.06106"}
{"text": "In addition , patients with ectopic secretion of ACTH may be treated while expecting confirmation of the source , in the presence of metastatic cancer , or in patients who are not candidates for surgery for some reason .", "label": "", "metadata": {}, "score": "60.067047"}
{"text": "Moreover , SHP2 and cytosolic tyrosine kinases ( c - Src ) were also detected in the sst2-associated multieffector complex [ 128 ] .", "label": "", "metadata": {}, "score": "60.264107"}
{"text": "Among receptors for many regulatory peptides , SST receptors expressed on the membrane of tumor cells have provided the rationale for the development of SST agonists able to selectively target tumor cells .", "label": "", "metadata": {}, "score": "60.274605"}
{"text": "10 , pp .1803 - 1808 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. d'Emmanuele di Villa Bianca , E. Mitidieri , F. Fusco et al . , \" Endogenous urotensin II selectively modulates erectile function through eNOS , \" PLoS One , vol .", "label": "", "metadata": {}, "score": "60.283966"}
{"text": "56 , no . 1 , pp .125 - 130 , 2011 .View at Google Scholar .S. Gao , B. P. Yu , Y. Li , W. G. Dong , and H. S. Luo , \" Antiproliferative effect of octreotide on gastric cancer cells mediated by inhibition of Akt / PKB and telomerase , \" World Journal of Gastroenterology , vol .", "label": "", "metadata": {}, "score": "60.304256"}
{"text": "282 - 286 , 1999 .View at Google Scholar . H. P. Nothacker , Z. Wang , A. M. McNeill et al . , \" Identification of the natural ligand of an orphan G - protein - coupled receptor involved in the regulation of vasoconstriction , \" Nature Cell Biology , vol .", "label": "", "metadata": {}, "score": "60.312477"}
{"text": "The identification and characterization of compound SB-706375 was originally described by Douglas et al . in 2005 [ 66 ] ( Figure 8 ) .This compound was identified as novel UT receptor antagonist , acting in a surmountable , reversible manner with high affinity across species ( binding . 4.7 - 20.7 nM ) and good selectivity .", "label": "", "metadata": {}, "score": "60.322353"}
{"text": "Preferred salts according to the present invention are salts of pasireotide .[ 0035 ]Preferred salts for pasireotide are the lactate , aspartate , benzoate , succinate and pamoate including mono- and di - salts , more preferably the aspartate di - salt and the pamoate monosalt .", "label": "", "metadata": {}, "score": "60.499508"}
{"text": "Patients receive pasireotide subcutaneously at a dose of 1200 \u03bcg twice daily .One treatment cycle is defined as four weeks of therapy .Complete blood counts are obtained , and neurologic examinations and contrast - enhanced cranial MR scans are performed .", "label": "", "metadata": {}, "score": "60.599022"}
{"text": "Long - term follow - up data are not available .Elevated Liver Tests .In the Phase III trial , there were transient mean elevations in aminotransferase values in patients treated with SIGNIFOR .", "label": "", "metadata": {}, "score": "60.755676"}
{"text": "Based on serum stability ( 4 h incubation at 37 degrees C in human serum ) and receptor binding affinity , the five most promising analogues were selected and further evaluated in in vitro internalisation studies in human colorectal adenocarcinoma HT29 cells , which overexpress NT receptors .", "label": "", "metadata": {}, "score": "60.75621"}
{"text": "5 - 9 , 2005 .View at Google Scholar \u00b7 View at Scopus . A. Vasilaki , D. Papasava , D. Hoyer , and K. Thermos , \" The somatostatin receptor ( sst 1 ) modulates the release of somatostatin in the nucleus accumbens of the rat , \" Neuropharmacology , vol .", "label": "", "metadata": {}, "score": "60.764027"}
{"text": "322 - 329 , 1988 .View at Google Scholar \u00b7 View at Scopus .T. Florio , H. Yao , K. D. Carey , T. J. Dillon , and P. J. S. Stork , \" Somatostatin activation of mitogen - activated protein kinase via somatostatin receptor 1 ( SSTR1 ) , \" Molecular Endocrinology , vol .", "label": "", "metadata": {}, "score": "60.77417"}
{"text": "This could reduce the receptor availability on the cell surface in the isolated rat aortic ring system .Functional assays showed that palosuran was a selective antagonist of UT receptor not antagonizing the action of other vasoconstrictor agents such as KCl , endothelin-1 , 5-hydroxytryptamine , and norepinephrine .", "label": "", "metadata": {}, "score": "60.77926"}
{"text": "Radiopeptides used in clinics are SST agonists , mainly octreotide , on the basis of their high - affinity binding and the induction of internalization of the ligand - receptor complex that leads to intracellular accumulation of the radioligand [ 96 ] .", "label": "", "metadata": {}, "score": "60.78681"}
{"text": "If SRL insufficiently suppresses GH secretion dopamine agonists can be added , preferentially Cabergoline , and this will normalise GH secretion in up to 50 % of these patients .", "label": "", "metadata": {}, "score": "60.798317"}
{"text": "3034 - 3040 , 1998 .View at Publisher \u00b7 View at Google Scholar .R. Baldelli , A. Colao , P. Razzore et al . , \" Two - year follow - up of acromegalic patients treated with slow release lanreotide ( 30 mg ) , \" Journal of Clinical Endocrinology and Metabolism , vol . 85 , no .", "label": "", "metadata": {}, "score": "60.815605"}
{"text": "Based on the search for a definitive pathophysiological role for U - II and its receptor in the cardiovascular homeostasis and aetiology of relating disorders , the design of suitable tool compounds of peptide or nonpeptide nature could be of significant utility .", "label": "", "metadata": {}, "score": "60.852203"}
{"text": "5 , pp .707 - 716 , 2002 .View at Google Scholar \u00b7 View at Scopus .G. Weckbecker , U. Briner , I. Lewis , and C. Bruns , \" SOM230 : a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone / insulin - like growth factor - I axis in rats , primates , and dogs , \" Endocrinology , vol .", "label": "", "metadata": {}, "score": "60.85448"}
{"text": "Accordingly , the peptide also elicits vasodilatory effects on the small arteries of rats and on the resistance arteries of humans , probably due to the release of endothelium - derived hyperpolarizing factor and nitric oxide [ 20 ] .", "label": "", "metadata": {}, "score": "60.904877"}
{"text": "1277 - 1285 , 1994 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .O. Meucci , E. Landolfi , A. Scorziello et al . , \" Dopamine and somatostatin inhibition of prolactin secretion from MMQ pituitary cells : role of adenosine triphosphate - sensitive potassium channels , \" Endocrinology , vol .", "label": "", "metadata": {}, "score": "60.910408"}
{"text": "10 , pp .4123 - 4130 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. Van Der Hoek , W. W. De Herder , R. A. Feelders et al . , \" A single - dose comparison of the acute effects between the new Somatostatin analog SOM230 and octreotide in acromegalic patients , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "60.911964"}
{"text": "115 - 120 , 1999 .View at Google Scholar \u00b7 View at Scopus .R. Cozzi , R. Attanasio , S. Lodrini , and G. Lasio , \" Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients : efficacy and lack of predictive value of prolactin status , \" Clinical Endocrinology , vol .", "label": "", "metadata": {}, "score": "60.932297"}
{"text": "138 , no . 9 , pp .3756 - 3763 , 1997 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. Massa , F. Barbieri , C. Aiello et al . , \" The expression of the phosphotyrosine phosphatase DEP-1/PTP \u03b7 dictates the responsivity of glioma cells to somatostatin inhibition of cell proliferation , \" The Journal of Biological Chemistry , vol .", "label": "", "metadata": {}, "score": "61.078026"}
{"text": "View at Publisher \u00b7 View at Google Scholar .S. R. George , K. Kovacs , and S. L. Asa , \" Effect of SMS 201 - 995 , a long - acting somatostatin analogue , on the secretion and morphology of a pituitary growth hormone cell adenoma , \" Clinical Endocrinology , vol .", "label": "", "metadata": {}, "score": "61.107063"}
{"text": "120 - 130 , 2012 .View at Google Scholar .C. Lo Nigro , M. Maffi , J. L. Fischel , P. Formento , G. Milano , and M. Merlano , \" The combination of docetaxel and the somatostatin analogue lanreotide on androgen - independent docetaxel - resistant prostate cancer : experimental data , \" BJU International , vol .", "label": "", "metadata": {}, "score": "61.141647"}
{"text": "However , reducing the distance of the primary aliphatic amine from the peptide backbone led to a progressive reduction of both potency and efficacy .[ Orn 8 ] U - II analogue showed a weak contraction of rat aorta strips corresponding to about 20 % of the U - II maximal effect at micromolar concentrations .", "label": "", "metadata": {}, "score": "61.22119"}
{"text": "6 , pp .229 - 237 , 2000 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .S. A. Douglas , D. Naselsky , Z. Ao et al . , \" Identification and pharmacological characterization of native , functional human urotensin - II receptors in rhabdomyosarcoma cell lines , \" British Journal of Pharmacology , vol .", "label": "", "metadata": {}, "score": "61.224422"}
{"text": "3229 - 3232 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .N. Tarui , T. Santo , H. Watanabe , K. Aso , T. Miwa , and S. Takekawa , \" Preparation of biphenylcarboxamide compounds as GPR14 antagonists or somatostatin receptor regulators , \" Takeda Chemical Industries , PCT International Application no .", "label": "", "metadata": {}, "score": "61.22657"}
{"text": "in 2012 [ 48 ] provided the replacement of the indole moiety in URP in order to obtain promising antagonists .In particular , the introduction of the more hydrophobic uncoded amino acid Bip led to the novel antagonist urocontrin , [ Bip 4 ] URP .", "label": "", "metadata": {}, "score": "61.29973"}
{"text": "5 , pp .559 - 564 , 1995 .View at Google Scholar \u00b7 View at Scopus .G. Minniti , M. L. Jaffrain - Rea , R. Baldelli et al . , \" Acute effects of octreotide , cabergoline and a combination of both drugs on GH secretion in acromegalic patients , \" Clinica Terapeutica , vol .", "label": "", "metadata": {}, "score": "61.332466"}
{"text": "- II in water were developed in order to provide for a putative agonist pharmacophore .Later , another agonist pharmacophore model was performed by studying conformation adopted by a less potent analogue without Val residue , that is , Ac-[Cys - Phe - DTrp - Lys - Tyr - Cys]-NH 2 ( 200-fold less potent than hUT - II ) .", "label": "", "metadata": {}, "score": "61.33339"}
{"text": "These compounds were reported to mediate both antisecretory and antiproliferative activity in experimental models [ 69 ] .More recently , based on molecular investigations of cell SST receptor expression profile showing in most cases coexpression of multiple receptors , it was developed the concept that a better pharmacological response could be obtained through the simultaneous activation of all the receptors in a given tissue .", "label": "", "metadata": {}, "score": "61.342617"}
{"text": "5 , pp .E769-E774 , 1997 .View at Google Scholar \u00b7 View at Scopus .T. Florio , \" Molecular mechanisms of the antiproliferative activity of somatostatin receptors ( SSTRs ) in neuroendocrine tumors , \" Frontiers in Bioscience , vol .", "label": "", "metadata": {}, "score": "61.37452"}
{"text": "5060 , pp .1215 - 1217 , 1992 .View at Google Scholar \u00b7 View at Scopus .Z. Csaba , S. Peineau , and P. Dournaud , \" Molecular mechanisms of somatostatin receptor trafficking , \" Journal of Molecular Endocrinology , vol .", "label": "", "metadata": {}, "score": "61.382355"}
{"text": "M. C. Zatelli , D. Piccin , F. Tagliati , A. Bottoni , A. Luchin , and E. C. D. Uberti , \" Src homology-2-containing protein tyrosine phosphatase-1 restrains cell proliferation in human medullary thyroid carcinoma , \" Endocrinology , vol .", "label": "", "metadata": {}, "score": "61.407204"}
{"text": "There is no guarantee that pasireotide will become commercially available .Disclaimer .You should not place undue reliance on these statements .Such forward - looking statements reflect the current views of management regarding future events , and involve known and unknown risks , uncertainties and other factors that may cause actual results with pasireotide to be materially different from any future results , performance or achievements expressed or implied by such statements .", "label": "", "metadata": {}, "score": "61.450146"}
{"text": "At 12 months , 26 % and 15 % of patients receiving , respectively , the higher and lower Pasireotide dose showed normalization of UFC levels .", "label": "", "metadata": {}, "score": "61.468273"}
{"text": "Thus , despite the antagonistic effects of SB-710411 observed at the rat UT receptor , this peptide acts as a full agonist at the monkey UT receptor .", "label": "", "metadata": {}, "score": "61.525986"}
{"text": "Kaiser et al .[ 55 ] reported a good response to cyclophosphamide , doxorubicin and 5-fluorouracil ( 5FU ) in a patient with adrenocorticotroph tumor , with regression of the metastases .", "label": "", "metadata": {}, "score": "61.63254"}
{"text": "Replacement of the Tyr residue with the bulkier 2-Nal [ ( 2-naphthyl)-L - alanine ] in the goby U - II sequence showed similar potency in agonist activity ( with a value of . nM ) , presumably due to enhanced hydrophobic interactions in the tyrosine - binding pocket .", "label": "", "metadata": {}, "score": "61.648552"}
{"text": "5 , pp .620 - 635 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. J. Behm , J. J. McAtee , J. W. Dodson et al . , \" Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues , \" British Journal of Pharmacology , vol .", "label": "", "metadata": {}, "score": "61.670376"}
{"text": "6 , pp .2692 - 2698 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .F. Lopez , J. P. Est\u00e8ve , L. Buscail et al . , \" The tyrosine phosphatase SHP-1 associates with the sst 2 somatostatin receptor and is an essential component of sst 2 -mediated inhibitory growth signaling , \" The Journal of Biological Chemistry , vol .", "label": "", "metadata": {}, "score": "61.751488"}
{"text": "Results of somatostatin - receptor scintigraphy do not predict tumour volume reduction [ 103 ] .Effect of Preoperative SRL Treatment on Surgical Outcome Early publications suggested that presurgical therapy improves surgical outcome [ 120 , 121 ] .", "label": "", "metadata": {}, "score": "61.872276"}
{"text": "Thus , using these highly sensitive tools may allow the prediction of an adenoma 's response to SRL and even the selection of receptor - specific SRL .", "label": "", "metadata": {}, "score": "61.880287"}
{"text": "Nor can there be any guarantee that pasireotide will achieve any particular levels of revenue in the future .Should one or more of these risks or uncertainties materialize , or should underlying assumptions prove incorrect , actual results may vary materially from those anticipated , believed , estimated or expected .", "label": "", "metadata": {}, "score": "61.894447"}
{"text": "399 - 407 , 1988 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .L. Vecsei and E. Widerlov , \" Effects of intracerebroventricularly administered somatostatin on passive avoidance , shuttle - box behaviour and open - field activity in rats , \" Neuropeptides , vol .", "label": "", "metadata": {}, "score": "61.908424"}
{"text": "Food effect is unlikely to occur since SIGNIFOR is administered via a parenteral route .Distribution between blood and plasma is concentration independent and shows that pasireotide is primarily located in the plasma ( 91 % ) .", "label": "", "metadata": {}, "score": "61.937286"}
{"text": "The affinity , specificity , biodistribution , and stability of these two DTPA - CCK analogs indicate that these compounds have substantial promise for use in the in vivo visualization of CCK - B receptor - expressing tumors .", "label": "", "metadata": {}, "score": "61.98458"}
{"text": "We found increased visceral obesity but no improvement of glucose tolerance in 5 patients after 6 months of Pegvisomant therapy resulting in normal IGF-1 concentrations .", "label": "", "metadata": {}, "score": "61.998627"}
{"text": "4 , pp .1203 - 1210 , 2008 .View at Publisher \u00b7 View at Google Scholar .M. Pfeiffer , T. Koch , H. Schr\u00f6der et al . , \" Homo- and heterodimerization of somatostatin receptor subtypes .", "label": "", "metadata": {}, "score": "62.009853"}
{"text": "5463 , pp .154 - 157 , 2000 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Grant , H. Alturaihi , P. Jaquet , B. Collier , and U. Kumar , \" Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization , \" Molecular Endocrinology , vol .", "label": "", "metadata": {}, "score": "62.0165"}
{"text": "407 - 414 , 2012 .View at Google Scholar . D. O'Toole , A. Saveanu , A. Couvelard et al . , \" The analysis of quantitative expression of somatostatin and dopamine receptors in gastro - entero - pancreatic tumours opens new therapeutic strategies , \" European Journal of Endocrinology , vol .", "label": "", "metadata": {}, "score": "62.15554"}
{"text": "The method according to claim 1 wherein the pasireotide , or pharmaceutically acceptable salt thereof , is administered parenterally .The method according to claim 1 wherein the pasireotide , or pharmaceutically acceptable salt thereof , is administered orally .", "label": "", "metadata": {}, "score": "62.171986"}
{"text": "Since corticotroph adenomas express DA and SST receptors simultaneously , some authors hypothesized the use of DA agonists with SS analogues to reach a synergic effect in the treatment of ACTH - dependent CS .", "label": "", "metadata": {}, "score": "62.179188"}
{"text": "5021 - 5024 , 1980 .View at Publisher \u00b7 View at Google Scholar .R. S. Ames , H. M. Sarau , J. K. Chambers et al . , \" Human urotensin - II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 , \" Nature , vol .", "label": "", "metadata": {}, "score": "62.20157"}
{"text": "compared the efficacy of Pegvisomant and Octreotide LAR in an open randomized multicentre study in 152 acromegalic patients .The normalisation rate of IGF-1 was similar in both groups , but Pegvisomant was more effective in those patients with higher IGF-1 baseline levels [ 179 ] .", "label": "", "metadata": {}, "score": "62.274696"}
{"text": "205 - 208 , 1986 .View at Google Scholar .P. Grieco , A. Carotenuto , P. Campiglia , et al . , \" A new , potent urotensin II receptor peptide agonist containing a Pen residue at the disulfide bridge , \" Journal of Medicinal Chemistry , vol .", "label": "", "metadata": {}, "score": "62.358837"}
{"text": "10 , pp .1838 - 1852 , 2001 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Theodoropoulou , J. Zhang , S. Laupheimer et al . , \" Octreotide , a somatostatin analogue , mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression , \" Cancer Research , vol .", "label": "", "metadata": {}, "score": "62.3876"}
{"text": "5 , pp .873 - 881 , 1989 .View at Google Scholar \u00b7 View at Scopus .M. L. Vance and A. G. Harris , \" Long - term treatment of 189 acromegalic patients with the somatostatin analog octreotide : results of the International Multicenter Acromegaly Study Group , \" Archives of Internal Medicine , vol .", "label": "", "metadata": {}, "score": "62.435196"}
{"text": "40 , no . 2 , pp .168 - 180 , 2011 .View at Google Scholar .T. Florio and G. Schettini , \" Multiple intracellular effecters modulate physiological functions of the cloned somatostatin receptors , \" Journal of Molecular Endocrinology , vol .", "label": "", "metadata": {}, "score": "62.473015"}
{"text": "sst2 antiproliferative effects , characterized by the inhibition of the entry in the S phase and the accumulation of the cells in G1 , due to .", "label": "", "metadata": {}, "score": "62.51825"}
{"text": "5 , pp .389 - 393 , 1993 .View at Google Scholar .T. Svoboda , H. Kotzmann , M. Clodi , P. Bernecker , G. Geyer , and A. Luger , \" The non ergot D2-dopamine agonist cv 205 - 502 decreases growth hormone concentrations in acromegalic patients , \" Endocrine Research , vol .", "label": "", "metadata": {}, "score": "62.543427"}
{"text": "Thus determination of the GH concentration during Pegvisomant with an assay that does not crossreact with the drug might identify those patients at risk for tumour growth .", "label": "", "metadata": {}, "score": "62.550316"}
{"text": "0002 ] Somatostatin is a tetradecapeptide having the structure : . # # STR00001 # # .[ 0003 ] The somatostatin class is a known class of small peptides comprising the naturally occurring somatostatin-14 and analogues having somatostatin related activity , e.g. as disclosed by A. S. Dutta in Small Peptides , Vol .", "label": "", "metadata": {}, "score": "62.567345"}
{"text": "12 , pp .1876 - 1885 , 2012 .View at Google Scholar .M. Fani , L. del Pozzo , K. Abiraj et al . , \" PET of somatostatin receptor - positive tumors using 64 Cu-", "label": "", "metadata": {}, "score": "62.56915"}
{"text": "Mifepristone is a synthetic steroid .It is a progesterone receptor antagonist and a powerful type-2 glucocorticoid receptor ( GR ) antagonist .It binds to human GR with an affinity three to four times higher than that of dexamethasone and about 18 times higher than that of cortisol .", "label": "", "metadata": {}, "score": "62.62809"}
{"text": "As a result , cells accumulate in G1 phase without entering S - phase and cell proliferation is blocked .Antisecretory effects of SST and its analogs ; SST inhibits the secretion / synthesis of many hormones through the inhibition of voltage - dependent Ca 2 + channels and activation of K + channels , decreasing intracellular Ca 2 + concentration , and inhibition of adenylyl cyclase , lowering intracellular cAMP levels .", "label": "", "metadata": {}, "score": "62.684578"}
{"text": "56S-63S , 2011 .View at Google Scholar .L. J. Hofland , \" Responsiveness to somatostatin analog treatment and potentials of novel somatostatin analog , \" Journal of endocrinological investigation , vol .", "label": "", "metadata": {}, "score": "62.69002"}
{"text": "97 - 101 , 1995 .View at Google Scholar \u00b7 View at Scopus .R. M. Goldberg , C. G. Moertel , H. S. Wieand , et al . , \" A phase III evaluation of a somatostatin analogue ( octreotide ) in the treatment of patients with asymptomatic advanced colon carcinoma .", "label": "", "metadata": {}, "score": "62.70326"}
{"text": "Somatostatin inhibits angiogenesis either directly or via growth factors , that is , vascular endothelial growth factor ( VEGF ) , basic fibroblast growth factor ( bFGF ) , and IGF-1 or through its immunomodulatory effects [ 69 ] .", "label": "", "metadata": {}, "score": "62.836514"}
{"text": "12 , pp .999 - 1017 , 2003 .View at Google Scholar .J. P. Casta\u00f1o , E. Ghigo , R. D. Kineman , L. de Lecea , M. M. Malag\u00f3n , and H. Vaudry , \" Somatostatin , cortistatin and their receptors in health and disease .", "label": "", "metadata": {}, "score": "62.85263"}
{"text": "6 , Article ID e39458 , 2012 .View at Google Scholar .R. Cozzi and R. Attanasio , \" Octreotide long - acting repeatable for acromegaly , \" Expert Review of Clinical Pharmacology , vol .", "label": "", "metadata": {}, "score": "62.853554"}
{"text": "In this paper the most recent findings on the expression and functional roles of SST and SST receptors in tumor cells are discussed .Somatostatin and Somatostatin Receptors : An Overview .", "label": "", "metadata": {}, "score": "62.87313"}
{"text": "- II .Thus , replacement of the Cys - Cys cyclic motif could be well tolerated by an appropriate longer lactam bridge despite the partial loss of activity , probably due to the different orientation of the key amino acid side chains . nM ) .", "label": "", "metadata": {}, "score": "62.904213"}
{"text": "Colao et al .compared the effect of Bromocriptine , Cabergoline , and Quinagolide in 34 acromegalic patients .They concluded that both , Cabergoline and Bromocriptine ( given as a LAR preparation ) , can not be considered useful medical approaches for acromegaly , whereas Quinagolide normalised circulating GH and IGF - I levels in 47.8 % of patients [ 150 ] .", "label": "", "metadata": {}, "score": "62.92594"}
{"text": "4 , pp .396 - 408 , 1999 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. Florio , S. Thellung , A. Corsaro et al . , \" Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH - secreting pituitary adenoma cells in vitro , \" Clinical Endocrinology , vol .", "label": "", "metadata": {}, "score": "62.93104"}
{"text": "Uptake of [ ( 111)In - DTPA0,Tyr3]octreotate in the target organs was also , in vivo , the highest of the radiolabeled peptides tested , whereas that of [ ( 111)In - DTPA0,D - Tyr1]octreotide was the lowest .", "label": "", "metadata": {}, "score": "62.944977"}
{"text": "A prospective study on the effect of octreotide LAR showed its efficacy in prolonging median time to tumor progression and increase the percentage of stable disease in patients with metastatic midgut NETs [ 169 ] .", "label": "", "metadata": {}, "score": "63.003403"}
{"text": "28 , pp .29004 - 29012 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. Massa , F. Barbieri , C. Aiello et al . , \" The phosphotyrosine phosphatase \u03b7 mediates somatostatin inhibition of glioma proliferation via the dephosphorylation of ERK1/2 , \" Annals of the New York Academy of Sciences , vol .", "label": "", "metadata": {}, "score": "63.00582"}
{"text": "52 , no . 7 , pp .1110 - 1118 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. Wild , M. Fani , M. Behe , et al . , \" First clinical evidence that imaging with somatostatin receptor antagonists is feasible , \" Journal of Nuclear Medicine , vol .", "label": "", "metadata": {}, "score": "63.014153"}
{"text": "These data demonstrate the possibility of active acromegaly even with very low GH concentrations .Thus stricter criteria , using a sensitive monoclonal assay , have been proposed .", "label": "", "metadata": {}, "score": "63.047653"}
{"text": "Heaney et al .[ 41 ] documented the abundant expression of PPAR- \u03b3 in a series of ACTH - secreting tumor samples compared with aactivate PPAR- \u03b3 receptors , might be effective as a treatment for Cushing 's disease .", "label": "", "metadata": {}, "score": "63.072548"}
{"text": "With the depot preparation the injection is easily performed , if instructions for preparing the intramuscular injection are properly adhered to .Lanreotide Autogel can be self - injected by the patients .", "label": "", "metadata": {}, "score": "63.088955"}
{"text": "10 , pp .759 - 764 , 2009 .View at Google Scholar \u00b7 View at Scopus . S. D. Prete , L. Montella , M. Caraglia et al . , \" Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma : multicenter phase II So .", "label": "", "metadata": {}, "score": "63.116367"}
{"text": "The change in the IGF - I concentration was significantly related to the baseline IGF - I concentration but not to the dose of Cabergoline , the duration of treatment , or the baseline prolactin concentration [ 151 ] .", "label": "", "metadata": {}, "score": "63.14376"}
{"text": "15 , pp .3344 - 3352 , 1998 .View at Google Scholar \u00b7 View at Scopus .B. Ambrosi , C. Dall'Asta , S. Cannav\u00f2 et al . , \" Effects of chronic administration of PPAR- \u03b3 ligand rosiglitazone in Cushing 's disease , \" European Journal of Endocrinology , vol .", "label": "", "metadata": {}, "score": "63.150383"}
{"text": "This analogue can be radiolabelled with both 111In and 125I. In autoradiography and immunohistochemistry studies , the 125I - labelled analogue appeared to bind specifically and with high affinity to \u03b1v\u03b23 receptors on neovascular blood vessel sections of different major human cancers , like prostate and breast cancer , which express these receptors .", "label": "", "metadata": {}, "score": "63.15574"}
{"text": "SB-710411 acts as a ligand for both the recombinant rat and monkey UT receptor ( 30 - 150 nM affinities , 56- and 87-fold less potent than U - II , resp . )", "label": "", "metadata": {}, "score": "63.184982"}
{"text": "Veldhuis et al .demonstrated , based upon CSF measurements , that the pegylated GH - receptor antagonist does not cross the human blood - brain barrier [ 172 ] .", "label": "", "metadata": {}, "score": "63.219795"}
{"text": "6 , pp .941 - 943 , 1972 .View at Google Scholar .R. Abs , J. Verhelst , D. Maiter et al . , \" Cabergoline in the treatment of acromegaly : a study in 64 patients , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "63.22178"}
{"text": "6 , pp .229 - 237 , 2000 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. J. Maguire , R. E. Kuc , and A. P. Davenport , \" Orphan - receptor ligand human urotensin II : receptor localization human tissues and comparison of vasoconstrictor responses with endothelin-1 , \" British Journal of Pharmacology , vol .", "label": "", "metadata": {}, "score": "63.304874"}
{"text": "Patacchini et al . in 2003 [ 42 ] described the pharmacological activities of two compounds : [ Pen 5 , Orn 8 ] h .", "label": "", "metadata": {}, "score": "63.31405"}
{"text": "S15-S20 , 2003 .View at Google Scholar \u00b7 View at Scopus . A. N. Paisley , K. Hayden , A. Ellis , J. Anderson , G. Wieringa , and P. J. Trainer , \" Pegvisomant interference in GH assays results in underestimation og GH levels , \" European Journal of Endocrinology , vol .", "label": "", "metadata": {}, "score": "63.344795"}
{"text": "The addition of dopamine agonists resulted in a further decline of the GH and IGF-1 concentration not achieved by SRL treatment alone [ 158 ] .", "label": "", "metadata": {}, "score": "63.39655"}
{"text": "259 - 266 , 1998 .View at Google Scholar .R. D. Murray , K. Kim , S. G. Ren , M. Chelly , Y. Umehara , and S. Melmed , \" Central and peripheral actions of somatostatin on the growth hormone - IGF - I axis , \" Journal of Clinical Investigation , vol .", "label": "", "metadata": {}, "score": "63.401344"}
{"text": "141 - 147 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .F. Gatto , F. Barbieri , M. Gatti , et al . , \" Balance between somatostatin and D2 receptor expression drives TSH - secreting adenoma response to somatostatin analogues and dopastatins , \" Clinical Endocrinology , vol .", "label": "", "metadata": {}, "score": "63.40834"}
{"text": "16 , pp .1171 - 1177 , 2000 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . E. Ghigo , B. M. K. Biller , A. Colao et al . , \" Comparison of pegvisomant and long - acting octreotide in patients with acromegaly na\u00efve to radiation and medical therapy , \" Journal of Endocrinological Investigation , vol .", "label": "", "metadata": {}, "score": "63.446983"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. Lavecchia , S. Cosconati , and E. Novellino , \" Architecture of the human urotensin II receptor : comparison of the binding domains of peptide and non - peptide urotensin II agonists , \" Journal of Medicinal Chemistry , vol .", "label": "", "metadata": {}, "score": "63.484283"}
{"text": "In other lesions ( pheochromocytomas and medullary thyroid carcinomas ) a definite usefulness of radiolabeled SST analogs is still not proven , mainly due to their limited detection rate [ 102 , 103 ] .", "label": "", "metadata": {}, "score": "63.50109"}
{"text": "20 , pp .4391 - 4394 , 2002 .View at Publisher \u00b7 View at Google Scholar .S. Foister , L. L. Taylor , J. J. Feng et al . , \" Design and synthesis of potent cystine - free cyclic hexapeptide agonists at the human urotensin receptor , \" Organic Letters , vol . 8 , no . 9 , pp .", "label": "", "metadata": {}, "score": "63.510727"}
{"text": "4 , pp .446 - 450 , 1993 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . H. J. Quabbe and U. Plockinger , \" Dose - response study and long term effect of the somatostatin analog octreotide in patients with therapy - resistant acromegaly , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "63.564457"}
{"text": "Conclusions .SST receptors represent a potential relevant drug target for the treatment of several tumor histotypes .In fact , starting from the identification of the expression , and in some cases overexpression , of these receptors in several human tumors , several clinical trials were performed to assess the possible clinical efficacy of SST agonists in almost all tumor types .", "label": "", "metadata": {}, "score": "63.582653"}
{"text": "However , their rate of growth can be fast and they can be resistant to standard medical , surgical and radiation treatment [ 49 ] , especially ACTH macroadenomas .", "label": "", "metadata": {}, "score": "63.60696"}
{"text": "In three of these patients preceding long - term tumour growth could be demonstrated , irrespective of the therapy applied .In two patients tumour growth was most probably due to the reexpansion of the adenoma after withdrawal of SRL therapy before initiating Pegvisomant .", "label": "", "metadata": {}, "score": "63.60797"}
{"text": "The effect was independent of the cosecretion of PRL [ 159 ] .With IGF-1 concentration as an endpoint , normalisation was observed in 19 patients ( 56 % ) with already relatively low IGF - I concentration on Octreotide LAR monotherapy .", "label": "", "metadata": {}, "score": "63.64538"}
{"text": "109 , pp .1425 - 1430 , 2011 .View at Google Scholar .F. Barbieri and T. Florio , \" Characterization of the differential efficiacy of somatostatin receptor agonists in the inhibition of the growth of experimental gliomas and identification of the intracellular mechanisms involved , \" European Journal of Clinical and Medical Oncology , vol .", "label": "", "metadata": {}, "score": "63.762157"}
{"text": "9180 - 9185 , 2000 .View at Google Scholar \u00b7 View at Scopus .N. Douziech , E. Calvo , Z. Coulombe et al . , \" Inhibitory and stimulatory effects of somatostatin on two human pancreatic cancer cell lines : a primary role for tyrosine phosphatase SHP-1 , \" Endocrinology , vol .", "label": "", "metadata": {}, "score": "63.787548"}
{"text": "However because of the high price of all SRL , dopamine agonists should be the initial therapeutic principle in patients with low basal GH / IGF-1 concentrations .", "label": "", "metadata": {}, "score": "63.805115"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . H. Aissaoui , C. Binkert , M. Clozel et al . , \" Preparation of 1-(piperazinylalkyl)-3-quinolinylurea derivatives as urotensin II antagonists , \" Actelion Pharmaceuticals Ltd. , PCT International Application no .", "label": "", "metadata": {}, "score": "63.823242"}
{"text": "41 , pp .39356 - 39371 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .P. Pag\u00e8s , N. Benali , N. Saint - Laurent et al . , \" sst 2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1 ) .", "label": "", "metadata": {}, "score": "63.824688"}
{"text": "View at Google Scholar .S. A. Douglas and E. H. Ohlstein , \" Human urotensin - II , the most potent mammalian vasoconstrictor identified To date , as a therapeutic target for the management of cardiovascular disease , \" Trends in Cardiovascular Medicine , vol .", "label": "", "metadata": {}, "score": "63.83258"}
{"text": "These results were possibly due to insufficient dose titration of Pegvisomant [ 180 ] .Combination Therapy of Pegvisomant and SRL In consideration of the high costs of Pegvisomant therapy Feenstra et al . investigated the effect of monthly Octreotide LAR treatment in combination with Pegvisomant injected once weekly with a dose of up to 80 mg / week [ 178 ] .", "label": "", "metadata": {}, "score": "63.88834"}
{"text": "On the contrary , sst3 and sst4 are poorly expressed .In intestinal cells , sst5 controls the release of glucagon - like peptide-1 ( GLP-1 ) .", "label": "", "metadata": {}, "score": "63.945793"}
{"text": "6B , pp .2687 - 2690 , 1995 .View at Google Scholar \u00b7 View at Scopus .J. N. Ingle , V. J. Suman , C. G. Kardinal , et al . , \" A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma , \" Cancer , vol . 85 , no .", "label": "", "metadata": {}, "score": "63.94677"}
{"text": "3090 - 3098 , 2003 .View at Publisher \u00b7 View at Google Scholar . A. Colao , D. Ferone , P. Marzullo et al . , \" Long - term effects of depot long - acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "63.973877"}
{"text": "Patient exhibiting one or more contraindications to anesthesia and surgery .Patient with a contra - indication to pasireotide .Patient with a congestive cardiac insufficiency ( NYHA category III or IV ) , an instable angina pectoris , sustained ventricular tachycardia or ventricular fibrillation episodes or history of myocardial infarction during the last 6 months .", "label": "", "metadata": {}, "score": "63.98728"}
{"text": "286 , no . 1 - 2 , pp . 1 - 2 , 2008 .View at Google Scholar \u00b7 View at Scopus .J. Guillermet - Guibert , H. Lahlou , P. Cordelier , C. Bousquet , S. Pyronnet , and C. Susini , \" Physiology of somatostatin receptors , \" Journal of Endocrinological Investigation , vol .", "label": "", "metadata": {}, "score": "63.9954"}
{"text": "Truncation studies are of prime importance for the detection of the minimal sequence of peptide required to retain the biological activity .The shortest and fully potent sequence of U - II was individuated in the octapeptide . nM , at human and rat UT receptor , respectively .", "label": "", "metadata": {}, "score": "64.02726"}
{"text": "sst1/sst5 , sst2/sst3 , and sst4/sst5 heterodimerizations have been described , although these studies mainly refer to heterologous cell models ( CHO - K1 or HEK-293 ) transfected with specific SST receptor subtypes [ 49 , 51 ] .", "label": "", "metadata": {}, "score": "64.03218"}
{"text": "4 - 6 , pp .217 - 235 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. Szolcsanyi , K. B\u00f6lcskei , A. Szab\u00f3 et al . , \" Analgesic effect of TT-232 , a heptapeptide somatostatin analogue , in acute pain models of the rat and the mouse and in streptozotocin - induced diabetic mechanical allodynia , \" European Journal of Pharmacology , vol .", "label": "", "metadata": {}, "score": "64.07338"}
{"text": "However , it has been demonstrated that this exchange does not affect affinity but removes two sites for polyethylene glycol ( PEG ) binding , which are within the native binding site [ 166 , 167 ] .", "label": "", "metadata": {}, "score": "64.14713"}
{"text": "Based on an HTS protocol involving hU- II - mediated calcium mobilization in hUT - expressing HEK293 cells , the lead compound SB-436811 was identified for its moderate potency ( .", "label": "", "metadata": {}, "score": "64.2257"}
{"text": "J. Jin , D. Dhanak , S. D. Knight et al . , \" Aminoalkoxybenzyl pyrrolidines as novel human urotensin - II receptor antagonists , \" Bioorganic and Medicinal Chemistry Letters , vol .", "label": "", "metadata": {}, "score": "64.23007"}
{"text": "10 , pp .914 - 924 , 2012 .View at Google Scholar . A. Saveanu , G. Gunz , S. Guillen , H. Dufour , M. D. Culler , and P. Jaquet , \" Somatostatin and dopamine - somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas , \" Neuroendocrinology , vol .", "label": "", "metadata": {}, "score": "64.27294"}
{"text": "To date , a subset of PTPs , namely , the cytosolic SHP1 , SHP2 , and the transmembrane PTP \u03b7 , are considered the main effectors of the antiproliferative activity of SST .", "label": "", "metadata": {}, "score": "64.2789"}
{"text": "( subtypes 2 and 5 ) and the dopamine D2 receptor [ 144 - 146 ] .A substantial number of somatotroph adenomas express both sst and D2 receptors .", "label": "", "metadata": {}, "score": "64.33801"}
{"text": "In the structure - function study performed by Kinney et al . in 2002 [ 32 ] , an alanine scan of truncated goby U - II demonstrated that the replacement of Trp , Lys , and Tyr is crucial for the maintenance of biological activity .", "label": "", "metadata": {}, "score": "64.358604"}
{"text": "On the other hand Abe and Luedecke saw an improvement especially in invasive adenomas [ 124 ] .However , others could not confirm any advantage of presurgical SRL therapy , neither on short- or long - term postoperative comparisons [ 125 - 127 ] .", "label": "", "metadata": {}, "score": "64.36013"}
{"text": "The efficacy of the depot preparation should not be evaluated before steady - state drug concentrations have been achieved , that is , after 3 injections for Octreotide LAR .", "label": "", "metadata": {}, "score": "64.360504"}
{"text": "229 - 246 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . E. Ferrante , C. Pellegrini , S. Bondioni et al . , \" Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2 , \" Endocrine - Related Cancer , vol .", "label": "", "metadata": {}, "score": "64.38159"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .F. Barbieri , A. Pattarozzi , M. Gatti et al . , \" Differential efficacy of SSTR1 , -2 , and -5 agonists in the inhibition of C6 glioma growth in nude mice , \" American Journal of Physiology , vol .", "label": "", "metadata": {}, "score": "64.39582"}
{"text": "There is abundant evidence that retinoids , via various signaling pathways , inhibit cell - cycle progression in a variety of human cancer cells by directly or indirectly modulating cyclins , CDKs , and cell - cycle inhibitors .", "label": "", "metadata": {}, "score": "64.40878"}
{"text": "This compound is selective to activate the UT receptor , although the other receptors included in the multiplex screening assay belong to somatostatin and opioid receptor classes that are the closest to UT receptor for genetic sequence homology .", "label": "", "metadata": {}, "score": "64.46429"}
{"text": "10 , pp .1837 - 1844 , 2005 .View at Publisher \u00b7 View at Google Scholar .S. J. C. M. M. Neggers , M. O. Van Aken , W. W. De Herder et al . , \" Quality of life in acromegalic patients during long - term somatostatin analog treatment with and without pegvisomant , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "64.55362"}
{"text": "For a detailed discussion of antiangiogenetic effects of SRL see Dasgupta [ 69 ] .Somatostatin Receptor Ligands Octreotide and Lanreotide The clinical available somatostatin analogues Octreotide and Lanreotide demonstrate a high affinity for sst2 and a moderate affinity for sst5 .", "label": "", "metadata": {}, "score": "64.66248"}
{"text": "5 , pp .622 - 627 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. V. Schally , J. B. Engel , G. Emons , N. L. Block , and J. Pinski , \" Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors , \" Current Drug Delivery , vol . 8 , no . 1 , pp .", "label": "", "metadata": {}, "score": "64.69732"}
{"text": "4 , pp .477 - 478 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. Selvarajah , J. Webster , R. Ross , and J. Newell - Price , \" Effectiveness of adding dopamine agonist therapy to long - acting somatostatin analogues in the management of acromegaly , \" European Journal of Endocrinology , vol .", "label": "", "metadata": {}, "score": "64.72211"}
{"text": "4142 - 4146 , 2002 .View at Publisher \u00b7 View at Google Scholar .C. B. Newman , S. Melmed , A. George et al . , \" Octreotide as primary therapy for acromegaly , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "64.80232"}
{"text": "Among the most potent compounds , Camarda et al . in 2002 [ 38 ] identified the hU- II derivative [ Orn 8 ] U - II , that was characterized in vitro as a novel peptide ligand for the UT receptor .", "label": "", "metadata": {}, "score": "64.814545"}
{"text": "To investigate the improvement of the efficacy it seems that the introduction of electron - donating groups contributed positively .Furthermore , among benzamide series more lipophilic compounds were approximately 1 order of magnitude more potent than the other amides .", "label": "", "metadata": {}, "score": "64.81661"}
{"text": "4 , pp .430 - 439 , 1995 .View at Google Scholar .U.Plockinger , D. Dienemann , and H. J. Quabbe , \" Gastrointestinal side - effects of octreotide during long term treatment of acromegaly , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "64.84631"}
{"text": "426 - 436 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .L. Canobbio , D. Cannata , L. Miglietta , and F. Boccardo , \" Somatuline ( BIM 23014 ) and tamoxifen treatment of postmenopausal breast cancer patients : clinical activity and effect on insulin - like growth factor - I ( IGF - I ) levels , \" Anticancer Research , vol .", "label": "", "metadata": {}, "score": "64.850334"}
{"text": "K. Szepeshazi , A. V. Schally , A. Nagy , B. W. Wagner , A. M. Bajo , and G. Halmos , \" Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas , \" Cancer , vol .", "label": "", "metadata": {}, "score": "64.85952"}
{"text": "2259- 2264 , 2002 .View at Publisher \u00b7 View at Google Scholar . D. McMaster , Y. Kobayashi , J. Rivier , and K. Lederis , \" Characterization of the biologically and antigenically important regions of urotensin II , \" Proceedings of the Western Pharmacology Society , vol .", "label": "", "metadata": {}, "score": "64.89021"}
{"text": "6 , pp .899 - 906 , 2006 .View at Publisher \u00b7 View at Google Scholar .R. A. Kristof , B. Stoffel - Wagner , D. Klingm\u00fcller , and J. Schramm , \" Does octreotide treatment improve the surgical results of macro - adenomas in acromegaly ?", "label": "", "metadata": {}, "score": "64.89404"}
{"text": "In LNCaP cells , an interaction between SST receptors and D2R was also documented .These cells constitutively express sst1 , 2 and 5 and D2R , and their activation by receptor selective SST agonists or SST / dopamine chimeras , that synergistically activates sst2/D2R dimers , significantly inhibited cell proliferation [ 55 ] .", "label": "", "metadata": {}, "score": "64.89816"}
{"text": "11 , pp .7862- 7869 , 2000 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. Baragli , H. Alturaihi , H. L. Watt , A. Abdallah , and U. Kumar , \" Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2 .", "label": "", "metadata": {}, "score": "64.94163"}
{"text": "However , highly sensitive assays demonstrated active acromegaly with a GH nadir during OGTT well below 1 \u03bc g / L. Freda et al . reported that five of fifteen newly diagnosed acromegalic patients reached a GH nadir during OGTT below 1 \u03bc g / L , even as low as 0.42 \u03bc g / L. The IGF-1 concentration was elevated in all patients , but signs and symptoms of acromegaly were subtle in three patients .", "label": "", "metadata": {}, "score": "64.956696"}
{"text": "13 - 16 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. V. Schally , J. B. Engel , G. Emons , N. L. Block , and J. Pinski , \" Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors , \" Current Drug Delivery , vol . 8 , no . 1 , pp .", "label": "", "metadata": {}, "score": "65.025566"}
{"text": "Antibody development against Pegvisomant has been observed , their clinical relevance is unknown .Overall Conclusions .Therapeutic interventions should be orientated on those biochemical indices that indicate a safe GH / IGF-1 concentration , as data on complete remission or even cure of acromegaly are still highly controversial due to problems of assay technologies and standardisation .", "label": "", "metadata": {}, "score": "65.030304"}
{"text": "- II but not URP - induced vasoconstriction in a rat aorta assay .Despite the structural homology between U - II and URP and their concurrent expression in several human tissues , recent studies have reported different actions for these two peptides such as cell proliferation [ 49 ] and distinctive myocardial contractile activities [ 50 ] .", "label": "", "metadata": {}, "score": "65.05083"}
{"text": "[ 61 ] described a case of an aggressive 3 cm corticotroph adenoma refractory to multiple surgery and radiotherapy which showed a 60 % regression in size after TMZ administration .", "label": "", "metadata": {}, "score": "65.06543"}
{"text": "4 , pp .477 - 483 , 2001 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. R. Grunstein , K. K. Y. Ho , and C. E. Sullivan , \" Effect of octreotide , a somatostatin analog , on sleep apnea in patients with acromegaly , \" Annals of Internal Medicine , vol .", "label": "", "metadata": {}, "score": "65.06882"}
{"text": "147 , no .5 , pp .485 - 493 , 2005 .View at Publisher \u00b7 View at Google Scholar .M. Losa , P. Mortini , L. Urbaz , P. Ribotto , T. Castrignan\u00f2 , and M. Giovanelli , \" Presurgical treatment with somatostatin analogs in patients with acromegaly : effects on the remission and complication rates , \" Journal of Neurosurgery , vol .", "label": "", "metadata": {}, "score": "65.12668"}
{"text": "222 - 229 , 2010 .View at Publisher \u00b7 View at Google Scholar .R. Pivonello , M. Galderisi , R. S. Auriemma et al . , \" Treatment with growth hormone receptor antagonist in acromegaly : effect on cardiac structure and performance , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "65.18324"}
{"text": "9 - 22 , 2002 .View at Google Scholar \u00b7 View at Scopus .M. Orbuch , J. E. Taylor , D. H. Coy et al . , \" Discovery of a novel class of neuromedin B receptor antagonists , substituted somatostatin analogues , \" Molecular Pharmacology , vol .", "label": "", "metadata": {}, "score": "65.216736"}
{"text": "Dimerization was shown to be either constitutive or ligand - dependent and , despite high structural homology , SST receptor subtypes show marked dimerization heterogeneity and differences between different species .", "label": "", "metadata": {}, "score": "65.22293"}
{"text": "11 , pp .1842 - 1850 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .B. Zhao , P. Yang , J. Yang , et al . , \" A randomized trial of somatostatin to regulate the VEGFs / VEGFRs in patients with gastric cancer , \" Hepatogastroenterology , vol .", "label": "", "metadata": {}, "score": "65.2424"}
{"text": "19 , pp .6000 - 6011 , 1996 .View at Google Scholar \u00b7 View at Scopus . H. J. Kreienkamp , H. H. H\u00f6nck , and D. Richter , \" Coupling of rat somatostatin receptor subtypes to a G - protein gated inwardly rectifying potassium channel ( GIRK1 ) , \" FEBS Letters , vol .", "label": "", "metadata": {}, "score": "65.24948"}
{"text": "- II induces contraction mediated by two distinct tonic and phasic components .However , its vasoconstrictor activity is well observed in primate arteries , in which it causes a concentration - dependent contraction of isolated arterial rings with an EC 50 value less than 1 nM , meaning a 10-fold more potency than endothelin-1 .", "label": "", "metadata": {}, "score": "65.2579"}
{"text": "33 - 38 , 2011 .View at Publisher \u00b7 View at Google Scholar .I. Bernabeu , C. Alvarez - Escol\u00e1 , C. Quinteiro et al . , \" The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "65.27373"}
{"text": "Patients who did not meet these criteria were unblinded and the dose was increased by 0.3 mg b.i.d .After the initial six months in the study , patients entered an additional 6-month open - label treatment period .", "label": "", "metadata": {}, "score": "65.2793"}
{"text": "299 - 304 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .S. I. Helle , W. Mietlowski , J. P. Guastalla et al . , \" Effects of tamoxifen and octreotide LAR on the IGF - system compared with tamoxifen monotherapy , \" European Journal of Cancer , vol .", "label": "", "metadata": {}, "score": "65.3035"}
{"text": "4 , pp .395 - 405 , 1987 .View at Google Scholar . D. Sautner , W. Saeger , G. Tallen , D. K. Ludecke , and W. Rehpenning , \" Effects of octreotide on morphology of pituitary adenomas in acromegaly , \" Pathology Research and Practice , vol .", "label": "", "metadata": {}, "score": "65.31282"}
{"text": "5 , pp .E1078-E1088 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. Cervia , D. Langenegger , E. Schuepbach et al . , \" Binding and functional properties of the novel somatostatin analogue KE 108 at native mouse somatostatin receptors , \" Neuropharmacology , vol .", "label": "", "metadata": {}, "score": "65.32041"}
{"text": "11 , pp .2919 - 2926 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .S. A. Douglas , D. J. Behm , N. V. Aiyar et al . , \" Nonpeptidic urotensin - II receptor antagonists I : in vitro pharmacological characterization of SB-706375 , \" British Journal of Pharmacology , vol .", "label": "", "metadata": {}, "score": "65.37084"}
{"text": "2957 - 2968 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. Hradec , J. Kral , T. Janota et al . , \" Regression of acromegalic left ventricular hypertrophy after lanreotide ( a slow - release somatostatin analog ) , \" American Journal of Cardiology , vol .", "label": "", "metadata": {}, "score": "65.39957"}
{"text": "To obtain optimal efficacy , RS should thus be reserved to small well - defined lesions .The management of aggressive adenomas invading adjacent structures is a real challenge , as they rarely respond to any treatment .", "label": "", "metadata": {}, "score": "65.44465"}
{"text": "6 , pp .2779 - 2786 , 2001 .View at Publisher \u00b7 View at Google Scholar . A. L. Barkan , R. V. Lloyd , W. F. Chandler et al . , \" Preoperative treatment of acromegaly with long - acting somatostatin analog SMS 201 - 995 : shrinkage of invasive pituitary macroadenomas and improved surgical remission rate , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "65.46197"}
{"text": "264 - 274 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .S. Arena , A. Pattarozzi , A. Massa et al . , \" An intracellular multi - effector complex mediates somatostatin receptor 1 activation of phospho - tyrosine phosphatase \u03b7 , \" Molecular Endocrinology , vol .", "label": "", "metadata": {}, "score": "65.518425"}
{"text": "105 - 114 , 1999 .View at Google Scholar \u00b7 View at Scopus .J. Schopohl , C. J. Strasburger , D. Caird et al . , \" Efficacy and acceptability of lanreotide autogel 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR , \" Experimental and Clinical Endocrinology and Diabetes , vol .", "label": "", "metadata": {}, "score": "65.56429"}
{"text": "170 - 171 , 2002 .View at Google Scholar .V. Camarda , W. Song , E. Marzola et al . , \" Urantide mimics urotensin - II induced calcium release in cells expressing recombinant UT receptors , \" European Journal of Pharmacology , vol .", "label": "", "metadata": {}, "score": "65.64098"}
{"text": "In GH secreting adenomas , octreotide and lanreotide , mainly acting on sst2 and slightly less effectively on sst5 , inhibit GH secretion [ 153 ] , normalize IGF-1 serum levels , and cause tumor size reduction [ 154 ] .", "label": "", "metadata": {}, "score": "65.64251"}
{"text": "390 - 402 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. Florio , F. Barbieri , R. Spaziante et al . , \" Efficacy of a dopamine - somatostatin chimeric molecule , BIM-23A760 , in the control of cell growth from primary cultures of human non - functioning pituitary adenomas : a multi - center study , \" Endocrine - Related Cancer , vol .", "label": "", "metadata": {}, "score": "65.680534"}
{"text": "[0017 ]However , octreotide is a relatively large lipophilic molecule ( consisting of 8 amino acids ) which preferentially binds to SSTR2 and , only to a lesser extent , to SSTR3 and SSTR5 having a half - life of only 1.5 hours .", "label": "", "metadata": {}, "score": "65.77167"}
{"text": "Jouanneau et al .[ 65 ] hypothesized its use in pituitary aggressive adenomas and carcinomas .The authors described the effects of a combination therapy with everolimus ( 5 mg / day ) and octreotide ( 30 mg / months ) and studied mTOR expression in 1 pituitary carcinoma against 17 ACTH adenomas .", "label": "", "metadata": {}, "score": "65.77665"}
{"text": "18 , pp .2990 - 3000 , 2001 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .F. Gatto and L. J. Hofland , \" The role of somatostatin and dopamine D2 receptors in endocrine tumors , \" Endocrine - Related Cancer , vol .", "label": "", "metadata": {}, "score": "65.79236"}
{"text": "1401 - 1410 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .G. Palmieri , L. Montella , C. Aiello et al . , \" Somatostatin analogues , a series of tissue transglutaminase inducers , as a new tool for therapy of mesenchimal tumors of the gastrointestinal tract , \" Amino Acids , vol .", "label": "", "metadata": {}, "score": "65.80881"}
{"text": "528 - 537 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. Colao , R. S. Auriemma , S. Savastano et al . , \" Glucose tolerance and somatostatin analog treatment in acromegaly : a 12-month study , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "65.85536"}
{"text": "Treatment related increased incidence of skeletal malformations were observed at 0.05 mg / kg / day , exposures less than the maximum therapeutic exposure based on AUC comparisons across species .", "label": "", "metadata": {}, "score": "65.938934"}
{"text": "103 - 109 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .L. Poitout , P. Roubert , M. O. Contour - Galc\u00e9ra et al . , \" Identification of potent non - peptide somatostatin antagonists with sst 3 selectivity , \" Journal of Medicinal Chemistry , vol .", "label": "", "metadata": {}, "score": "65.945175"}
{"text": "Probably due to the longer washout phase of depot preparations no such complications have been reported with the slow release formulations .SRL reduce gastrin secretion .", "label": "", "metadata": {}, "score": "66.02704"}
{"text": "Manufactured by : Novartis Pharma Stein AG Stein , Switzerland .Distributed by : Novartis Pharmaceuticals Corporation East Hanover , NJ 07936 [ Show abstract ] [ Hide abstract ] ABSTRACT : It has been shown that some primary human tumours and their metastases , including prostate and breast tumours , overexpress gastrin - releasing peptide ( GRP ) receptors .", "label": "", "metadata": {}, "score": "66.04825"}
{"text": "209 - 215 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .B. Gatta , D. H. Hau , B. Catargi , P. Roger , and A. Tabarin , \" Re - evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patients , \" Clinical Endocrinology , vol .", "label": "", "metadata": {}, "score": "66.087906"}
{"text": "2459 - 2463 , 2009 .View at Publisher \u00b7 View at Google Scholar .C. Jimenez , M. Ayala - Ramirez , J. Liu , R. Nunez , and R. F. Gagel , \" Inhibition of growth hormone receptor activation by pegvisomant may increase bone density in acromegaly , \" Hormone and Metabolic Research , vol .", "label": "", "metadata": {}, "score": "66.08923"}
{"text": "4 , pp .1942 - 1947 , 1992 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .G. Schettini , T. Florio , O. Meucci et al . , \" Somatostatin inhibition of adenylate cyclase activity in different brain areas , \" Brain Research , vol .", "label": "", "metadata": {}, "score": "66.106094"}
{"text": "Moreover , NMR studies performed by Flohr et al . in 2002 [ 24 ] revealed that the distances between the pharmacophoric points are key elements in the development of SAR .", "label": "", "metadata": {}, "score": "66.11163"}
{"text": "- II - induced intracellular calcium mobilization in HEK293 cell lines expressing either the human or rat UT receptor was evaluated by generating hU - II concentration - response curves .", "label": "", "metadata": {}, "score": "66.13684"}
{"text": "These more flexible compounds led to molecules most retained in activity and efficacy compared to AC-7954 except for ethers and sulfonamide probably due to the absence of conformational effects induced by the pharmacophoric carbonyl group .", "label": "", "metadata": {}, "score": "66.14808"}
{"text": "21 - 30 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. Colao , D. Ferone , P. Marzullo et al . , \" Effect of different dopaminergic agents in the treatment of acromegaly , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "66.150696"}
{"text": "11 , pp .4519 - 4524 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . U.Pl\u00f6ckinger , S. Albrecht , C. Mawrin et al . , \" Selective loss of somatostatin receptor 2 in octreotide - resistant growth hormone - secreting adenomas , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "66.158585"}
{"text": "studied the acute effect of the combination of Octreotide s.c . and Cabergoline in 21 patients with acromegaly .In 14 patients with insufficient response to either drug , combination therapy was initiated ( Octreotide 100 \u03bc g s.c . plus Cabergoline 0.5 mg p.o .", "label": "", "metadata": {}, "score": "66.17587"}
{"text": "Immunohistochemically SRL treatment induced a lower expression of Ki-67 staining , an indicator of dividing cells , compared to untreated somatotropinomas .The lower Ki-67 index indicates a suppressive effect of SRL on cell cycling [ 113 ] .", "label": "", "metadata": {}, "score": "66.215706"}
{"text": "727 - 737 , 2012 .View at Google Scholar .N. Dizeyi , L. Konrad , A. Bjartell et al . , \" Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines , \" Urologic Oncology , vol .", "label": "", "metadata": {}, "score": "66.2437"}
{"text": "Other classes of compound that turned out from this screening were represented by piperazino - phtalimide and piperazino - isoindolinone derivatives , very different structural type of UT receptor antagonists from those previously reported in literature .", "label": "", "metadata": {}, "score": "66.28267"}
{"text": "Table 1 : Binding affinities of native SST and synthetic agonists for SST receptor subtypes .This has relevant implications in SST - based diagnostic imaging and pharmacological approaches .", "label": "", "metadata": {}, "score": "66.33954"}
{"text": "17 , no .23 , pp .6489 - 6492 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . E. C. Lawson , D. K. Luci , S. Ghosh et al . , \" Nonpeptide urotensin - II receptor antagonists : a new ligand class based on piperazino - phthalimide and piperazino - isoindolinone subunits , \" Journal of Medicinal Chemistry , vol .", "label": "", "metadata": {}, "score": "66.37221"}
{"text": "Because of these reported advantages over the analogues currently used for somatostatin receptor - mediated radiotherapy , we decided to compare [ 177Lu - DOTA0,Tyr3]octreotate ( 177Lu - octreotate ) with [ 111In - DTPA0]octreotide ( 111In - octreotide ) in six patients with somatostatin receptor - positive tumours .", "label": "", "metadata": {}, "score": "66.38384"}
{"text": "4 , pp .1574 - 1584 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. Florio , S. Arena , A. Pattarozzi et al . , \" Basic fibroblast growth factor activates endothelial nitric - oxide synthase in CHO - K1 cells via the activation of ceramide synthesis , \" Molecular Pharmacology , vol .", "label": "", "metadata": {}, "score": "66.38841"}
{"text": "mTOR Inhibitors .Mammalian target of rapamycin ( mTOR ) functions as a central element in a signaling pathway involved in the control of cell growth and proliferation .", "label": "", "metadata": {}, "score": "66.41336"}
{"text": "10 , pp .2278 - 2292 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Grant , R. C. Patel , and U. Kumar , \" The role of subtype - specific ligand binding and the C - tail domain in dimer formation of human somatostatin receptors , \" The Journal of Biological Chemistry , vol .", "label": "", "metadata": {}, "score": "66.42894"}
{"text": "View at Google Scholar \u00b7 View at Scopus . U.Kumar , S. I. Grigorakis , H. L. Watt et al . , \" Somatostatin receptors in primary human breast cancer : quantitative analysis of mRNA for subtypes 1 - 5 and correlation with receptor protein expression and tumor pathology , \" Breast Cancer Research and Treatment , vol .", "label": "", "metadata": {}, "score": "66.44647"}
{"text": "The analogues could be labelled with ( 111)In to a high specific activity .The ( 111)In - labelled compounds were found to be very stable in serum .", "label": "", "metadata": {}, "score": "66.56535"}
{"text": "- II .First structural studies performed on U - II by nuclear magnetic resonance ( NMR ) spectroscopy [ 23 - 25 ] have revealed that the peptide adopted a preferential conformation both in DMSO and water solution , which did not show any classical secondary structures .", "label": "", "metadata": {}, "score": "66.57907"}
{"text": "173 - 178 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .G. F. Pecori , C. Scaroni , E. Arvat et al . , \" Effect of protracted treatment with rosiglitazone , a PPAR \u03b3 agonist , in patients with Cushing 's disease , \" Clinical Endocrinology , vol .", "label": "", "metadata": {}, "score": "66.58"}
{"text": "SST ability of inhibiting tumor growth and metastatic spread involves SST receptor activation located on both cancer and microenvironment cells , particularly endothelial cells of tumor vessels responsible of the neovascularization of the tumor .", "label": "", "metadata": {}, "score": "66.58246"}
{"text": "10 , pp .914 - 924 , 2012 .View at Publisher \u00b7 View at Google Scholar .M. Losa , E. Mazza , M. R. Terreni et al . , \" Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas : experience in six cases , \" European Journal of Endocrinology , vol .", "label": "", "metadata": {}, "score": "66.58531"}
{"text": "65 - 71 , 1989 .View at Google Scholar \u00b7 View at Scopus .G. Schettini , T. Florio , O. Meucci , E. Landolfi , G. Lombardi , and A. Marino , \" Somatostatin inhibition of anterior pituitary adenylate cyclase activity : different sensitivity between male and female rats , \" Brain Research , vol .", "label": "", "metadata": {}, "score": "66.59781"}
{"text": "425 , no . 1 , pp .137 - 140 , 1998 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . H. Yoshitomi , Y. Fujii , M. Miyazaki , N. Nakajima , N. Inagaki , and S. Seino , \" Involvement of MAP kinase and c - fos signaling in the inhibition of cell growth by somatostatin , \" American Journal of Physiology , vol .", "label": "", "metadata": {}, "score": "66.63707"}
{"text": "Octreotide reduced gastric carcinoma cell line proliferation in vitro interfering with Akt and telomerase activity [ 210 ] , an effect that was dependent on the expression of sst3 .", "label": "", "metadata": {}, "score": "66.63985"}
{"text": "Figure 1 : A comparison of urotensin - II ( U - II ) isopeptides sequences isolated from different species of vertebrates .The length of urotensin - II peptides is variable across species and it ranged from 17 amino acid residues in mice to 11 in humans , depending on the proteolytic cleavages that occur in precursors .", "label": "", "metadata": {}, "score": "66.673"}
{"text": ", also known as UFP-803 , closely related to the urantide sequence [ 45 ] .In the present molecule , the residual agonist activity is less than that of urantide .", "label": "", "metadata": {}, "score": "66.67488"}
{"text": "59 - 63 , 1994 .View at Google Scholar \u00b7 View at Scopus .P. Jaquet , \" CV 205 - 502 : a more effective dopamine agonist m the treatment of acromegaly ? \" European Journal of Endocrinology , vol .", "label": "", "metadata": {}, "score": "66.75459"}
{"text": "6 , pp .383 - 385 , 1999 .View at Google Scholar \u00b7 View at Scopus .S. A. Douglas and E. H. Ohlstein , \" Human urotensin - II , the most potent mammalian vasoconstrictor identified to date , as a therapeutic target for the management of cardiovascular disease , \" Trends in Cardiovascular Medicine , vol .", "label": "", "metadata": {}, "score": "66.77588"}
{"text": "155 - 165 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. Kubota , K. Koshizuka , E. A. Williamson et al . , \" Ligand for peroxisome proliferator - activated receptor \u03b3 ( Troglitazone ) has potent antitumor effect against human prostate cancer both in vitro and in vivo , \" Cancer Research , vol .", "label": "", "metadata": {}, "score": "66.777435"}
{"text": "An additional study showed a significant reduction of the diastolic blood pressure but no effect on systolic blood pressure in four hypertensive patients on antihypertensive medication during Pegvisomant therapy [ 183 ] .", "label": "", "metadata": {}, "score": "66.81323"}
{"text": "20 , pp .21374 - 21382 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. C. Reubi , B. Waser , R. Cescato , B. Gloor , C. Stettler , and E. Christ , \" Internalized somatostatin receptor subtype 2 in neuroendocrine tumors of octreotide - treated patients , \" The Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "66.81793"}
{"text": "The side chain can also contain an aromatic ring substituted with polar groups such as OH and NO 2 , which is of great interest in the development of antagonists based on the previously identified somatostatin antagonist octapeptides .", "label": "", "metadata": {}, "score": "66.84546"}
{"text": "82 - 92 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .P. Mattar , M. R. Alves Martins , and J. Abucham , \" Short - and long - term efficacy of combined cabergoline and octreotide treatment in controlling IGF - I levels in acromegaly , \" Neuroendocrinology , vol .", "label": "", "metadata": {}, "score": "66.874855"}
{"text": "12 , pp .5545 - 5552 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. Ferone , M. Arvigo , C. Semino et al . , \" Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin - dopamine molecules on cell proliferation , \" American Journal of Physiology , vol .", "label": "", "metadata": {}, "score": "66.890335"}
{"text": "In particular , penicillamine residue in replacement of Cys 5 resulted to be very useful in order to obtain a potent agonist , [ Pen 5 ] h .", "label": "", "metadata": {}, "score": "66.90805"}
{"text": "11 , pp .5194 - 5200 , 2001 .View at Publisher \u00b7 View at Google Scholar .K. Thapar , K. T. Kovacs , L. Stefaneanu et al . , \" Antiproliferative effect of the somatostatin analogue octreotide on growth hormone - producing pituitary tumors : results of a multicenter randomized trial , \" Mayo Clinic Proceedings , vol .", "label": "", "metadata": {}, "score": "66.92284"}
{"text": "Sst5 was seen in all , sst2 in 83 % to 85 % of the somatotropinomas .However , interindividual variability in the percentage of positive cells and the intensity of staining was pronounced [ 63 - 65 ] .", "label": "", "metadata": {}, "score": "66.958015"}
{"text": "However , kinetics studies showed that sst1 activation in CHO - K1 cells also caused a delayed and long - lasting PTP activity , besides SHP2 whose activation was , on the other hand , rapid and transient [ 28 ] .", "label": "", "metadata": {}, "score": "66.98449"}
{"text": "Yet most of the specific mechanisms inducing receptor dimerisation , as well as the molecular consequences of this process , are still not clear .Further investigations are necessary to predict the effects of these many interactions on the decline of the GH concentration and inhibition of tumour growth .", "label": "", "metadata": {}, "score": "67.00058"}
{"text": "It would , however , be compatible with the good response to DA treatment in monohormonal prolactinomas .Cabergoline Cabergoline is more effective than Bromocriptine , Methysergid , or Lisurid .", "label": "", "metadata": {}, "score": "67.03086"}
{"text": "1284 - 1292 , 1999 .View at Google Scholar .J. T. Dolan , D. M. Miltenburg , T. S. Granchi , C. C. Miller , and F. C. Brunicardi , \" Treatment of metastatic breast cancer with somatostatin analogues - a meta - analysis , \" Annals of Surgical Oncology , vol . 8 , no . 3 , pp .", "label": "", "metadata": {}, "score": "67.05134"}
{"text": "A common pattern of SST receptor binding ability is shared by these analogs : high affinity for sst2 and sst5 , medium / low affinity for sst3 , and lack of binding to sst1 and sst4 [ 1 ] .", "label": "", "metadata": {}, "score": "67.05149"}
{"text": "The antitumor effects described above are to be considered as examples and not exhaustive of all tumors expressing SST receptors in which preclinical and clinical investigations have been performed with SST analogs .", "label": "", "metadata": {}, "score": "67.08127"}
{"text": "4 , pp .841 - 850 , 1993 .View at Google Scholar \u00b7 View at Scopus .C. L. Herold , D. J. Behm , P. T. Buckley et al . , \" The neuromedin B receptor antagonist , BIM-23127 , is a potent antagonist at human and rat urotensin - II receptors , \" British Journal of Pharmacology , vol .", "label": "", "metadata": {}, "score": "67.1008"}
{"text": "It has been demonstrated that combined therapy with SRL is almost as effective as Pegvisomant monotherapy , but can be substantially more cost - effective .", "label": "", "metadata": {}, "score": "67.14805"}
{"text": "374 - 386 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. Wu , D. Gao , R. Biediger , J. Chen , and R. V. Market , \" Phenylenediamine urotensin - II receptor antagonists and CCR-9 antagonists , \" Encysive Pharmaceuticals , Inc. , US patent no .", "label": "", "metadata": {}, "score": "67.17949"}
{"text": "433 - 438 , 1986 .View at Google Scholar \u00b7 View at Scopus .S. Arena , F. Barbieri , S. Thellung et al . , \" Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity , \" Journal of Neuro - Oncology , vol .", "label": "", "metadata": {}, "score": "67.18311"}
{"text": "Bevan , in a careful review , found contradictory reports with respect to the positive correlation of pretreatment tumour volume and response to SRL .Tumour shrinkage does occur in both , macro- and microadenomas [ 117 ] .", "label": "", "metadata": {}, "score": "67.210144"}
{"text": "In a Belgian multicentre trial with 64 acromegalic patients receiving Cabergoline 1 - 1.75 mg / d once weekly , the IGF-1 concentration declined to below 300 \u03bc g / L in 8 of 16 ( 50 % ) patients with GH / PRL cosecretion and in 39 % of the whole group .", "label": "", "metadata": {}, "score": "67.266716"}
{"text": "502 - 511 , 2006 .View at Google Scholar \u00b7 View at Scopus .M. Ginj , H. Zhang , B. Waser et al . , \" Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors , \" Proceedings of the National Academy of Sciences of the United States of America , vol .", "label": "", "metadata": {}, "score": "67.28016"}
{"text": "91 - 98 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .L. Lattanzio , F. Tonissi , M. Monteverde , et al . , \" Differential molecular mechanism of docetaxel - octreotide combined treatment according to the docetaxel - resistance status in PC3 prostate cancer cells , \" Anticancer Drugs , vol .", "label": "", "metadata": {}, "score": "67.2849"}
{"text": "In particular , sst2 has been found to be uniquely upregulated during the angiogenic switch , from quiescent to proliferative endothelium [ 141 ] .Indeed , SST is a powerful inhibitor of neovascularization in several experimental models and , consequently , the inhibition of tumor angiogenesis is considered one of the mechanisms mediating SST antineoplastic effects .", "label": "", "metadata": {}, "score": "67.28998"}
{"text": "Radiotherapy studies were carried out using ( 153)Sm - CMDTPA - Tyr(3)-octreotate and CA20948 tumor bearing Lewis rats at 7 days post implant .Dose regimens consisting of single and multiple i.v .", "label": "", "metadata": {}, "score": "67.29495"}
{"text": "Therefore , first attempts came out from observations on somatostatin system , due to sharing sequence peculiarities between hU- II and somatostatin .Indeed , some somatostatin analogues such as PRL-2903 Table 1 , H-4Fpa - c[Cys - Pal - DTrp - Lys - Tle - Cys]-Nal - NH 2 , resulted in the ability to block the hU", "label": "", "metadata": {}, "score": "67.32112"}
{"text": "Moreover , the results for the nadir GH concentration during an OGGT and the IGF-1 concentration may be divergent or both tests may slightly fail to reach the predefined criteria .", "label": "", "metadata": {}, "score": "67.44426"}
{"text": "The therapeutic dose adjustments should be based on these parameters .Mifepristone is often associated with the development of endometrial hyperplasia , so regular vaginal ultrasound is recommended in long - term treatment .", "label": "", "metadata": {}, "score": "67.57004"}
{"text": "In contrast , in another study referred to by the authors , this dose , given as monotherapy , resulted in normalisation of the IGF-1 concentration only in about one third of the patients .", "label": "", "metadata": {}, "score": "67.583755"}
{"text": "12 , pp .3731 - 3739 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. H. Coy , W. J. Rossowski , B. L. Cheng , and J. E. Taylor , \" Structural requirements at the N - terminus of urotensin II octapeptides , \" Peptides , vol .", "label": "", "metadata": {}, "score": "67.632614"}
{"text": "313 - 322 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .O. Szokol\u00f3czi , R. Schwab , I. Pet\u00e1k , et al . , \" TT232 , a novel signal transduction inhibitory compound in the therapy of cancer and inflammatory diseases , \" Journal of Receptors and Signal Transduction , vol .", "label": "", "metadata": {}, "score": "67.64487"}
{"text": "Isidori et al .[ 3 ] proposed a classification based on the detection of the source of ectopic secretion .Occult EAS is one of the most intriguing challenges for the clinical endocrinologist , as in some cases no tumor is found even after long - term followup or on autopsy [ 3 ] .", "label": "", "metadata": {}, "score": "67.75082"}
{"text": "955 - 962 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. Guillermet , N. Saint - Laurent , P. Rochaix et al . , \" Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand - induced apoptosis , \" Proceedings of the National Academy of Sciences of the United States of America , vol .", "label": "", "metadata": {}, "score": "67.750824"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. J. Behm , C. L. Herold , V. Camarda , N. V. Aiyar , and S. A. Douglas , \" Differential agonistic and antagonistic effects of the urotensin - II ligand SB-710411 at rodent and primate UT receptors , \" European Journal of Pharmacology , vol .", "label": "", "metadata": {}, "score": "67.78058"}
{"text": "The screening was based on their two agonist pharmacophore models : one associated with the human U - II peptide and one associated with Ac-[Cys - Phe - DTrp - Lys - Tyr - Cys]-NH 2 .", "label": "", "metadata": {}, "score": "67.791176"}
{"text": "This is a fast - acting drug that quickly reduces urinary free cortisol ( UFC ) levels [ 14 ] .Its use has been reported as effective in 50 % of patients with ectopic ACTH secretion .", "label": "", "metadata": {}, "score": "67.811356"}
{"text": "Figure 11 : Structures of piperazino - isoindolinone derivatives compound 4 and compound 5 ( JNJ-28318706 ) were optimized into the novel compound 6 ( JNJ-39319202 ) .", "label": "", "metadata": {}, "score": "67.81218"}
{"text": "With long - term therapy the SRL dose can be reduced in most patients .The determination of the GH and IGF-1 concentration should be performed immediately before the next injection , that is , at the nadir of the drug 's plasma concentration .", "label": "", "metadata": {}, "score": "67.81939"}
{"text": "View at Google Scholar \u00b7 View at Scopus . A. Yoshihara , O. Isozaki , N. Hizuka et al . , \" Expression of type 5 somatostatin receptor in TSH - secreting pituitary adenomas : a possible marker for predicting longterm response to octreotide therapy , \" Endocrine Journal , vol .", "label": "", "metadata": {}, "score": "67.881935"}
{"text": "While some authors found that the decline of GH and/or IGF-1 concentration predicted tumour shrinkage in therapy naive patients , other could not demonstrate a correlation between biochemical efficacy and tumour shrinkage [ 117 ] .", "label": "", "metadata": {}, "score": "68.01041"}
{"text": "M. Rocheville , D. C. Lange , U. Kumar , S. C. Patel , R. C. Patel , and Y. C. Patel , \" Receptors for dopamine and somatostatin : formation of hetero - oligomers with enhanced functional activity , \" Science , vol .", "label": "", "metadata": {}, "score": "68.02942"}
{"text": "While Lanreotide SR has been shown to be slightly less effective than Octreotide LAR , a comparable efficacy has been demonstrated for Octreotide LAR and Lanreotide Autogel in two clinical trials [ 81 , 82 ] .", "label": "", "metadata": {}, "score": "68.03639"}
{"text": "1281 - 1287 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . E. Elstner , E. A. Williamson , C. Zang et al . , \" Novel therapeutic approach : ligands for PPAR \u03b3 and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells , \" Breast Cancer Research and Treatment , vol .", "label": "", "metadata": {}, "score": "68.05024"}
{"text": "However , in the same way described for sst2 and SHP1 ( see before ) , the activation of PTP \u03b7 by sst1 requires the constitution of a multieffector complex , composed of both kinases and PTPs .", "label": "", "metadata": {}, "score": "68.11827"}
{"text": "16 - 26 , 2003 .View at Google Scholar .S. Jehle , C. M. Reyes , R. E. Sundeen , and P. U. Freda , \" Alternate - day administration of pegvisomant maintains normal serum insulin - like growth factor - I levels in patients with acromegaly , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "68.16371"}
{"text": "View at Publisher \u00b7 View at Google Scholar .J. Ayuk , S. E. Stewart , P. M. Stewart , and M. C. Sheppard , \" Long - term safety and efficacy of depot long - acting somatostatin analogs for the treatment of acromegaly , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "68.19501"}
{"text": "4 , pp .612 - 618 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .G. Schettini , T. Florio , G. Magri et al . , \" Somatostatin and SMS 201 - 995 reverse the impairment of cognitive functions induced by cysteamine depletion of brain somatostatin , \" European Journal of Pharmacology , vol .", "label": "", "metadata": {}, "score": "68.21477"}
{"text": "113 - 116 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .N. A. Elshourbagy , S. A. Douglas , U. Shabon et al . , \" Molecular and pharmacological characterization of genes encoding urotensin - II peptides and their cognate G - protein - coupled receptors from the mouse and monkey , \" British Journal of Pharmacology , vol .", "label": "", "metadata": {}, "score": "68.26073"}
{"text": "The supra - therapeutic dose ( 1.95 mg b.i.d ) produced mean steady - state C max values 3.3-fold the mean C max for the 0.6 mg b.i.d dose in the study .", "label": "", "metadata": {}, "score": "68.277664"}
{"text": "Freda et al . suggested very strict criteria for remission using a sensitive immunoradiometric assay ( GH below 0.14 \u03bc g / L during OGTT and normal IGF-1 concentration )", "label": "", "metadata": {}, "score": "68.32592"}
{"text": "Other nonpeptide molecules reported in patent applications were based on 4-aminoquinolines [ 63 ] and quinolone , such as 2-aminoquinolines and 2-aminoalkylquinolin-4-ones derivatives [ 64 ] , template ( Figure 6 ) .", "label": "", "metadata": {}, "score": "68.33066"}
{"text": "35 , pp .4958 - 4961 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . Y. Wang , Z. Wu , B. F. Guida et al . , \" N - alkyl-5 H -pyrido[4,3- b ] indol-1-amines and derivatives as novel urotensin - II receptor antagonists , \" Bioorganic and Medicinal Chemistry Letters , vol .", "label": "", "metadata": {}, "score": "68.33552"}
{"text": "For this reason identification of a novel and selective antagonist was achieved by examining ligand - evoked UT receptor agonism under conditions of both low and high receptor density and efficient coupling and amplification .", "label": "", "metadata": {}, "score": "68.39718"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. Sugo , Y. Murakami , Y. Shimomura et al . , \" Identification of urotensin II - related peptide as the urotensin II - immunoreactive molecule in the rat brain , \" Biochemical and Biophysical Research Communications , vol .", "label": "", "metadata": {}, "score": "68.41342"}
{"text": "5 , pp .608 - 615 , 2012 .View at Publisher \u00b7 View at Google Scholar .M. Jarry , M. Diallo , C. Lecointre et al . , \" The vasoactive peptides urotensin II and urotensin II - related peptide regulate astrocyte activity through common and distinct mechanisms : involvement in cell proliferation , \" Biochemical Journal , vol .", "label": "", "metadata": {}, "score": "68.41934"}
{"text": "Individual SST receptors have different internalization rates ( internalization is higher for sst2 , 3 and 5 than for sst1 and 4 ) [ 61 ] , since their interaction with \u03b2 -arrestins results in receptor / arrestin complexes with lower or higher stability .", "label": "", "metadata": {}, "score": "68.44167"}
{"text": "141 , no .4 , pp .399 - 405 , 1999 .View at Publisher \u00b7 View at Google Scholar .S. M. Carlsen , M. Lund - Johansen , T. Schreiner et al . , \" Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short - term postoperative rates : a prospective , randomized trial , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "68.496765"}
{"text": "41 - 46 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. Tateno , M. Kato , Y. Tani , K. Oyama , S. Yamada , and Y. Hirata , \" Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin ( ACTH)-secreting pituitary tumors and silent corticotroph adenomas , \" Endocrine Journal , vol .", "label": "", "metadata": {}, "score": "68.50427"}
{"text": "6 , pp .921 - 932 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. Bhaskaran and C. Yu , \" NMR spectra and restrained molecular dynamics of the mushroom toxin viroisin , \" International Journal of Peptide and Protein Research , vol .", "label": "", "metadata": {}, "score": "68.50907"}
{"text": "The distances characterized for the pharmacophoric sequence were 11.2 \u00c5 between the Lys 8 amino and Tyr 9 aryl groups , 8.4 \u00c5 between the indole Trp 7 and Lys 8 amine , and 8.2 \u00c5 between the Trp 7 and Tyr 9 aryl groups .", "label": "", "metadata": {}, "score": "68.59061"}
{"text": "For their behavior , presentation , and outcome , ACTH secreting macroadenomas present a distinct profile compared with microadenomas , although they probably represent one end of a spectrum of tumor autonomy , with specific growth and biochemical characteristics [ 1 ] .", "label": "", "metadata": {}, "score": "68.59865"}
{"text": "289 - 297 , 1980 .View at Google Scholar .R. Barrie , E. A. Woltering , H. Hajarizadeh , C. Mueller , T. Ure , and W. S. Fletcher , \" Inhibition of angiogenesis by somatostatin and somatostatin - like compounds is structurally dependent , \" Journal of Surgical Research , vol .", "label": "", "metadata": {}, "score": "68.636635"}
{"text": "These several structural modifications led to both increased and decreased activities , although beneficial effects were obtained when substituents were introduced in the aromatic part of the isochromanone ring system , whereas more sterically demanding amino groups resulted to be damaging to the activity .", "label": "", "metadata": {}, "score": "68.65623"}
{"text": "441 - 446 , 2000 .View at Google Scholar \u00b7 View at Scopus .M. Matsushita , M. Shichiri , T. Imai et al . , \" Co - expression of urotensin II and its receptor ( GPR14 ) in human cardiovascular and renal tissues , \" Journal of Hypertension , vol .", "label": "", "metadata": {}, "score": "68.70039"}
{"text": "46 - 53 , 2011 .View at Google Scholar \u00b7 View at Scopus .J. C. Reubi , R. Maurer , and J. G. M. Klijn , \" High incidence of somatostatin receptors in human meningiomas : biochemical characterization , \" The Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "68.70389"}
{"text": "sst5 is monomeric and displays dimerization upon agonist binding in a concentration - dependent manner .Figure 2 : Dimerization pattern of somatostatin receptors .Each SST receptor subtype show a different constitutive tendency to dimerize .", "label": "", "metadata": {}, "score": "68.78338"}
{"text": "115 - 122 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .V. A. S. H. Dalm , L. J. Hofland , and S. W. J. Lamberts , \" Future clinical prospects in somatostatin / cortistatin / somatostatin receptor field , \" Molecular and Cellular Endocrinology , vol .", "label": "", "metadata": {}, "score": "68.879456"}
{"text": "DAs bind preferentially with high affinity to dopamine 2 ( D2 ) receptors .Due to a high first - pass effect in the liver only 6 % of a given dose will appear in the peripheral circulation .", "label": "", "metadata": {}, "score": "68.92729"}
{"text": "The doses to the kidneys were reduced by a mean of 47 % after co - infusion of amino acids .It is concluded that in comparison with the radionuclide - coupled somatostatin analogues that are currently available for somatostatin receptor - mediated radiotherapy , 177Lu - octreotate potentially represents an important improvement .", "label": "", "metadata": {}, "score": "68.93592"}
{"text": "884 - 901 , 2006 .View at Google Scholar .S. Suzuki , Z. Wenyi , M. Hirai et al . , \" Genetic variations at urotensin II and urotensin II receptor genes and risk of type 2 diabetes mellitus in Japanese , \" Peptides , vol .", "label": "", "metadata": {}, "score": "68.95614"}
{"text": "10 - 14 , 1994 .View at Google Scholar \u00b7 View at Scopus . A. Colao , D. Ferone , P. Cappabianca et al . , \" Effect of octreotide pretreatment on surgical outcome in acromegaly , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "69.03438"}
{"text": "156 - 162 , 2011 .View at Publisher \u00b7 View at Google Scholar .S. W. van Thiel , J. A. Romijn , N. R. Biermasz et al . , \" Octreotide long - acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients , \" European Journal of Endocrinology , vol .", "label": "", "metadata": {}, "score": "69.056915"}
{"text": "29 , no .29 , pp .3869 - 3876 , 2011 .View at Google Scholar .V. Vuaroqueaux , A. Dutour , N. Bourhim et al . , \" Increased expression of the mRNA encoding the somatostatin receptor subtype five in human colorectal adenocarcinoma , \" Journal of Molecular Endocrinology , vol .", "label": "", "metadata": {}, "score": "69.05699"}
{"text": "Curt\u00f2 et al .[ 60 ] published a case report of a patient with a corticotroph carcinoma in whom a 90 % reduction in the size of the tumor , and a stabilization of the metastases volume was documented after four cycles of TMZ .", "label": "", "metadata": {}, "score": "69.06495"}
{"text": "395 - 400 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. Florio , L. Montella , A. Corsaro et al . , \" In vitro and in vivo expression of somatostatin receptors in intermediate and malignant soft tissue tumors , \" Anticancer Research , vol .", "label": "", "metadata": {}, "score": "69.07469"}
{"text": "Thus , the chemical modification brought by the unusual more constrained penicillamine residue mainly influences the proximal Phe 6 position , leaving Trp , Lys , and Tyr residue nearly unaffected .", "label": "", "metadata": {}, "score": "69.07965"}
{"text": "6 , pp .2789 - 2796 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .P. U. Freda , L. Katznelson , A. J. Van Der Lely , C. M. Reyes , S. Zhao , and D. Rabinowitz , \" Long - acting somatostatin analog therapy of acromegaly : a meta - analysis , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "69.08469"}
{"text": "89 - 98 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. Liuzzi , P. G. Chiodini , L. Botalla , G. Cremascoli , and F. Silvestrini , \" Inhibitory effect of L - Dopa on GH release in acromegalic patients , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "69.18066"}
{"text": "demonstrating a decreased growth fraction and an increased proportion of cells in G1 and M - phases .Thus the antiproliferative effects of SRL are probably related to an inhibition of cell growth , that is , reduced cell cycling rather than an increase in apoptosis [ 113 , 114 ] .", "label": "", "metadata": {}, "score": "69.21659"}
{"text": "Cabergoline was effective and safe in 28 % of 20 treated patients .This drug is generally well tolerated by most patients , and none of the subjects treated in these clinical trials showed signs of secondary heart dysfunction or valvulopathy , except a patient with a history of tricuspid regurgitation [ 40 ] .", "label": "", "metadata": {}, "score": "69.24846"}
{"text": "123 - 129 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. Pivonello , D. Ferone , W. W. De Herder et al . , \" Dopamine receptor expression and function in corticotroph ectopic tumors , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "69.2967"}
{"text": "With their enhanced receptor affinity and their rapid receptor - mediated internalisation in vitro and in vivo , the new BN analogues , and especially Cmp 3 , are promising candidates for use in diagnostic molecular imaging and targeted radionuclide therapy of GRP receptor - expressing cancers .", "label": "", "metadata": {}, "score": "69.31023"}
{"text": "Internalisation was receptor - specific and appeared to be time and temperature dependent .In vivo in rats , we investigated administration of different peptide amounts ( 0.1 , 0.5 , and 100 \u03bcg ) .", "label": "", "metadata": {}, "score": "69.320206"}
{"text": "It has been shown that sst interact with each other or with other G - protein coupled receptors forming homo- or heterodimers , further increasing the complexity of somatostatin receptor activation .", "label": "", "metadata": {}, "score": "69.33823"}
{"text": "2984 - 2990 , 2008 .View at Publisher \u00b7 View at Google Scholar .Z. G. Mao , Y. H. Zhu , H. L. Tang et al . , \" Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short - term postoperative cure rates : a prospective , randomised trial , \" European Journal of Endocrinology , vol .", "label": "", "metadata": {}, "score": "69.37749"}
{"text": "721 - 727 , 2004 .View at Google Scholar \u00b7 View at Scopus .K. Elekes , Z. Helyes , L. Kereskai , et al . , \" Inhibitory effects of synthetic somatostatin receptor subtype 4 agonists on acute and chronic airway inflammation and hyperreactivity in the mouse , \" European Journal of Pharmacology , vol .", "label": "", "metadata": {}, "score": "69.39258"}
{"text": "SST and analogs activation of SHP1 resulted in tyrosine phosphorylation of the PTP , mediated by the cytosolic kinase JAK2 whose activity was identified as an absolute requirement for both sst2-mediated activation of SHP1 and the inhibition of cell proliferation [ 127 ] .", "label": "", "metadata": {}, "score": "69.438644"}
{"text": "6 , pp .829 - 835 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. C. De Martino , R. S. Auriemma , G. Brevetti et al . , \" The treatment with growth hormone receptor antagonist in acromegaly : effect on vascular structure and function in patients resistant to somatostatin analogues , \" Journal of Endocrinological Investigation , vol .", "label": "", "metadata": {}, "score": "69.46181"}
{"text": "Radiolabeled peptides have acquired increasing interest in nuclear medicine for tumor diagnosis , staging , therapy ( peptide receptor radionuclide therapy , PRRT ) and follow - up .", "label": "", "metadata": {}, "score": "69.476395"}
{"text": "23 , pp .7432 - 7445 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. K. Luci , E. C. Lawson , S. Ghosh et al . , \" Generation of novel , potent urotensin - II receptor antagonists by alkylation - cyclization of isoindolinone C3-carbanions , \" Tetrahedron Letters , vol .", "label": "", "metadata": {}, "score": "69.52515"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Dur\u00e1n - Prado , M. D. Gahete , A. J. Mart\u00ednez - Fuentes et al . , \" Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors , \" The Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "69.542076"}
{"text": "- II is a partial agonist .In 2002 Grieco et al .[29 ] generated a novel peptide UT receptor agonist by introduction of an unusual amino acid in the disulphide bridge of hUT- . , also known as P5U. This \u03b2 , \u03b2 -dimethyl - substituted cysteine residue led to higher conformational rigidity in the sequence of hU", "label": "", "metadata": {}, "score": "69.57022"}
{"text": "In human ACTH - secreting tumors [ 67 ] gefitinib ( a tyrosine kinase inhibitor targeting EGFR ) was found to suppress in vitro POMC expression by approximately 95 % .", "label": "", "metadata": {}, "score": "69.61731"}
{"text": "The various available assays for the determination of GH use different antibodies with distinct affinity to the GH molecule .These antibodies may recognise not only separate epitopes but even different GH isoforms .", "label": "", "metadata": {}, "score": "69.62225"}
{"text": "590 - 593 , 2001 .View at Publisher \u00b7 View at Google Scholar .P. J. Trainer , W. M. Drake , L. Katznelson et al . , \" Treatment of acromegaly with the growth hormone - receptor antagonist pegvisomant , \" New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "69.630806"}
{"text": "63 - 68 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Rocheville , D. C. Lange , U. Kumar , R. Sasi , R. C. Patel , and Y. C. Patel , \" Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers , \" The Journal of Biological Chemistry , vol .", "label": "", "metadata": {}, "score": "69.64223"}
{"text": "The seven patients unresponsive to Quinagolide were subjected to a combination therapy of Octreotide ( 600 \u03bc g / d ) , and Quinagolide ( 600 \u03bc g / d ) for three months .", "label": "", "metadata": {}, "score": "69.67706"}
{"text": "137 - 145 , 2001 .View at Google Scholar .N. R. Biermasz , H. Van Dulken , and F. Roelfsema , \" Direct postoperative and follow - up results of transsphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared to those in untreated matched controls , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "69.72949"}
{"text": "DTrp 4 ] URP showed also reduced efficacy appearing to behave as a partial agonist with moderate potency and a full antagonist with low potency , indicating that point substitution of the Trp residue in U - II and URP sequence could lead to the development of antagonists .", "label": "", "metadata": {}, "score": "69.74069"}
{"text": "View at Google Scholar . A. Ben - Shlomo , H. Schmid , K. Wawrowsky et al . , \" Differential ligand - mediated pituitary somatostatin receptor subtype signaling : implications for corticotroph tumor therapy , \" The Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "69.774536"}
{"text": "51 - 74 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .W. Ruan , F. Fahlbusch , D. R. Clemmons et al . , \" SOM230 inhibits insulin - like growth factor - I action in mammary gland development by pituitary independent mechanism : mediated through somatostatin subtype receptor 3 ? \" Molecular Endocrinology , vol .", "label": "", "metadata": {}, "score": "69.79666"}
{"text": "All of the five SST receptors are detectable in prostate cancer tissues , with sst1 the most expressed , followed by sst5 and sst2 [ 172 , 173 ] .", "label": "", "metadata": {}, "score": "69.8495"}
{"text": "239 - 250 , 2000 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. E. Hershberger , B. L. Newman , T. Florio et al . , \" The somatostatin receptors SSTR1 and SSTR2 are coupled to inhibition of adenylyl cyclase in Chinese hamster ovary cells via pertussis toxin - sensitive pathways , \" Endocrinology , vol .", "label": "", "metadata": {}, "score": "69.952736"}
{"text": "44 , pp .16436 - 16441 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .X. Wang , M. Fani , S. Schulz , et al . , \" Comprehensive evaluation of a somatostatin - based radiolabelled antagonist for diagnostic imaging and radionuclide therapy , \" European Journal of Nuclear Medicine and Molecular Imaging , vol .", "label": "", "metadata": {}, "score": "69.98259"}
{"text": "4 , pp .555 - 559 , 2011 .View at Publisher \u00b7 View at Google Scholar .G. Brabant , A. Von Zur M\u00fchlen , C. W\u00fcster et al . , \" Serum insulin - like growth factor I reference values for an automated chemiluminescence immunoassay system : results from a multicenter study , \" Hormone Research , vol .", "label": "", "metadata": {}, "score": "69.99589"}
{"text": "It is thus of potential therapeutic use in CD [ 62 , 63 ] .Castillo et al .[ 63 ] published an in vivo animal study in which retinoic acid or ketoconazole was administered to 42 dogs with Cushing 's canine syndrome .", "label": "", "metadata": {}, "score": "70.001656"}
{"text": "In order to evaluate the correct orientation of amino acid side chains belonging to the cyclic region of URP in the activity of the peptide , each amino acid has been replaced with the corresponding stereoisomer in a D - scan analysis [ 47 ] .", "label": "", "metadata": {}, "score": "70.00564"}
{"text": "2147 - 2154 , 2010 .View at Publisher \u00b7 View at Google Scholar . D. Buyuktas , O. Celik , F. Kantarci , and P. Kadioglu , \" Lipodystrophy during pegvisomant therapy : a case report and review of the literature , \" Clinics , vol .", "label": "", "metadata": {}, "score": "70.0554"}
{"text": "S3-S10 , 2009 .View at Publisher \u00b7 View at Google Scholar .I. Bernabeu , J. Cameselle - Teijeiro , F. F. Casanueva , and M. Marazuela , \" Pegvisomant - induced cholestatic hepatitis with jaundice in a patient with Gilbert 's syndrome , \" European Journal of Endocrinology , vol .", "label": "", "metadata": {}, "score": "70.06477"}
{"text": "2907 - 2914 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Arosio , S. Macchelli , C. M. Rossi , G. Casati , O. Biella , and G. Faglia , \" Effects of treatment with octreotide in acromegalic patients - a multicenter Italian study , \" European Journal of Endocrinology , vol .", "label": "", "metadata": {}, "score": "70.06537"}
{"text": "[ 0014 ] Meningiomas are tumors with a high frequency of surface somatostatin receptors .It has been reported that the addition of somatostatin inhibits meningioma growth in vitro .", "label": "", "metadata": {}, "score": "70.08229"}
{"text": "Finally , an algorithm for the medical treatment of acromegaly will be proposed .Indication for Medical Therapy .A high GH- and IGF-1 concentration persisting after incomplete surgery or prevailing in the first years after irradiation is a clear indication for medical therapy .", "label": "", "metadata": {}, "score": "70.0837"}
{"text": "87 , no . 7 , pp .3142 - 3147 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . E. V. Dimaraki , C. A. Jaffe , R. Demott - Friberg , W. F. Chandler , and A. L. Barkan , \" Acromegaly with apparently normal GH secretion : implications for diagnosis and follow - up , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "70.14924"}
{"text": "10 , pp .3308 - 3314 , 1997 .View at Publisher \u00b7 View at Google Scholar . A. Stevenaert and A. Beckers , \" Presurgical octreotide : treatment in acromegaly , \" Metabolism : Clinical and Experimental , vol .", "label": "", "metadata": {}, "score": "70.155334"}
{"text": "Therefore new ( 111)In - labelled BN analogues were synthesised and evaluated in vitro and in vivo .The receptor affinity of the new BN analogues was tested on human GRP receptor - expressing prostate tumour xenografts and rat colon sections .", "label": "", "metadata": {}, "score": "70.15616"}
{"text": "Somatostatin Receptor Signaling in Tumor Cells .SST receptors are commonly expressed in tumors including both endocrine ( pituitary adenoma , neuroendocrine and gastropancreatic neoplasms , thyroid , adrenal , and small cell lung carcinomas ) and nonendocrine ( gliomas , meningiomas , breast , and ovarian cancers , osteosarcomas ) histotypes .", "label": "", "metadata": {}, "score": "70.18569"}
{"text": "As previously discussed , SST receptor trafficking ( endocytosis , recycling or degradation ) after agonist binding is well documented [ 58 ] .On the contrary , less is known about functional SST receptor travelling along the secretory pathway to the plasma membrane .", "label": "", "metadata": {}, "score": "70.24129"}
{"text": "12 , pp .601 - 607 , 1997 .View at Google Scholar \u00b7 View at Scopus .P. Marzullo , D. Ferone , C. Di Somma et al . , \" Efficacy of combined treatment with lanreotide and cabergoline in selected therapy - resistant acromegalic patients , \" Pituitary , vol .", "label": "", "metadata": {}, "score": "70.25766"}
{"text": "Figure 4 : Structures of FL-104 and its optimized derivative compound 1 .Analogues of FL-104 were designed and synthesized in order to enable comparisons between SAR in the isochromanone and benzamide series of UT agonists [ 58 ] .", "label": "", "metadata": {}, "score": "70.27643"}
{"text": "P\u00e1ez - Pereda et al .[ 62 ] examined its effects on human in vitro and mouse in vivo pituitary cells .RA inhibited ACTH biosynthesis only in tumorous corticotroph cells , while normal cells were unaffected .", "label": "", "metadata": {}, "score": "70.283844"}
{"text": "Suppression of tumor growth rate was observed in all treated animals compared to untreated controls .Greater inhibition of tumor growth was observed in animals that received multiple doses .", "label": "", "metadata": {}, "score": "70.28634"}
{"text": "The human UT - II ( hU- II ) is a cyclic undecapeptide , H - Glu - Thr - Pro - Asp - c[Cys - Phe - Trp - Lys - Tyr - Cys]-Val - OH , recognized as the natural ligand of an orphan G - protein coupled receptor , first named as a rat receptor with high affinity for U - II , GPR14 [ 10 - 12 ] .", "label": "", "metadata": {}, "score": "70.43489"}
{"text": "4 , pp .569 - 574 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. S. Jallad and M. D. Bronstein , \" Optimizing medical therapy of acromegaly : beneficial effects of cabergoline in patients uncontrolled with long - acting release octreotide , \" Neuroendocrinology , vol .", "label": "", "metadata": {}, "score": "70.447174"}
{"text": "89 - 98 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . H. L. Watt , G. D. Kharmate , and U. Kumar , \" Somatostatin receptors 1 and 5 heterodimerize with epidermal growth factor receptor : agonist - dependent modulation of the downstream MAPK signalling pathway in breast cancer cells , \" Cellular Signalling , vol .", "label": "", "metadata": {}, "score": "70.49931"}
{"text": "Few case - report studies demonstrated the efficacy and safety of radiolabeled SST - analogs in pituitary metastasis in a patient with NET [ 104 ] and in a case of relapsed prolactin - secreting giant pituitary adenoma [ 105 ] .", "label": "", "metadata": {}, "score": "70.52297"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. Bousquet , C. Lasfargues , M. Chalabi , et al . , \" Clinical review : current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy , \" The Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "70.53069"}
{"text": "209 - 217 , 2009 .View at Google Scholar \u00b7 View at Scopus .R. Pivonello , D. Ferone , W. W. De Herder et al . , \" Dopamine receptor expression and function in corticotroph pituitary tumors , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "70.61272"}
{"text": "24 - 37 , 1999 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . F. Viana and B. Hille , \" Modulation of high voltage - activated calcium channels by somatostatin in acutely isolated rat amygdaloid neurons , \" The Journal of Neuroscience , vol .", "label": "", "metadata": {}, "score": "70.66354"}
{"text": "A test dose of Octreotide ( 50 \u03bc g or 100 \u03bc g ) injected subcutaneously followed by a GH - profile can have some prognostic value [ 99 - 101 ] .", "label": "", "metadata": {}, "score": "70.677"}
{"text": "Again there was no difference between Octreotide LAR and Lanreotide Autogel [ 83 ] .The comparable efficacy of both , Octreotide LAR and Lanreotide Autogel has been further confirmed in a meta - analysis investigating the potency of different SRL formulations [ 84 ] .", "label": "", "metadata": {}, "score": "70.69183"}
{"text": "10 , pp .3551 - 3555 , 1999 .View at Google Scholar . U.Pl\u00f6ckinger and H.-J. Quabbe , \" Presurgical octreotide treatment in acromegaly : no improvement of final growth hormone ( GH ) concentration and pituitary function .", "label": "", "metadata": {}, "score": "70.711136"}
{"text": "10 , pp .3419 - 3426 , 1998 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .P. C. Kao , E. R. Laws Jr. , and D. Zimmerman , \" Somatomedin C / insulin - like growth factor I levels after treatment of acromegaly , \" Annals of Clinical and Laboratory Science , vol .", "label": "", "metadata": {}, "score": "70.721695"}
{"text": "TMZ may also inhibit angiogenesis .Its use was firstly described in 2006 for the treatment of a pituitary carcinoma , and the first corticotroph adenoma was treated in 2007 [ 58 ] .", "label": "", "metadata": {}, "score": "70.7379"}
{"text": "6 , pp .1443 - 1445 , 1989 .View at Google Scholar \u00b7 View at Scopus .J. S. Bevan , \" The antitumoral effects of somatostatin analog therapy in acromegaly , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "70.776535"}
{"text": "61 - 62 , 1996 .View at Google Scholar \u00b7 View at Scopus . A. Colao , R. S. Auriemma , M. Galdiero et al . , \" Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly : results of a 5-year observational , open , prospective study , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "70.79906"}
{"text": "39 , pp .24448 - 24454 , 1997 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. Bousquet , N. Delesque , F. Lopez et al . , \" sst 2 somatostatin receptor mediates negative regulation of insulin receptor signaling through the tyrosine phosphatase SHP-1 , \" The Journal of Biological Chemistry , vol .", "label": "", "metadata": {}, "score": "70.91904"}
{"text": "NETs represent the major tumor targets for SST analogs presently used in clinical practice .In clinically nonfunctioning pituitary adenomas sst3 is highly expressed , followed by sst2 and , at low level , sst5 [ 53 , 150 ] , while , in TSH - secreting tumors , sst2 is mainly coexpressed with sst3 and sst5 [ 151 ] .", "label": "", "metadata": {}, "score": "70.92229"}
{"text": "Regarding to the design of nonpeptide ligands , the conformation and the size of the peptide backbone is often difficult to mimic by using as scaffold organic molecules and modifications onto hydrophobic , steric , and electronic properties could generate potential active compounds and optimize their affinity and selectivity .", "label": "", "metadata": {}, "score": "70.955734"}
{"text": "Thus quality of life evaluation may offer additional clues with respect to treatment indications .The lack of correlation between QoL and biochemical markers of the disease does not come as a surprise , as duration of the disease , extent of physical disfigurement , and comorbidities may have additional and individual impacts on the quality of life with acromegaly .", "label": "", "metadata": {}, "score": "71.02521"}
{"text": "SAR Studies on U - II .The potential therapeutic application of urotensin - II system has continuously stimulated structure - activity relationship studies ( SARs ) , which could elucidate the structural features of this important hormone .", "label": "", "metadata": {}, "score": "71.0764"}
{"text": "More recently , two putative CST receptors , that do not bind SST were also identified : MrgX2 ( MAS - related gene X2 ) receptor [ 12 ] and GHS - R1a ( growth hormone secretagogue receptor 1a ) [ 13 ] , whose biological function is still not completely characterized .", "label": "", "metadata": {}, "score": "71.138664"}
{"text": "470 - 474 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. T. Huang , Z. X. Chen , B. Wei et al . , \" Preoperative growth inhibition of human gastric adenocarcinoma treated with a combination of celecoxib and octreotide , \" Acta Pharmacologica Sinica , vol .", "label": "", "metadata": {}, "score": "71.18083"}
{"text": "[53 ] recommended the use of CCNU/5FU for relatively indolent tumor in the first instance .There have been partial and short - lasting responses to other combinations of chemotherapy agents [ 2 ] , such as paclitaxel and etoposide in ectopic Cushing 's syndrome [ 56 ] .", "label": "", "metadata": {}, "score": "71.31177"}
{"text": "Despite of the large number of studies performed on U - II system , less knowledge even belongs to the issue regarding the pathophysiological role of urotensin - II / UT receptor interaction .", "label": "", "metadata": {}, "score": "71.31861"}
{"text": "Substituted diarylsulfonamides , reported in other patent applications , possessed significant affinity for UT receptors ( .\u03bc M ) .They were designed as UT receptor antagonists and CCR-9 antagonists for the treatment of congestive heart failure , stroke , ischemic heart disease , and so forth [ 68 ] .", "label": "", "metadata": {}, "score": "71.33409"}
{"text": "Despite the finding of an initial reduction of ACTH and cortisol levels in a subset of patients with CD , clinical symptoms and biochemical parameters subsequently relapsed in this group of subjects .", "label": "", "metadata": {}, "score": "71.380356"}
{"text": "Slow release formulations are more convenient for the patients and thus compliance is increased .Difficulties with injecting Octreotide LAR or Lanreotide Autogel can be reduced by delivering the injections with the help of specifically trained personnel .", "label": "", "metadata": {}, "score": "71.44682"}
{"text": "As mentioned above , the human U - II is involved in several pathophysiological pathways of disorders especially regarding cardiovascular system along with the observation that the interaction U - II / UT receptor regulates the contractility and growth properties of cardiac and peripheral vascular vessels led to identifying selective ligands .", "label": "", "metadata": {}, "score": "71.57056"}
{"text": "Peptide receptors involved in pathophysiological processes represent promising therapeutic targets .Neuropeptide somatostatin ( SST ) is produced by specialized cells in a large number of human organs and tissues .", "label": "", "metadata": {}, "score": "71.57495"}
{"text": "Details of medical therapy with a GH - antagonist will be discussed below .Thus , while the decision for treatment with a GH receptor antagonist may still rely on the nonsuppressibility of GH during OGTT , the follow - up during therapy and dose adjustment have to be based on a methodology demonstrated to lack sufficient sensitivity for the diagnosis of remission in acromegaly .", "label": "", "metadata": {}, "score": "71.614975"}
{"text": "1588 - 1593 , 2005 .View at Publisher \u00b7 View at Google Scholar .C. Muto , K. Chiba , and T. Suwa , \" Population pharmacokinetic and pharmacodynamic modeling of pegvisomant in Asian and Western acromegaly patients , \" Journal of Clinical Pharmacology , vol .", "label": "", "metadata": {}, "score": "71.62248"}
{"text": "injections were positively correlated to tumour shrinkage [ 78 ] , while no such correlation was reported with the slow release preparations [ 118 , 119 ] .", "label": "", "metadata": {}, "score": "71.6237"}
{"text": "Mifepristone affects both the central actions of cortisol ( negative feedback on CRH / ACTH secretion ) and its peripheral actions and increases plasma ACTH and cortisol levels due to the loss of negative feedback of cortisol .", "label": "", "metadata": {}, "score": "71.71112"}
{"text": "Although in most cases all subtypes can be identified in tumor cells a tumor - specific pattern of expression can be identified in some cases .", "label": "", "metadata": {}, "score": "71.7353"}
{"text": "The determination of the IGF-1 concentration is used for follow - up during therapy and dose adjustment .Problems of the IGF-1 assay have already been discussed .", "label": "", "metadata": {}, "score": "71.76361"}
{"text": "1416 - 1423 , 1994 .View at Publisher \u00b7 View at Google Scholar .S. Barakat and S. Melmed , \" Reversible shrinkage of a growth hormone - secreting pituitary adenoma by a long - acting somatostatin analogue , octreotide , \" Archives of Internal Medicine , vol .", "label": "", "metadata": {}, "score": "71.77249"}
{"text": "Peptide analogues synthesized in this study were characterized by ring - closing sequence that ranges from 20 to 24 atoms and , interestingly , the smallest peptide sequence , having the same length as the native peptide containing the disulphide bridge , does not show any biological activity .", "label": "", "metadata": {}, "score": "71.784355"}
{"text": "4 , pp .237 - 242 , 1988 .View at Google Scholar \u00b7 View at Scopus .T. Florio , C. Ventra , A. Postiglione , and G. Schettini , \" Age - related alterations of somatostatin gene expression in different rat brain areas , \" Brain Research , vol .", "label": "", "metadata": {}, "score": "71.80589"}
{"text": "860 - 868 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. Chatenet , Q. T. Nguyen , M. L\u00e9tourneau , J. Dupuis , and A. Fournier , \" Urocontrin , a novel UT receptor ligand with a unique pharmacological profile , \" Biochemical Pharmacology , vol .", "label": "", "metadata": {}, "score": "71.813126"}
{"text": "557 - 561 , 2001 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .K. I. Pritchard , L. E. Shepherd , J. A. Chapman , et al . , \" Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR therapy in the adjuvant treatment of early - stage breast cancer in postmenopausal women : NCIC CTG MA .", "label": "", "metadata": {}, "score": "71.81527"}
{"text": "Urotensin - II was originally isolated from the goby urophysis in the 1960s as a vasoactive peptide with a prominent role in cardiovascular homeostasis .The identification of human isoform of urotensin - II and its specific UT receptor by Ames et al . in 1999 led to investigating the putative role of the interaction U - II / UT receptor in multiple pathophysiological effects in humans .", "label": "", "metadata": {}, "score": "71.84633"}
{"text": "However , compound 1 was the most interesting among the series ( Figure 4 ) .Its racemate mixture was resolved and the ( + ) -(S)-enantiomer corresponded to the most active nonpeptide agonist compound with a .", "label": "", "metadata": {}, "score": "71.86936"}
{"text": "Evaluation of Remission Criteria .Whether failure to achieve these criteria for complete remission of acromegaly is identical to the indication for medical therapy is still a matter of debate .", "label": "", "metadata": {}, "score": "71.90369"}
{"text": "From the series of compounds synthesized in this study , FL-68 was found the most interesting since it was very active versus UT receptor and not showing at the same time any activity versus the closely related somatostatin receptors .", "label": "", "metadata": {}, "score": "71.98093"}
{"text": "3746 - 3756 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. D. Murray and S. Melmed , \" A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "72.0017"}
{"text": "SST receptors are highly expressed in neuroendocrine tumors ( NET , including pituitary adenomas , endocrine pancreatic tumors , gastrointestinal and lung carcinoids , small cell carcinomas , thyroid medullary cancer , and others ) .", "label": "", "metadata": {}, "score": "72.02264"}
{"text": "Mechanism of Action Pegvisomant , the only available GHA , is an analogue of the 22 kD GH molecule .Modification of the GH molecule , exchanging the amino acid glycin at position 120 in the third helix , results in a GH antagonistic effect .", "label": "", "metadata": {}, "score": "72.052414"}
{"text": "Octreotide , which acts predominantly on SSTR2 receptors , has not proven effective in inhibiting ACTH secretion in patients with Cushing 's disease .Chemotherapy .", "label": "", "metadata": {}, "score": "72.07816"}
{"text": "Native SST has two molecular forms , SST-28 and SST-14 , consisting of 28 or 14 a.a . , respectively , derived from proteolysis of a larger precursor molecule , pre - pro - SST .", "label": "", "metadata": {}, "score": "72.111465"}
{"text": "Hence evaluation after a 3 to 6 months interval is supposed to be the most reliable [ 15 , 33 - 36 ] .The slow decline of the IGF-1 concentration is probably related to the high sensitivity of the liver after surgery , due to the now lower GH concentration .", "label": "", "metadata": {}, "score": "72.21184"}
{"text": "Cabergoline is most often used .DA monotherapy results in complete remission in less than one third of the patients .Patients with insufficient GH / IGF-1 suppression during SRL monotherapy may benefit from addition of a dopamine agonist , which will further lower GH / IGF-1 concentration in up to 50 % .", "label": "", "metadata": {}, "score": "72.253235"}
{"text": "5 , pp .312 - 320 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . Y. Xie , S. Chen , C. H. Wang , and C. W. Tang , \" Induction of necrosis in the hepatocellular carcinoma HepG2 xenografts treated with SOM230 , \" Zhonghua Gan Zang Bing Za Zhi , vol .", "label": "", "metadata": {}, "score": "72.26125"}
{"text": "155 - 160 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. Guillermet - Guibert , N. Saint - Laurent , L. Davenne et al . , \" Novel synergistic mechanism for sst 2 somatostatin and TNF \u03b1 receptors to induce apoptosis : crosstalk between NF- \u03ba B and JNK pathways , \" Cell Death and Differentiation , vol .", "label": "", "metadata": {}, "score": "72.27004"}
{"text": "6 , pp .849 - 857 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .K. E. \u00d6berg , J. Reubi , D. J. Kwekkeboom , and E. P. Krenning , \" Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy , \" Gastroenterology , vol .", "label": "", "metadata": {}, "score": "72.277115"}
{"text": "In particular , most structurally different from other UT receptor antagonists , benzazepines represented one of the most potent antagonists at the human UT receptor so far described ( .", "label": "", "metadata": {}, "score": "72.34859"}
{"text": "found a significantly better surgical outcome for those patients pretreated with SRL ( 50 % versus 16 % ) [ 129 ] .Thus it is still an open question whether presurgical therapy with subsequent tumour shrinkage really improves short- or long - term outcome of transsphenoidal surgery in acromegaly .", "label": "", "metadata": {}, "score": "72.36824"}
{"text": "The phenyl ring of the indole and the naphthalenemethylamine side chain are localized onto the two aromatic features of the pharmacophore .The basic benzamidine group in S6716 was shown to form a charged interaction with Asp 130 residue within TM3 of the human UT receptor .", "label": "", "metadata": {}, "score": "72.372925"}
{"text": "Indications for medical therapy are ( i ) failure to sufficiently reduce GH secretion by surgery , ( ii ) bridging the time lag until complete remission will be achieved after irradiation , ( iii ) the rare patient with contraindication to surgery .", "label": "", "metadata": {}, "score": "72.398865"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . E. Resmini , P. Dadati , J. L. Ravetti et al . , \" Clinical case seminar : rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long - acting octreotide in an acromegalic patient , \" The Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "72.449936"}
{"text": "Preoperative SRL therapy offers no advantage in microadenomas , but may be indicated in large macroadenomas to reduce tumour volume and/or perioperative complications .Dopamine Agonists ( DAs ) .", "label": "", "metadata": {}, "score": "72.45058"}
{"text": "578 - 583 , 1992 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. M. Conlon , N. Chartrel , J. Leprince , C. Suaudeau , J. Costentin , and H. Vaudry , \" A proenkephalin A - derived peptide analogous to bovine adrenal peptide E from frog brain : purification , synthesis , and behavioral effects , \" Peptides , vol .", "label": "", "metadata": {}, "score": "72.45901"}
{"text": "10 , pp .1330 - 1336 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . F. Roncaroli , M. Faustini - Fustini , F. Mauri , S. Asioli , and G. Frank , \" Crooke 's hyalinization in silent corticotroph adenoma : report of two cases , \" Endocrine Pathology , vol .", "label": "", "metadata": {}, "score": "72.47465"}
{"text": "In contrast , the [ DTrp 4 ] URP analogue retained important binding affinity , suggesting relative tolerance in the interaction with the receptor by stereoinversion occurring in that position .", "label": "", "metadata": {}, "score": "72.481155"}
{"text": "42S-55S , 2011 .View at Google Scholar .M. M. Graham and Y. Menda , \" Radiopeptide imaging and therapy in the United States , \" Journal of Nuclear Medicine , vol .", "label": "", "metadata": {}, "score": "72.49356"}
{"text": "307 - 311 , 1980 .View at Google Scholar \u00b7 View at Scopus .R. Pivonello , M. C. De Martino , P. Cappabianca et al . , \" The medical treatment of Cushing 's disease : effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "72.59534"}
{"text": "In the immune system , SST acts as autocrine / paracrine factor within the complex cellular structure of lymphoid organs .sst1 , sst2 , and sst3 were identified in thymus with a higher expression of sst2 in immature thymocytes .", "label": "", "metadata": {}, "score": "72.60721"}
{"text": "Medical literature suggests that mifepristone can improve clinical symptoms in 73 - 80 % of patients [ 27 ] within one month after starting treatment .", "label": "", "metadata": {}, "score": "72.70355"}
{"text": "Single agonists of sst1 , 2 , and 5 affected both tumor growth and neoangiogenesis via the inactivation of ERK1/2 and the upregulation of . , representing a common intracellular pathway for all the receptors .", "label": "", "metadata": {}, "score": "72.72366"}
{"text": "6 , pp .2781 - 2789 , 2010 .View at Publisher \u00b7 View at Google Scholar .M. Afargan , E. T. Janson , G. Gelerman et al . , \" Novel long - acting somatostatin analog with endocrine selectivity : potent suppression of growth hormone but not of insulin , \" Endocrinology , vol .", "label": "", "metadata": {}, "score": "72.7512"}
{"text": "This may be due to ( i ) an SRL - induced direct suppression of the IGF-1 generation of the hepatocyte or ( ii ) a disturbance of the physiologic response of GH to oral glucose induced by SRL .", "label": "", "metadata": {}, "score": "72.78682"}
{"text": "Studies on corticotroph adenomas have shown that 80 % of these tumors express D2 receptors [ 30 , 31 ] .In recent decades , published case reports and case series have demonstrated the effective use of DA agonists in persistent or recurrent Cushing 's disease .", "label": "", "metadata": {}, "score": "72.80128"}
{"text": "In the Phase III trial , the development of pre - diabetes and diabetes was observed [ see Clinical Studies ( 14 ) ] .In this trial , nearly all patients - including those with normal glucose status at baseline , pre - diabetes , and diabetes - developed worsening glycemia in the first two weeks of treatment .", "label": "", "metadata": {}, "score": "72.91716"}
{"text": "These data reinforce the discussion about the concept of \" extra - hepatic acromegaly \" [ 173 ] and the resulting need for new biomarkers for the evaluation of therapeutic efficacy in acromegaly .", "label": "", "metadata": {}, "score": "72.93404"}
{"text": "Combination Therapy of SRL and Dopamine Agonists In patients insufficiently responding to SRL or dopamine agonist treatment , combination therapy may be an option to further decrease GH secretion [ 151 , 157 - 163 ] .", "label": "", "metadata": {}, "score": "72.9415"}
{"text": "Despite of the potent UT receptor antagonist activity in the rat aorta bioassay , urantide showed residual agonist activity at human recombinant assay in a calcium mobilization assay [ 44 ] .", "label": "", "metadata": {}, "score": "72.98898"}
{"text": "- II , suggesting competitive antagonism .Moreover , BIM-23127 showed about 0.5 log unit lower affinity in competition binding experiments to human or rat UT receptors and inhibition of hU", "label": "", "metadata": {}, "score": "73.00456"}
{"text": "5 , pp .1040 - 1048 , 1988 .View at Google Scholar .T. Lucas - Morante , J. Garcia - Uria , J. Estrada et al . , \" Treatment of invasive growth hormone pituitary adenomas with long - acting somatostatin analog SMS 201 - 995 before transsphenoidal surgery , \" Journal of Neurosurgery , vol .", "label": "", "metadata": {}, "score": "73.02675"}
{"text": "4 , pp .519 - 528 , 1992 .View at Google Scholar \u00b7 View at Scopus .S. Ezzat , E. Horvath , A. G. Harris , and K. Kovacs , \" Morphological effects of octreotide on growth hormone - producing pituitary adenomas , \" Journal of Clinical Endocrinology and Metabolism , vol . 79 , no . 1 , pp .", "label": "", "metadata": {}, "score": "73.037125"}
{"text": "In fact , SST receptors and D2R are frequently coexpressed in endocrine and pituitary tumors [ 54 ] and both receptor activations lead to inhibition of hormonal secretion and cell proliferation .", "label": "", "metadata": {}, "score": "73.051285"}
{"text": "113 - 124 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . H. C. G. Prosser , J. Leprince , H. Vaudry , A. M. Richards , M. E. Forster , and C. J. Pemberton , \" Cardiovascular effects of native and non - native urotensin II and urotensin II - related peptide on rat and salmon hearts , \" Peptides , vol .", "label": "", "metadata": {}, "score": "73.05951"}
{"text": "These uncertainties render the role of IGF-1 or the GH nadir during OGTT as the sole parameter for the estimation of prognosis ( recurrence , morbidity , and mortality ) of acromegaly problematic [ 10 , 46 , 47 ] .", "label": "", "metadata": {}, "score": "73.07825"}
{"text": "Moreover , patients with a microadenoma will probably not profit from presurgical SRL treatment , while those with large macroadenomas may benefit [ 24 , 61 ] .", "label": "", "metadata": {}, "score": "73.081314"}
{"text": "Asymptomatic and reversible elevations in lipase and amylase were observed in patients receiving SIGNIFOR in clinical studies .Pancreatitis is a potential adverse reaction associated with the use of somatostatin analogs due to the association between cholelithiasis and acute pancreatitis .", "label": "", "metadata": {}, "score": "73.08325"}
{"text": "C. Berg , T. E. Wessendorf , F. Mortsch et al . , \" Influence of disease control with pegvisomant on sleep apnoea and tongue volume in patients with active acromegaly , \" European Journal of Endocrinology , vol .", "label": "", "metadata": {}, "score": "73.12939"}
{"text": "In the following a short overview on the indications for medical therapy in acromegaly will be given .The different available forms of medical therapy will be treated in detail .", "label": "", "metadata": {}, "score": "73.1679"}
{"text": "251 - 258 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .I. E. Bonapart , R. van Domburg , S. M. T. H. ten Have et al . , \" The \" bio - assay \" quality of life might be a better marker of disease activity in acromegalic patients than serum total IGF - I concentrations , \" European Journal of Endocrinology , vol .", "label": "", "metadata": {}, "score": "73.19262"}
{"text": "37 - 43 , 2012 .View at Publisher \u00b7 View at Google Scholar . H. Fukuoka , O. Cooper , A. Ben - Shlomo et al . , \" EGFR as a therapeutic target for human , canine , and mouse ACTH - secreting pituitary adenomas , \" Journal of Clinical Investigation , vol .", "label": "", "metadata": {}, "score": "73.28376"}
{"text": "For this reason , palosuran was considered as an interesting tool and a novel and interesting UT receptor antagonist for evaluating the pathophysiological role of endogenous U - II in renal system , since both U - II and UT receptor are highly expressed in the kidney [ 15 ] .", "label": "", "metadata": {}, "score": "73.30737"}
{"text": "A 20 % lower dose per kg bodyweight achieved normalisation of the IGF-1 concentration compared to patients with the full - length receptor variant [ 181 ] .", "label": "", "metadata": {}, "score": "73.315414"}
{"text": "5 , pp .526 - 533 , 1991 .View at Google Scholar \u00b7 View at Scopus .N. Nader , G. Raverot , A. Emptoz - Bonneton et al . , \" Mitotane has an estrogenic effect on sex hormone - binding globulin and corticosteroid - binding globulin in humans , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "73.37672"}
{"text": "6.1 Clinical Trials Experience .Because clinical trials are conducted under widely varying conditions , adverse reaction rates observed in clinical trials of a drug can not be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice .", "label": "", "metadata": {}, "score": "73.37674"}
{"text": "198 - 209 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . S. Cascinu , E. del Ferro , and G. Catalano , \" A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy , \" British Journal of Cancer , vol .", "label": "", "metadata": {}, "score": "73.38082"}
{"text": "4 , pp .371 - 376 , 2011 .View at Publisher \u00b7 View at Google Scholar .M. Buchfelder , S. Schlaffer , M. Droste et al . , \" The German ACROSTUDY : past and present , \" European Journal of Endocrinology , vol .", "label": "", "metadata": {}, "score": "73.38203"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . K. Kovacs , B. W. Scheithauer , M. Lombardero et al . , \" MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy , \" Acta Neuropathologica , vol .", "label": "", "metadata": {}, "score": "73.44124"}
{"text": "The mode of interaction of ( + ) -AC-7954 with human UT receptor was clarified by later docking studies [ 31 ] .As first nonpeptide agonist the compound named AC-7954 has been considered as a lead compound and a series of analogues of this compound have been developed in order to obtain more potent nonpeptide ligands at the human UT receptor [ 56 ] .", "label": "", "metadata": {}, "score": "73.45648"}
{"text": "Individual patients showed varying degrees of improvement in Cushing 's disease manifestations but because of the variability in response and the absence of a control group in this trial , it is uncertain whether these changes could be ascribed to the effects of SIGNIFOR .", "label": "", "metadata": {}, "score": "73.51155"}
{"text": "In retrospective analyses of long - term outcome in acromegaly a normal IGF-1 concentration correlated positively with a normal survival of the patients [ 14 , 23 , 51 , 52 ] .", "label": "", "metadata": {}, "score": "73.52716"}
{"text": "However , the introduction of pharmacophoric elements in small organic structures is fascinating and favourable in the treatment of some diseases .Thereby , organic compounds represent the key for obtaining promising drug candidates by reaching easily a compromise between stability and selectivity .", "label": "", "metadata": {}, "score": "73.562"}
{"text": "Jimenez et al . showed in a small heterogeneous group of seven acromegalic patients , treated with 20 mg Pegvisomant for at least 18 months , a small but significant increase in bone mineral density [ 188 , 189 ] .", "label": "", "metadata": {}, "score": "73.5656"}
{"text": "In contrast Freda and coworkers found a persistently normal IGF-1 concentration in only 3 of 14 ( 21 % ) patients , without a preferential effect in patients with hyperprolactinemia [ 149 ] .", "label": "", "metadata": {}, "score": "73.61417"}
{"text": "95 - 99 , 1992 .View at Google Scholar \u00b7 View at Scopus . D. Milani , J. D. Carmichael , J. Welkowitz et al . , \" Variability and reliability of single serum IGF - I measurements : impact on determining predictability of risk ratios in disease development , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "73.64631"}
{"text": "SRL induce the inhibition of cholecystokinin secretion and the synthesis of a more vicious and lithogenic bile , resulting in gallbladder sludge or gallstones in up to 30 % to 60 % of the patients , respectively [ 97 ] .", "label": "", "metadata": {}, "score": "73.690414"}
{"text": "171 - 179 , 2012 .View at Google Scholar .F. Castinetti , B. Conte - Devolx , and T. Brue , \" Medical treatment of Cushing 's syndrome : glucocorticoid receptor antagonists and mifepristone , \" Neuroendocrinology , vol .", "label": "", "metadata": {}, "score": "73.69654"}
{"text": "P. G. Chiodini , R. Attanasio , R. Cozzi et al . , \" CV 205 - 502 in acromegaly , \" Acta Endocrinologica , vol .", "label": "", "metadata": {}, "score": "73.69728"}
{"text": "- II and McMaster et al . in 1986 [ 28 ] reported a lack of biological activity for the corresponding \" ring - opened \" analogue .", "label": "", "metadata": {}, "score": "73.75128"}
{"text": "1044 - 1051 , 1993 .View at Google Scholar \u00b7 View at Scopus .M. Losa , E. Ciccarelli , P. Mortini et al . , \" Effects of octreotide treatment on the proliferation and apoptotic index of GH - secreting pituitary adenomas , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "73.79083"}
{"text": "In monkeys Octreotide inhibits the GH secretion 45 times more than somatostatin [ 75 ] .Initially Octreotide was available for thrice daily subcutaneous injections .", "label": "", "metadata": {}, "score": "73.79921"}
{"text": "120 - 127 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Kars , V. Delgado , E. R. Holman et al . , \" Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "73.8006"}
{"text": "Cabergoline has a higher affinity for D2 receptors and a longer half - life compared to bromocriptine .In the short term [ 31 ] UFC levels normalized ( 40 % ) or decreased ( 20 % ) in a total cohort of 20 patients , 10 of whom underwent remission during long - term treatment ( 12 - 24 months ) [ 35 ] .", "label": "", "metadata": {}, "score": "73.82634"}
{"text": "Temozolomide .Temozolomide ( TMZ ) is a second - generation alkylating cytostatic agent .Combined with radiotherapy , it is known to be effective in some patients with glioblastoma multiforme and cerebral metastases of malignant melanoma .", "label": "", "metadata": {}, "score": "73.86564"}
{"text": "UFC levels were normalized in 26.3 % and 14.6 % of patients with Cushing 's disease randomized to receive pasireotide 900 micrograms and 600 micrograms twice daily , respectively , at six months of treatment .", "label": "", "metadata": {}, "score": "73.880554"}
{"text": "287 - 317 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. Trepp , R. Everts , C. Stettler et al . , \" Assessment of quality of life in patients with uncontrolled vs. controlled acromegaly using the acromegaly quality of life questionnaire ( AcroQoL ) , \" Clinical Endocrinology , vol .", "label": "", "metadata": {}, "score": "73.96507"}
{"text": "Severe liver toxicity is rare and liver function is usually restored after discontinuation .The drug does not inhibit the growth of the ACTH - secreting tumor .", "label": "", "metadata": {}, "score": "74.02744"}
{"text": "L. J. Hofland , R. A. Feelders , W. W. de Herder , and S. W. J. Lamberts , \" Pituitary tumours : the sst / D2 receptors as molecular targets , \" Molecular and Cellular Endocrinology , vol .", "label": "", "metadata": {}, "score": "74.031044"}
{"text": "In comparison with normal pituitary tissue , somatotroph adenomas are characterized by a higher density of sst2 and sst5 .The expression of sst in adenoma tissue is inhomogeneous and tumour specific .", "label": "", "metadata": {}, "score": "74.04032"}
{"text": "However , they are much cheaper than SRL or Pegvisomant and can be taken orally .At present they are mainly used as an adjunct to insufficient SRL therapy .", "label": "", "metadata": {}, "score": "74.09926"}
{"text": "15 , Supplement 1 , pp .57 - 60 , 2012 .View at Google Scholar .V. Ambrosini , M. Fani , S. Fanti , et al . , \" Radiopeptide imaging and therapy in Europe , \" Journal of Nuclear Medicine , vol .", "label": "", "metadata": {}, "score": "74.17169"}
{"text": "226 - 238 , 1996 .View at Google Scholar \u00b7 View at Scopus .P. Brazeau , W. Vale , R. Burgus et al . , \" Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone , \" Science , vol .", "label": "", "metadata": {}, "score": "74.19464"}
{"text": "The IGF-1 concentration may be elevated , despite an already normal GH suppression during OGTT , leading to divergent results .This can be observed in up to 30 % of postoperative patients [ 16 , 19 ] .", "label": "", "metadata": {}, "score": "74.20964"}
{"text": "The high incidence of SST receptors in human meningiomas is known since decades [ 219 ] and the inhibitory role of SST in the control of proliferation in primary cultures of human meningioma cells has been described [ 220 ] .", "label": "", "metadata": {}, "score": "74.24918"}
{"text": "Before you use SIGNIFOR for the first time , your doctor should do a blood test to check your blood sugar levels and your liver tests .", "label": "", "metadata": {}, "score": "74.44254"}
{"text": "95 , no .11 , pp .E280-E290 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. M. Isidori , G. A. Kaltsas , C. Pozza et al . , \" The ectopic adrenocorticotropin syndrome : clinical features , diagnosis , management , and long - term follow - up , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "74.46225"}
{"text": "To dissolve gallbladder sludge , both chenodeoxycholic acid and ursodeoxycholic acid are highly efficient .Immediately after the conclusion of subcutaneous Octreotide therapy a short - lived hyperactive gallbladder contraction can be observed .", "label": "", "metadata": {}, "score": "74.47414"}
{"text": "10 , pp .893 - 900 , 1997 .View at Google Scholar .U.Plockinger , M. Reichel , U. Fett , W. Saeger , and H.-J. Quabbe , \" Preoperative octreotide treatment of growth hormone - secreting and clinically nonfunctioning pituitary macroadenomas : effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy , \" Journal of Clinical Endocrinology and Metabolism , vol . 79 , no .", "label": "", "metadata": {}, "score": "74.478745"}
{"text": "The very closely related compound SB-657510 [ 67 ] was also indicated as potent antagonist in isolated arteries from rats , cats , monkeys , and hUT - transgenic mice ( Figure 8 ) .", "label": "", "metadata": {}, "score": "74.49808"}
{"text": "165 - 171 , 1995 .View at Google Scholar \u00b7 View at Scopus .M. Deuschle , O. Lecei , G. K. Stalla et al . , \" Steroid synthesis inhibition with ketoconazole and its effect upon the regulation of the hypothalamus - pituitary - adrenal system in healthy humans , \" Neuropsychopharmacology , vol .", "label": "", "metadata": {}, "score": "74.56038"}
{"text": "( i ) Poor assay standardisation is one of the basic problems .The only available standard preparation ( 87/518 ) is impure , containing only 40 % of IGF-1 .", "label": "", "metadata": {}, "score": "74.614845"}
{"text": "663 - 670 , 2010 .View at Publisher \u00b7 View at Google Scholar .C. E. Higham , S. Rowles , D. Russell - Jones , A. M. Umpleby , and P. J. Trainer , \" Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "74.70323"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . E. Bajetta , G. Procopio , L. Ferrari et al . , \" A randomized , multicenter prospective trial assessing long - acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma , \" Cancer , vol .", "label": "", "metadata": {}, "score": "74.704254"}
{"text": "However , as already discussed , receptor interactions modulated by subtype specific SRL may profoundly influence the mechanisms of action of SRL .In addition to the inhibition of GH secretion the native somatostatin , as well as the SRL , also reduce the secretion of insulin , glucagon , cholecystokinin and gastrin .", "label": "", "metadata": {}, "score": "74.71739"}
{"text": "10 , pp .2362 - 2365 , 2003 .View at Google Scholar \u00b7 View at Scopus .C. Tang , C. Liu , X. Zhou , and C. Wang , \" Enhanced inhibitive effects of combination of rofecoxib and octreotide on the growth of human gastric cancer , \" International Journal of Cancer , vol .", "label": "", "metadata": {}, "score": "74.79276"}
{"text": "353 - 358 , 1998 .View at Google Scholar \u00b7 View at Scopus .Z. Arihara , K. Sakurai , S. Yamada , O. Murakami , and K. Takahashi , \" Acromegaly with normal IGF-1 levels probably due to poorly controlled diabetes mellitus , \" Tohoku Journal of Experimental Medicine , vol .", "label": "", "metadata": {}, "score": "74.79808"}
{"text": "Thus peak - trough fluctuations at steady state during once daily dosing are small [ 171 ] .Pegvisomant circulates at concentrations 100 - 1000 times those of endogenous GH .", "label": "", "metadata": {}, "score": "74.865906"}
{"text": "In particular , since the modulation of the U - II system offers a great potential for therapeutic strategies related to the treatment of several diseases , like cardiovascular diseases , the research of selective and potent ligands at UT receptor is more fascinating .", "label": "", "metadata": {}, "score": "74.88464"}
{"text": "Acknowledgment .The support of the Italian Association for Cancer Research is gratefully acknowledged .References .J. Epelbaum , J. L. Guillou , F. Gastambide , D. Hoyer , E. Duron , and C. Viollet , \" Somatostatin , Alzheimer 's disease and cognition : an old story coming of age ?", "label": "", "metadata": {}, "score": "74.88983"}
{"text": "This regimen resulted in fluctuating drug concentrations , with an increase in GH usually observable six hours after the injection [ 76 ] .Comparable results were published by Ezzat et al . in a similar population of 152 acromegalic patients treated with two different dose regimens ( 300 \u03bc g / d or 750 \u03bc g / d ) .", "label": "", "metadata": {}, "score": "74.94332"}
{"text": "Interestingly , SST receptors also affect glial function , for example controlling IL-6 secretion from astrocytes [ 20 ] .SST receptors are also localized in the peripheral nervous system , in proximity of pain terminals , where they were reported to play a role in nociception [ 21 ] .", "label": "", "metadata": {}, "score": "75.10085"}
{"text": "Somatostatin Receptor Ligands ( SRL ) .Mechanism of Action GH secretion is physiologically regulated by the interaction of stimulating and inhibiting hypothalamic peptides , growth hormone releasing hormone , and somatostatin , respectively .", "label": "", "metadata": {}, "score": "75.24066"}
{"text": "Data showed that P5U has a 3-fold higher affinity for the UT receptor than the endogenous ligand as competition experiments witnessed its ability to displace the iodinated radioligand with comparable affinity ( iodinated hU", "label": "", "metadata": {}, "score": "75.2491"}
{"text": "16 , pp .2049 - 2061 , 2012 .View at Google Scholar . D. L. Kleinberg , T. L. Wood , P. A. Furth , and A. V. Lee , \" Growth hormone and insulin - like growth factor - I in the transition from normal mammary development to preneoplastic mammary lesions , \" Endocrine Reviews , vol .", "label": "", "metadata": {}, "score": "75.25391"}
{"text": "To reduce this interference several methods with varying efficacy are used .The \" gold standard \" is the addition of IGF-2 .IGF-2 has a higher binding affinity for IGF - binding proteins than IGF-1 .", "label": "", "metadata": {}, "score": "75.25847"}
{"text": "or a median dose of Pegvisomant of 130 mg / week [ 176 , 177 ] .The dose of Pegvisomant needed for normalisation of the IGF-1 concentration is positively correlated to the basal age- and sex - adjusted IGF-1 concentration and is independent of pretreatment modalities ( primary medical therapy versus postoperative therapy or combination therapy ) [ 178 ] .", "label": "", "metadata": {}, "score": "75.27398"}
{"text": "1856 - 1863 , 2005 .View at Publisher \u00b7 View at Google Scholar .R. Cozzi , R. Attanasio , M. Montini et al . , \" Four - year treatment with octreotide - long - acting repeatable in 110 acromegalic patients : predictive value of short - term results ? \"", "label": "", "metadata": {}, "score": "75.33949"}
{"text": "View at Publisher \u00b7 View at Google Scholar . A. C. F. Costa , A. Rossi , E. M. Carlos , H. R. Machado , and A. C. Moreira , \" Assessment of disease activity in treated acromegalic patients using a sensitive GH assay : should we achieve strict normal GH levels for a biochemical cure ? \"", "label": "", "metadata": {}, "score": "75.36537"}
{"text": "Today subcutaneous therapy has been superseded by long - acting preparations .Slow Release Formulations of SRL .The introduction of slow release formulations , Octreotide long - acting repeatable ( LAR ) , Lanreotide slow release ( SR ) , and Lanreotide Autogel makes possible an intramuscular or deep subcutaneous injection every 2 - 6 weeks ( Table 1 ) .", "label": "", "metadata": {}, "score": "75.381744"}
{"text": "In basal conditions , sst2 and sst3 exist as homodimers but , in response to agonists , dissociate to monomers that are rapidly internalized for sst2 , while monomers of sst3 are retained in membrane [ 51 ] .", "label": "", "metadata": {}, "score": "75.41341"}
{"text": "These assays are very sensitive with a lower limit of detection of 0.002 \u03bc g / L to 0.2 \u03bc g / L. Preanalytic handling is straight forward as GH , in a serum sample , remains stable for at least 24 hours [ 49 ] .", "label": "", "metadata": {}, "score": "75.41846"}
{"text": "It has been reported [ 59 ] that the initial response does not always correlate with long - term control of the disease and that the absence of MGMT expression may be associated with a better response .", "label": "", "metadata": {}, "score": "75.4499"}
{"text": "More recently , improved formulations of the above molecules were introduced in clinical use , such as octreotide long - acting - release ( LAR ) , lanreotide - sustained - release and lanreotide autogel , that improved the pharmacokinetic parameters allowing a single administration every 14 or 28 days [ 66 , 67 ] .", "label": "", "metadata": {}, "score": "75.51285"}
{"text": "Thus combination therapy is also more cost efficient than monotherapy .Clinical Efficacy In addition to assessing the biochemical effects of Pegvisomant therapy a small number of trials focused on specific endpoints .", "label": "", "metadata": {}, "score": "75.54672"}
{"text": "Upon phosphorylation , SHP2 is also activated , dissociates from the receptor and dephosphorylates the inhibitory tyrosine on c - Src C - terminus .Active c - Src , in turn , phosphorylates PTP . causing the sustained activity of this PTP to inactivate ERK1/2 [ 135 ] .", "label": "", "metadata": {}, "score": "75.57651"}
{"text": "Serum IGF-1 had normalised in 75 % of the patients , but there was no correlation to the observed metabolic changes [ 183 ] .Bone Formation Patients with acromegaly tend to have normal or even slightly increased bone mineral density .", "label": "", "metadata": {}, "score": "75.598465"}
{"text": "6 , no .4 , pp .175 - 180 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . S. Gullu , H. Keles , T. Delibasi , V. Tonyukuk , N. Kamel , and G. Erdogan , \" Remission criteria for the follow - up of patients with acromegaly , \" European Journal of Endocrinology , vol .", "label": "", "metadata": {}, "score": "75.63516"}
{"text": "300 , no . 9 , pp .459 - 464 , 1979 .View at Google Scholar \u00b7 View at Scopus . A. P. Van Seters and A. J. Moolenaar , \" Mitotane increases the blood levels of hormone - binding proteins , \" Acta Endocrinologica , vol .", "label": "", "metadata": {}, "score": "75.672"}
{"text": "This extensive expression has revealed the multiple pathophysiological effects mediated by the hUT / UT receptor interaction such as cardiovascular disorders ( heart failure , cardiac remodelling , and atherosclerosis ) , smooth muscle cell proliferation , renal disease , diabetes , and tumour growth [ 18 ] .", "label": "", "metadata": {}, "score": "75.884384"}
{"text": "12 , pp .854 - 857 , 2011 .View at Google Scholar .S. W. J. Lamberts , W. H. Bakker , J. C. Reubi , and E. P. Krenning , \" Somatostatin - receptor imaging in the localization of endocrine tumors , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "75.897194"}
{"text": "Introduction .Surgical therapy of acromegaly aims for elimination of the tumour and normalisation of both , growth hormone ( GH ) secretion and Insulin - like growth factor-1 ( IGF-1 ) concentration .", "label": "", "metadata": {}, "score": "75.89841"}
{"text": "Patients who were initiated on anti - diabetic therapy as a result of SIGNIFOR may require closer monitoring after discontinuation of SIGNIFOR , especially if the anti - diabetic therapy has a risk of causing hypoglycemia .", "label": "", "metadata": {}, "score": "75.909164"}
{"text": "Earlier investigation , that is , an oral glucose load one week after surgery , has been claimed to be as reliable [ 8 , 33 ] .", "label": "", "metadata": {}, "score": "75.91579"}
{"text": "The reduced activity of MAP kinase resulted in a low level of phosphorylation of the CDKI . that , in the unphosphorylated form , can not be ubiquitinated and degraded by the proteasome [ 38 , 109 , 132 ] .", "label": "", "metadata": {}, "score": "76.01527"}
{"text": "2730 - 2734 , 1998 .View at Publisher \u00b7 View at Google Scholar .S. M. Webb , L. Prieto , X. Badia et al . , \" Acromegaly Quality of Life Questionnaire ( ACROQOL ) a new health - related quality of life questionnaire for patients with acromegaly : development and psychometric properties , \" Clinical Endocrinology , vol .", "label": "", "metadata": {}, "score": "76.03451"}
{"text": "72 - 74 , 1996 .View at Google Scholar \u00b7 View at Scopus .T. Abe and D. K. L\u00fcdecke , \" Effects of preoperative octreotide treatment on different subtypes of 90 GH - secreting pituitary adenomas and outcome in one surgical centre , \" European Journal of Endocrinology , vol .", "label": "", "metadata": {}, "score": "76.04941"}
{"text": "538 - 544 , 1999 .View at Publisher \u00b7 View at Google Scholar . H. J. Quabbe and U. Pl\u00f6ckinger , \" Metabolic aspects of acromegaly and its treatment , \" Metabolism : Clinical and Experimental , vol .", "label": "", "metadata": {}, "score": "76.094894"}
{"text": "669 - 692 , 1992 .View at Google Scholar .G. T. Tindall , N. M. Oyesiku , N. B. Watts , R. V. Clark , J. H. Christy , and D. A. Adams , \" Transsphenoidal adenomectomy for growth hormone - secreting pituitary adenomas in acromegaly : outcome analysis and determinants of failure , \" Journal of Neurosurgery , vol .", "label": "", "metadata": {}, "score": "76.11343"}
{"text": "5 , pp .557 - 558 , 1995 .View at Google Scholar \u00b7 View at Scopus .G. Lombardi , A. Colao , D. Ferone et al . , \" CV 205 - 502 treatment in therapy - resistant acromegalic patients , \" European Journal of Endocrinology , vol .", "label": "", "metadata": {}, "score": "76.14172"}
{"text": "U - II binds to its receptor in a \" pseudo - irreversible \" manner , and slow dissociation rate from the UT receptor leads to prolonged activation of the receptor and a functionally silent system [ 22 ] .", "label": "", "metadata": {}, "score": "76.16062"}
{"text": "In fact , in these tumors , a significant inhibition of hormone secretion ( responsible of most clinical symptoms ) and , although less evident in all the tumors , cell cycle arrest was documented .", "label": "", "metadata": {}, "score": "76.23771"}
{"text": "242 - 248 , 1997 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. Ferone , P. M. van Hagen , R. Pivonello , A. Colao , S. W. J. Lamberts , and L. J. Hofland , \" Physiological and pathophysiological role of somatostatin receptors in the human thymus , \" European Journal of Endocrinology , vol .", "label": "", "metadata": {}, "score": "76.252914"}
{"text": "5.1 Hypocortisolism .Treatment with SIGNIFOR leads to suppression of adrenocorticotropic hormone ( ACTH ) secretion in Cushing 's disease .Suppression of ACTH may lead to a decrease in circulating levels of cortisol and potentially hypocortisolism .", "label": "", "metadata": {}, "score": "76.254234"}
{"text": "197 - 208 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . K. Sharma and C. B. Srikant , \" Induction of wild - type p53 , Bax , and acidic endonuclease during somatostatin - signaled apoptosis in MCF-7 human breast cancer cells , \" International Journal of Cancer , vol .", "label": "", "metadata": {}, "score": "76.28473"}
{"text": "Growth - Hormone Receptor - Antagonist .Following incomplete surgery established medical therapies with SRL , dopamine agonists or a combination of both successfully reduce GH secretion in up to 75 - 80 % of the patients .", "label": "", "metadata": {}, "score": "76.306046"}
{"text": "This paper outlines the present status of medical therapy of acromegaly .Indications for permanent postoperative treatment , postirradiation treamtent to bridge the interval until remission as well as primary medical therapy are elaborated .", "label": "", "metadata": {}, "score": "76.35454"}
{"text": "27 - 35 , 2009 .View at Publisher \u00b7 View at Google Scholar . A. Soto Moreno , R. Guerrero V\u00e1zquez , E. Venegas Moreno , S. Palma Milla , J. P. Casta\u00f1o , and A. Leal Cerro , \" Self - limited acute hepatotoxicity caused by pegvisomant , \" Pituitary , vol .", "label": "", "metadata": {}, "score": "76.37538"}
{"text": "12 , pp .741 - 745 , 1999 .View at Google Scholar \u00b7 View at Scopus .P. U. Freda , K. D. Post , J. S. Powell , and S. L. Wardlaw , \" Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "76.43873"}
{"text": "10 , pp .1506 - 1509 , 1999 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. Colao , P. Marzullo , D. Ferone et al . , \" Prostatic hyperplasia : an unknown feature of acromegaly , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "76.480225"}
{"text": "37 , pp .38636 - 38643 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .S. A. War , R. K. Somvanshi , and U. Kumar , \" Somatostatin receptor-3 mediated intracellular signaling and apoptosis is regulated by its cytoplasmic terminal , \" Biochimica et Biophysica Acta , vol .", "label": "", "metadata": {}, "score": "76.54716"}
{"text": "Historically , first approaches for the discovery of new nonpeptide ligands at GPCR receptors were based on high - throughput screening ( HTS ) studies or knowledge of the 3D structure and secondary conformation adopted by the natural ligand .", "label": "", "metadata": {}, "score": "76.6356"}
{"text": "2 - 44 , 2011 .View at Google Scholar .P. Nomikos , M. Buchfelder , and R. Fahlbusch , \" The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ' cure ' , \" European Journal of Endocrinology , vol .", "label": "", "metadata": {}, "score": "76.638"}
{"text": "822 - 840 , 2008 .View at Google Scholar \u00b7 View at Scopus .M. Dur\u00e1n - Prado , M. M. Malag\u00f3n , F. Gracia - Navarro , and J. P. Casta\u00f1o , \" Dimerization of G protein - coupled receptors : new avenues for somatostatin receptor signalling , control and functioning , \" Molecular and Cellular Endocrinology , vol .", "label": "", "metadata": {}, "score": "76.665146"}
{"text": "Inhibition of NO production by both eNOS and nNOS was also described after sst1 - 3 , but not sst4 , activation [ 115 ] via the interference with different molecular mechanisms involving both classical ( PLC activity and PI3k / Akt ) and novel ( ceramide synthesis ) pathways [ 144 ] .", "label": "", "metadata": {}, "score": "76.66677"}
{"text": "Etomidate , an imidazole derivative , is an i.v .nonopioid anesthetic used for both induction and maintenance of anesthesia .It suppresses corticosteroid synthesis in the adrenal cortex by reversibly inhibiting 11- \u03b2 -hydroxylase and 17,20 lyase at non - hypnotic doses .", "label": "", "metadata": {}, "score": "76.673164"}
{"text": "Intraindividual variability ranged from 3 % to 36 % [ 55 ] .( iv )Recently it was demonstrated , that even two high quality assays , using the same international standard , were not comparable [ 42 ] .", "label": "", "metadata": {}, "score": "76.67395"}
{"text": "This paper will focus on traditional and novel medical therapy for hypercortisolism secondary to ACTH - secreting pituitary macroadenoma or carcinoma ( Cushing 's disease , CD ) or to ectopic ACTH secretion .", "label": "", "metadata": {}, "score": "76.720856"}
{"text": "10 , pp .3853 - 3859 , 2008 .View at Publisher \u00b7 View at Google Scholar .M. Buchfelder , D. Weigel , M. Droste et al . , \" Pituitary tumor size in acromegaly during pegvisomant treatment : experience from MR re - evaluations of the German Pegvisomant Observational Study , \" European Journal of Endocrinology , vol .", "label": "", "metadata": {}, "score": "76.746826"}
{"text": "11 - 16 , 2011 .View at Publisher \u00b7 View at Google Scholar . U.Pl\u00f6ckinger and T. Reuter , \" Pegvisomant increases intra - abdominal fat in patients with acromegaly : a pilot study , \" European Journal of Endocrinology , vol .", "label": "", "metadata": {}, "score": "76.793755"}
{"text": "6 , pp .2165 - 2170 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .V. A. Preda , J. Sen , N. Karavitaki , and A. Grossman , \" THERAPY IN ENDOCRINE DISEASE :", "label": "", "metadata": {}, "score": "76.81262"}
{"text": "W. Y. Chen , D. C. Wight , B. V. Mehta , T. E. Wagner , and J. J. Kopchick , \" Glycine 119 of bovine growth hormone is critical for growth - promoting activity , \" Molecular Endocrinology , vol .", "label": "", "metadata": {}, "score": "76.83676"}
{"text": "46 - 52 , 2010 .View at Google Scholar \u00b7 View at Scopus . D. J. Kwekkeboom , B. L. Kam , M. Van Essen et al . , \" Somatostatin receptor - based imaging and therapy of gastroenteropancreatic neuroendocrine tumors , \" Endocrine - Related Cancer , vol .", "label": "", "metadata": {}, "score": "76.844666"}
{"text": "Co- administration of somatostatin analogues with bromocriptine may increase the blood levels of bromocriptine .Dose reduction of bromocriptine may be necessary . 8.1 Pregnancy .", "label": "", "metadata": {}, "score": "76.872696"}
{"text": "Pegvisomant therapy resulted in a reduction of the tongue volume and this was accompanied by a decrease of the apnoea - hypopnoea index in patients with sleep - apnoea .", "label": "", "metadata": {}, "score": "76.88724"}
{"text": "Alternate day injections of Pegvisomant failed to maintain IGF-1 within the age - adjusted range [ 170 ] .Peak serum Pegvisomant concentrations are attained between 33 - 77 hours after administration .", "label": "", "metadata": {}, "score": "76.90094"}
{"text": "The possible pitfalls of the IGF-1 determination are either due to technical issues related to the assay system or to the reference preparation .In addition physiological variations of the IGF-1 concentration have to be taken into account .", "label": "", "metadata": {}, "score": "76.98656"}
{"text": "Cancers of the digestive tract differently express SST receptors according to the localization [ 196 ] .Moreover , also gastrointestinal stromal tumors ( GIST ) were reported to express all five SST receptors in variable percentages [ 200 , 201 ] .", "label": "", "metadata": {}, "score": "76.996635"}
{"text": "257 - 262 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. Kliewer , A. Mann , A. Petrich , et al . , \" A transplantable phosphorylation probe for direct assessment of G protein - coupled receptor activation , \" PloS ONE , vol .", "label": "", "metadata": {}, "score": "77.13187"}
{"text": "12 , pp .1845 - 1852 , 1991 .View at Google Scholar \u00b7 View at Scopus .J. J. Kopchick , \" Discovery and development of a new class of drugs : GH antagonists , \" Journal of Endocrinological Investigation , vol .", "label": "", "metadata": {}, "score": "77.1389"}
{"text": "2730 - 2735 , 1986 .View at Google Scholar \u00b7 View at Scopus . D. Pearson , J. E. Shively , B. R. Clark et al . , \" Urotensin II : a somatostatin - like peptide in the caudal neurosecretory system of fishes , \" Proceedings of the National Academy of Sciences of the United States of America , vol .", "label": "", "metadata": {}, "score": "77.19594"}
{"text": "The volume increase was considered clinically irrelevant and Pegvisomant therapy was continued .In six of the eight patients with tumour growth , the GH concentration could be determined by a specific assay excluding cross - reaction with Pegvisomant .", "label": "", "metadata": {}, "score": "77.19667"}
{"text": "Quinagolide Quinagolide is a nonergot selective D2 agonist .Half - life during steady state is about 17 hours .There are relatively few data on the effect of Quinagolide in acromegaly [ 152 - 156 ] .", "label": "", "metadata": {}, "score": "77.20619"}
{"text": "4 , pp .661 - 666 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. Colao , \" The importance of presurgical somatostatin analogue therapy in acromegaly , \" Endokrynologia Polska , vol .", "label": "", "metadata": {}, "score": "77.23207"}
{"text": "The slow release formulations Octreotide LAR and Lanreotide Autogel are equally effective .Up to 60 % of the patients will achieve complete remission and the rate increases with prolonged treatment .", "label": "", "metadata": {}, "score": "77.270294"}
{"text": "4 , pp .451 - 457 , 1985 .View at Google Scholar \u00b7 View at Scopus .J. A. Verhelst , P. J. Trainer , T. A. Howlett et al . , \" Short and long - term responses to metyrapone in the medical management of 91 patients with Cushing 's syndrome , \" Clinical Endocrinology , vol .", "label": "", "metadata": {}, "score": "77.278336"}
{"text": "6 , pp .E1044-E1050 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. D. Culler , \" Somatostatin - dopamine chimeras : a novel approach to treatment of neuroendocrine tumors , \" Hormone and Metabolic Research , vol .", "label": "", "metadata": {}, "score": "77.2926"}
{"text": "Vasoconstriction induced by exogenous U - II is indeed subjected to significant species and/or regional differences .Thus , from our point of view , the investigation of structure - activity relationships of U - II system represents the keystone that could address the unsolved question regarding the putative role of U - II in several disorders and physiological effects .", "label": "", "metadata": {}, "score": "77.32372"}
{"text": "Tumor cell invasiveness , a feature characterizing the aggressiveness of malignant tumors , also represents a SST receptor target via the inhibition of the PI3K / Akt pathway and the modulation of proteins responsible of actin filament assembly ( namely , Rac and Rho ) [ 146 ] .", "label": "", "metadata": {}, "score": "77.338326"}
{"text": "The corresponding content thereof is hereby incorporated by reference .Any person skilled in the art is fully enabled to identify the active ingredients and , based on these references , likewise enabled to manufacture and test the pharmaceutical indications and properties in standard test models , both in vitro and in vivo .", "label": "", "metadata": {}, "score": "77.3405"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .P. Grieco , A. Carotenuto , R. Patacchini , C. A. Maggi , E. Novellino , and P. Rovero , \" Design , synthesis , conformational analysis , and biological studies of urotensin - II lactam analogues , \" Bioorganic and Medicinal Chemistry , vol .", "label": "", "metadata": {}, "score": "77.341835"}
{"text": "Thus , with reduced liver function a dose reduction is recommended .Gastrointestinal side - effects of bromocriptine ( nausea , vomiting , abdominal discomfort , constipation , or diarrhoea ) can be reduced by a very slow dose increase .", "label": "", "metadata": {}, "score": "77.35103"}
{"text": "Furthermore GH - receptor blockade induces a feedback increase of the endogenous GH concentration .Therefore the determination of GH can no longer be used as a parameter for therapeutic efficacy .", "label": "", "metadata": {}, "score": "77.39681"}
{"text": "Thus it is important to shortly review the problems of diagnosing persistent acromegaly in patients with a relatively low GH concentration after pituitary surgery and relating them to the commonly accepted remission criteria .", "label": "", "metadata": {}, "score": "77.40279"}
{"text": "( iii )The variability of the IGF-1 determination can be substantial .Two samples , measured at baseline and after two weeks , showed an overall good correlation ( . %", "label": "", "metadata": {}, "score": "77.4536"}
{"text": "12 , pp .1628 - 1643 , 2011 .View at Publisher \u00b7 View at Google Scholar .J. D. Veldhuis , M. Bidlingmaier , J. Bailey , D. Erickson , and P. Sandroni , \" A pegylated growth hormone receptor antagonist , pegvisomant , does not enter the brain in humans , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "77.52047"}
{"text": "2634 - 2643 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .G. Weckbecker , I. Lewis , R. Albert , et al . , \" Opportunities in somatostatin research : biological , chemical and therapeutic aspects , \" Nature Reviews Drug Discovery , vol .", "label": "", "metadata": {}, "score": "77.54918"}
{"text": "4 , pp .356 - 360 , 2007 .View at Google Scholar \u00b7 View at Scopus . A. Ben - Shlomo and S. Melmed , \" Clinical review 154 : the role of pharmacotherapy in perioperative management of patients with acromegaly , \" Journal of Clinical Endocrinology and Metabolism , vol . 88 , no . 3 , pp .", "label": "", "metadata": {}, "score": "77.56554"}
{"text": "261 - 262 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .G. Raverot , N. Sturm , F. De Fraipont et al . , \" Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas : a French multicenter experience , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "77.57127"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. P. Matta , E. Couture , L. Cazals , D. Vezzosi , A. Bennet , and P. Caron , \" Impaired quality of life of patients with acromegaly : control of GH / IGF - I excess improves psychological subscale appearance , \" European Journal of Endocrinology , vol .", "label": "", "metadata": {}, "score": "77.63534"}
{"text": "12 , pp .2185 - 2190 , 2001 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . Y. C. Zhu , Y. Z. Zhu , and P. K. Moore , \" The role of urotensin II in cardiovascular and renal physiology and diseases , \" British Journal of Pharmacology , vol .", "label": "", "metadata": {}, "score": "77.63725"}
{"text": "With Pegvisomant 40 mg / week QoL and symptoms scores improved .However , there was no correlation between the IGF-1 concentration and the improvement of QoL [ 190 ] .", "label": "", "metadata": {}, "score": "77.64403"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. Krakoff , C. A. Koch , K. A. Calis , R. H. Alexander , and L. K. Nieman , \" Use of a parenteral propylene glycol - containing etomidate preparation for the long - term management of ectopic Cushing 's syndrome , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "77.65123"}
{"text": "This again highlights the difficulties in deciding on medical therapy based on the postoperative biochemical indicators in acromegaly [ 50 ] .Insulin - Like Growth Factor-1 .", "label": "", "metadata": {}, "score": "77.67692"}
{"text": "Abosch , J. B. Tyrrell , K. R. Lamborn , L. T. Hannegan , C. B. Applebury , and C. B. Wilson , \" Transsphenoidal microsurgery for growth hormone - secreting pituitary adenomas : initial outcome and long - term results , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "77.683426"}
{"text": "S. Melmed , R. Sternberg , D. Cook et al . , \" A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly , \" The Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "77.691605"}
{"text": "- immunoprecipitation and fluorescence resonance energy transfer analysis , \" Cellular Signalling , vol .19 , no .11 , pp .2304 - 2316 , 2007 .", "label": "", "metadata": {}, "score": "77.73627"}
{"text": "Yet the clinical relevance is not clear .During an OGTT the first phase of insulin - secretion is reduced and the subsequent insulin increase is delayed .", "label": "", "metadata": {}, "score": "77.74999"}
{"text": "twice daily for 28 days each ) for the effect on GH , tumour growth , and glucose metabolism .The GH concentration was reduced to below 2.5 \u03bc g / L in 9 % and 19 % of the patients for Octreotide and Pasireotide , respectively .", "label": "", "metadata": {}, "score": "77.78471"}
{"text": "( i )The IGF-1 concentration is age dependent .Hence age - adjusted reference values have to be provided by each manufacturer .However most available assays provide insufficient data for reliable interpretation of the IGF-1 results [ 56 ] .", "label": "", "metadata": {}, "score": "77.788414"}
{"text": "5 , pp .2452 - 2462 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. Invitti , M. De Martin , L. Danesi , and F. Cavagnini , \" Effect of injectable bromocriptine in patients with Cushing 's disease , \" Experimental and Clinical Endocrinology and Diabetes , vol .", "label": "", "metadata": {}, "score": "77.80641"}
{"text": "478 - 483 , 1994 .View at Google Scholar \u00b7 View at Scopus .R. S. Auriemma , M. Galdiero , M. C. De Martino et al . , \" The kidney in acromegaly : renal structure and function in patients with acromegaly during active disease and 1 year after disease remission , \" European Journal of Endocrinology , vol .", "label": "", "metadata": {}, "score": "77.83492"}
{"text": "In a 2001 case report , Etomidate was administered over 5.5 months , with daily dose modulation on the basis of serum cortisol levels .Suppression of steroidogenesis persisted for at least 14 days after cessation of the medication [ 25 ] .", "label": "", "metadata": {}, "score": "77.83702"}
{"text": "262 - 277 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .F. Gatto , F. Barbieri , L. Castelletti et al . , \" In vivo and in vitro response to octreotide LAR in a TSH - secreting adenoma : characterization of somatostatin receptor expression and role of subtype 5 , \" Pituitary , vol .", "label": "", "metadata": {}, "score": "77.9601"}
{"text": "The different physiological effects of SST in different tissues are mainly ascribed to the specific characteristics of the cell types that express the SST receptors , resulting in the activation of distinct signal transduction pathways .", "label": "", "metadata": {}, "score": "78.00503"}
{"text": "If resolution of abnormalities to normal or near normal occurs , resuming treatment with SIGNIFOR may be done cautiously , with close observation , and only if some other likely cause has been found .", "label": "", "metadata": {}, "score": "78.13936"}
{"text": "4 , pp .369 - 376 , 1997 .View at Google Scholar . H. J. Quabbe , \" Treatment of acromegaly by trans - sphenoidal operation , 90-yttrium implantation and bromocriptine : results in 230 patients , \" Clinical Endocrinology , vol .", "label": "", "metadata": {}, "score": "78.2129"}
{"text": "Both regimens achieved comparable results concerning the percentage of patients in remission as well as the mean GH ( mean of a 5-point GH profile ) or the IGF-1 concentration .", "label": "", "metadata": {}, "score": "78.22429"}
{"text": "Aminoglutethimide .Aminoglutethimide is a potent reversible inhibitor of adrenal mineralocorticoid and glucocorticoid synthesis .It blocks cholesterol side - chain cleavage to pregnenolone , by inhibiting P450 enzymes .", "label": "", "metadata": {}, "score": "78.227356"}
{"text": "It is effective in reducing UFC levels in 83 % of treated patients [ 19 , 20 ] .It is commonly used in patients with adrenal carcinoma .", "label": "", "metadata": {}, "score": "78.25317"}
{"text": "Moreover , the synthesis of many growth factors ( insulin - like growth factor 1 , IGF-1 ; epidermal growth factor , EGF ; fibroblast growth factor , FGF ; vascular - endothelial growth factor , VEGF ) is also inhibited by SST [ 3 , 4 ] .", "label": "", "metadata": {}, "score": "78.31984"}
{"text": "The optimal treatment for the management of SIGNIFOR - induced hyperglycemia is not known .If uncontrolled hyperglycemia persists , despite appropriate medical management , the dose of SIGNIFOR should be reduced or discontinued .", "label": "", "metadata": {}, "score": "78.398155"}
{"text": "For example , SST suppresses GH , prolactin , and TSH production from pituitary gland , insulin , glucagon and exocrine secretions from pancreas , and several gastrointestinal peptides [ 1 ] .", "label": "", "metadata": {}, "score": "78.44942"}
{"text": "Unfortunately the spectrum of isoforms recognised is rarely indicated .Furthermore the reference preparation used for the assay may differ between assays .Thus GH determination with different assays leads to divergent results .", "label": "", "metadata": {}, "score": "78.47251"}
{"text": "Their mechanism of action involves blocking adrenal steroidogenesis ( ketoconazole , metyrapone , aminoglutethimide , mitotane , etomidate ) or inhibiting the peripheral action of cortisol through blocking its receptors ( mifepristone \" RU-486 \" ) .", "label": "", "metadata": {}, "score": "78.47644"}
{"text": "Other Side Effects Increase of Liver Enzymes Overall the drug is well tolerated and subjective complaints are few .An increase in liver enzymes has been observed and is reversible after ending treatment with Pegvisomant [ 192 ] .", "label": "", "metadata": {}, "score": "78.52556"}
{"text": "315 - 319 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .S. W. J. Lamberts , A. J. van der Lely , and L. J. Hofland , \" New somatostatin analogs : will they fulfil old promises ? \" European Journal of Endocrinology , vol .", "label": "", "metadata": {}, "score": "78.56372"}
{"text": "This has been confirmed in five acromegalic patients on Pegvisomant .We demonstrated a significant increase of intra - abdominal fat by electron beam computer tomography , while the amount of subcutaneous abdominal fat remained unchanged [ 174 ] .", "label": "", "metadata": {}, "score": "78.63404"}
{"text": "At study entry , patients were randomized to receive twice a day ( b.i.d . ) doses of either 0.6 mg or 0.9 mg of SIGNIFOR given subcutaneously .", "label": "", "metadata": {}, "score": "78.802216"}
{"text": "Tumour Shrinkage SRL reduce tumour volume in about 50 % of previously untreated acromegalic patients .The extent of tumour shrinkage in these patients has been reported to be as high an 50 % .", "label": "", "metadata": {}, "score": "78.867645"}
{"text": "Both the approaches present several advantages and disadvantages .Although peptides offer several advantages as therapeutic tools over small organic molecules , when they are composed of natural amino acids they are not very good drug candidates because of their intrinsic physicochemical and pharmacokinetic properties such as low bioavailability and biodistribution .", "label": "", "metadata": {}, "score": "78.87588"}
{"text": "SST receptors may form heterodimers with other member of SST receptor family , either in resting conditions or upon ligand binding .SST receptors also dimerize with receptors of other GPCR families , ( e.g. , D2R ) or with other receptor families , such as tyrosine kinase receptors ( i.e. , EGFR ) , originating heterodimers .", "label": "", "metadata": {}, "score": "78.88399"}
{"text": "41 , pp .533 - 552 , 1985 .View at Google Scholar \u00b7 View at Scopus .J. M. Conlon , F. O'Harte , D. D. Smith , M. C. Tonon , and H. Vaudry , \" Isolation and primary structure of urotensin II from the brain of a tetrapod , the frog Rana ridibunda , \" Biochemical and Biophysical Research Communications , vol .", "label": "", "metadata": {}, "score": "78.88499"}
{"text": "55 - 61 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .S. Bonadonna , G. Mazziotti , M. Nuzzo et al . , \" Increased prevalence of radiological spinal deformities in active acromegaly : a cross - sectional study in postmenopausal women , \" Journal of Bone and Mineral Research , vol .", "label": "", "metadata": {}, "score": "78.931"}
{"text": "428 - 439 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. G. Pan , T. Florio , and P. J. S. Stork , \" G protein activation of a hormone - stimulated phosphatase in human tumor cells , \" Science , vol .", "label": "", "metadata": {}, "score": "78.94141"}
{"text": "53 - 60 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .G. Brabant , \" Insulin - like growth factor - I : marker for diagnosis of acromegaly and monitoring the efficacy of treatment , \" European Journal of Endocrinology , Supplement , vol .", "label": "", "metadata": {}, "score": "78.94862"}
{"text": "[57 ] chose to obtain new molecules by breaking of C3-C4 bond in the isochromanone scaffold .This synthetic strategy adopting for development of novel urotensin - II agonists was primarily focused to the introduction of different linkers between the two aromatic rings .", "label": "", "metadata": {}, "score": "79.030136"}
{"text": "An important improvement of surgical results in pretreated patients was reported by Colao et al .with a remission rate of 55 % ( . ) in treated versus untreated patients , respectively [ 122 ] .", "label": "", "metadata": {}, "score": "79.06639"}
{"text": "In embryofetal development studies in rats given 1 , 5 , and 10 mg / kg / day subcutaneously throughout organogenesis , maternal toxicity was observed at all doses , including the lowest dose tested which had exposures 4-times higher than that at the maximum therapeutic dose based on AUC comparisons across species .", "label": "", "metadata": {}, "score": "79.1288"}
{"text": "Int . J. Cancer ( Radiat .Oncol .Invest . )\u00a9 2000 Wiley - Liss , Inc. .[ Show abstract ] [ Hide abstract ] ABSTRACT : Receptors for regulatory peptides such as somatostatin or vasoactive intestinal polypeptide are expressed by a number of human neoplasms and can be visualized in vivo with peptide receptor scintigraphy .", "label": "", "metadata": {}, "score": "79.15143"}
{"text": "The hU - II binds with high affinity to this receptor , resulting in intracellular calcium mobilization via phospholipase C - dependent increase in inositol phosphates .", "label": "", "metadata": {}, "score": "79.15325"}
{"text": "7989 , p. 811 , 1976 .View at Google Scholar \u00b7 View at Scopus .S. W. J. Lamberts , J. G. M. Klijn , and M. De Quijada , \" The mechanism of the suppressive action of bromocriptine on adrenocorticotropin secretion in patients with Cushing 's disease and Nelson 's syndrome , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "79.160065"}
{"text": "Serum levels should be monitored to optimize therapy .The compound is distributed in the adipose tissue and has a long half - life .Gastrointestinal and neurologic symptoms are the most common side effects .", "label": "", "metadata": {}, "score": "79.163956"}
{"text": "Inhibition of pituitary adenoma cell proliferation in response to native SST or lanreotide is mediated by increased PTP activity , as observed in primary cell cultures of human GH - secreting or nonfunctioning pituitary adenomas [ 157 , 158 ] .", "label": "", "metadata": {}, "score": "79.1974"}
{"text": "765 - 777 , 1999 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Thangaraju , K. Sharma , D. Liu , S. H. Shen , and C. B. Srikant , \" Interdependent regulation of intracellular acidification and SHP-1 in apoptosis , \" Cancer Research , vol .", "label": "", "metadata": {}, "score": "79.311005"}
{"text": "However , in a recent consensus discussion , this criterion failed to be seen as reliable and sufficiently evidenced based .The GH concentration determined by new and more sensitive assays is generally lower compared to the earlier used polyclonal assays .", "label": "", "metadata": {}, "score": "79.321686"}
{"text": "During primary therapy , remission criteria for GH or IGF-1 were achieved by both SRL in 50 % or 60 % , respectively [ 80 ] .", "label": "", "metadata": {}, "score": "79.33217"}
{"text": "[ 94 ] reported a phase II study on a large series of patients with metastasized neuroendocrine cancers treated with repeated cycles [ 90 Y - DOTA]-TOC reporting that response is associated with longer survival .", "label": "", "metadata": {}, "score": "79.39369"}
{"text": "TMZ promotes apoptosis of target cells and induces massive cell shrinkage and necrosis , depleting the DNA repair enzyme O6-methylguanine - DNA - methyl transferase ( MGMT ) in various cell types .", "label": "", "metadata": {}, "score": "79.44795"}
{"text": "These receptor subtypes are expressed in different tissues under normal physiological conditions .Corticotroph tumor cells from Cushing 's disease patients frequently over - express SSTR5 whereas the other receptor subtypes are often not expressed or are expressed at lower levels .", "label": "", "metadata": {}, "score": "79.52178"}
{"text": "Tyrosine Kinase Inhibitors .Epidermal growth factor receptor ( EGFR ) activation , due to either mutation or ligand or receptor overexpression , is associated with a variety of human cancers .", "label": "", "metadata": {}, "score": "79.55625"}
{"text": "4068 , pp .77 - 79 , 1973 .View at Google Scholar \u00b7 View at Scopus .S. Ohsako , I. Ishida , T. Ichikawa , and T. Deguchi , \" Cloning and sequence analysis of cDNAs encoding precursors of urotensin II- \u03b1 and - \u03b3 , \" Journal of Neuroscience , vol .", "label": "", "metadata": {}, "score": "79.55862"}
{"text": "Pegylation of the molecule prolongs the plasma half - life from 15 minutes to 72 hours [ 168 , 169 ] .Furthermore pegylation reduces immunogenicity of the molecule as well as interaction with GH - binding proteins [ 167 ] .", "label": "", "metadata": {}, "score": "79.56124"}
{"text": "Injection Site Reactions .Injection site reactions were reported in 17 % of patients enrolled in the Phase III trial in Cushing 's disease .The events were most frequently reported as local pain , erythema , hematoma , hemorrhage , and pruritus .", "label": "", "metadata": {}, "score": "79.57105"}
{"text": "Metyrapone predominantly inhibits 11 \u03b2 hydroxylase and has been used either as a monotherapy , leading to a normalization of cortisol levels in 75 - 80 % of patients , or in combination with other steroidogenesis inhibitors or with radiation therapy , achieving even higher efficacy [ 15 , 16 ] .", "label": "", "metadata": {}, "score": "79.76027"}
{"text": "583 - 596 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .L. J. Hofland , R. A. Feelders , W. W. de Herder , and S. W. J. Lamberts , \" Pituitary tumours : the sst / D2 receptors as molecular targets , \" Molecular and Cellular Endocrinology , vol .", "label": "", "metadata": {}, "score": "79.81058"}
{"text": "No studies have been performed in pediatric patients [ see Use in Specific Populations ( 8.4)].Geriatric Patients .No clinical pharmacology studies have been performed in geriatric patients .", "label": "", "metadata": {}, "score": "79.82002"}
{"text": "Gastrointestinal Disorders .Gastrointestinal disorders , predominantly diarrhea , nausea , abdominal pain and vomiting were reported frequently in the Phase III trial ( see Table 1 ) .", "label": "", "metadata": {}, "score": "79.99946"}
{"text": "There were no deaths during the study .Serious adverse events were reported in 25 % of patients .Adverse events leading to study discontinuation were reported in 17 % of patients .", "label": "", "metadata": {}, "score": "80.12483"}
{"text": "In addition , its intravenous administration makes it easily used in patients with no oral or enteral access .Studies and case reports support its use in patients with Cushing 's syndrome .", "label": "", "metadata": {}, "score": "80.137085"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . F. Lehmann , L. Lake , E. A. Currier , R. Olsson , U. Hacksell , and K. Luthman , \" Design , parallel synthesis and SAR of novel urotensin II receptor agonists , \" European Journal of Medicinal Chemistry , vol .", "label": "", "metadata": {}, "score": "80.14244"}
{"text": "The extent of neovascularisation , as well as the expression of VEGF , correlates positively with the degree of invasiveness in some pituitary adenomas [ 69 ] .", "label": "", "metadata": {}, "score": "80.17679"}
{"text": "2480 - 2492 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .W. A. Kinney , H. R. Almond Jr. , J. Qi et al . , \" Structure - function analysis of urotensin II and its use in the construction of a ligand - receptor working model , \" Angewandte Chemie - International Edition , vol .", "label": "", "metadata": {}, "score": "80.28287"}
{"text": "This may be due the exon-3 polymorphism of the human GH - receptor gene .40%-50 % of the Western population carries an exon-3 deleted GH - receptor .", "label": "", "metadata": {}, "score": "80.32625"}
{"text": "Pre existing psychiatric illness is a relative contraindication to DA therapy .High dose Cabergoline therapy has been reported to cause cardiac valvular abnormalities .With long - term , high dose Cabergoline therapy echocardiographic follow - up has been recommended [ 61 , 164 , 165 ] .", "label": "", "metadata": {}, "score": "80.40172"}
{"text": "A study [ 38 ] describes 6 cases of ectopic tumors , three of which were not cured by surgery .UFC was normalized in two of these patients , although one exhibited treatment escape .", "label": "", "metadata": {}, "score": "80.40838"}
{"text": "R. R. Grunstein , K. Y. Ho , and C. E. Sullivan , \" Sleep apnea in acromegaly , \" Annals of Internal Medicine , vol .", "label": "", "metadata": {}, "score": "80.432755"}
{"text": "View at Google Scholar \u00b7 View at Scopus . D. A. Calhoun , W. B. White , H. Krum et al . , \" Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension : results of a randomized , double - blind , placebo- and active - controlled phase 2 trial , \" Circulation , vol .", "label": "", "metadata": {}, "score": "80.45021"}
{"text": "We hope that the several offered noninvasive medical strategies can serve as a guide for the oncologists to improve the quality of life of their patients .", "label": "", "metadata": {}, "score": "80.45508"}
{"text": "3537 - 3542 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .N. R. Biermasz , F. W. Dekker , A. M. Pereira et al . , \" Determinants of survival in treated acromegaly in a single center : predictive value of serial insulin - like growth factor I measurements , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "80.46181"}
{"text": "No tachyphylaxia has been observed during long - term therapy .This is in contrast to the declining efficacy in neuroendocrine gastrointestinal tumours treated with SRL .", "label": "", "metadata": {}, "score": "80.52154"}
{"text": "Nursing Mothers .It is not known whether this drug is excreted in human milk .Because many drugs are excreted in human milk , caution should be exercised when SIGNIFOR is administered to a nursing woman [ see Nonclinical Toxicology ( 13.1 ) ] .", "label": "", "metadata": {}, "score": "80.532684"}
{"text": "223 - 230 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. Godbout , M. Manavela , K. Danilowicz , H. Beauregard , O. D. Bruno , and A. Lacroix , \" Cabergoline monotherapy in the long - term treatment of Cushing 's disease , \" European Journal of Endocrinology , vol .", "label": "", "metadata": {}, "score": "80.53726"}
{"text": "If the values are confirmed or rising , interrupt SIGNIFOR treatment and investigate for probable cause of the findings , which may or may not be SIGNIFOR - related .", "label": "", "metadata": {}, "score": "80.58949"}
{"text": "A multidisciplinary approach that includes endocrinologists , neurosurgeons , oncologists , and radiotherapists should be adopted .This paper will focus on traditional and novel medical therapy for aggressive ACTH - dependent CS .", "label": "", "metadata": {}, "score": "80.798416"}
{"text": "In the SIGNIFOR 0.6 mg group , HbA1c increased from 5.8 % at baseline to 7.2 % at Month 6 .In the SIGNIFOR 0.9 mg group , HbA1c increased from 5.8 % at baseline to 7.3 % at Month 6 [ see Warning and Precautions ( 5.2 ) ] .", "label": "", "metadata": {}, "score": "80.82991"}
{"text": "Information on their mechanism of action , and some pharmakokinetic data are included .Special emphasis is given to the difficulties to define remission criteria of acromegaly due to technical assay problems .", "label": "", "metadata": {}, "score": "80.889694"}
{"text": "However , for this criterion insufficient data are available to date .Of course , stricter criteria will result in fewer complete remissions .Medical therapy is indicated in those acromegalic patients , who failed to achieve remission after surgery or in the rare patient with contraindication for surgical therapy .", "label": "", "metadata": {}, "score": "80.921234"}
{"text": "Optimal precision in achieving concentration of the active ingredients within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the active ingredients ' availability to target sites .", "label": "", "metadata": {}, "score": "80.9946"}
{"text": "Reduction of soft tissue swelling occurring early in the time course of medical treatment may reduce difficulties of intubation .Thus presurgical therapy may be indicated in high - risk patients and should be discussed with the anaesthetist [ 122 , 131 , 132 ] .", "label": "", "metadata": {}, "score": "80.99573"}
{"text": "Ectopic ACTH Secretion ( EAS ) accounts for 15 - 20 % of cases of Cushing 's syndrome and covers a spectrum of tumors from undetectable isolated lesions to extensive metastatic and aggressive malignancies .", "label": "", "metadata": {}, "score": "81.085846"}
{"text": "155 - 166 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. C. Chamberlain , \" The role of chemotherapy and targeted therapy in the treatment of intracranial meningioma , \" Current Opinion in Oncology , vol .", "label": "", "metadata": {}, "score": "81.1101"}
{"text": "371 - 377 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .B. M. K. Biller , A. B. Grossman , P. M. Stewart et al . , \" Treatment of adrenocorticotropin - dependent cushing 's syndrome : a consensus statement , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "81.13575"}
{"text": "- II .In contrast of this noncompetitive antagonism of contraction to U - II in isolated rat aorta , BIM-23127 inhibited calcium mobilization in human embryonic kidney 293 cells expressing UT receptors in a competitive manner .", "label": "", "metadata": {}, "score": "81.157135"}
{"text": "2132 - 2138 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. H. Dillard , S. H. Gultekin , J. B. Delashaw , C. G. Yedinak , E. A. Neuwelt , and M. Fleseriu , \" Temozolomide for corticotroph pituitary adenomas refractory to standard therapy , \" Pituitary , vol .", "label": "", "metadata": {}, "score": "81.19833"}
{"text": "The second generation DAs have to be taken daily ( Quinagolide ) or once to twice weekly ( Cabergoline ) .Increasing the dose to more than the recommended maximal dose does not increase efficacy , but results in worse side effects .", "label": "", "metadata": {}, "score": "81.31691"}
{"text": "[ 75 ] .However , these series were correlated to problems such as cytochrome P450 inhibition and low oral bioavailability .Therefore , some improvements were obtained by using a piperazine core in such promising compounds .", "label": "", "metadata": {}, "score": "81.37373"}
{"text": "496 - 497 , 1998 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. M. Conlon , K. Yano , D. Waugh , and N. Hazon , \" Distribution and molecular forms of urotensin II and its role in cardiovascular regulation in vertebrates , \" Journal of Experimental Zoology , vol .", "label": "", "metadata": {}, "score": "81.37664"}
{"text": "[ 128 ] , ( ii ) a small , nonsignificant improvement ( 45 % versus 23 % , . , pretreated versus primary surgery ) [ 130 ] .", "label": "", "metadata": {}, "score": "81.57849"}
{"text": "699 - 706 , 1989 .View at Google Scholar \u00b7 View at Scopus .M. Thoren , U. Adamson , and H. E. Sjoberg , \" Aminoglutethimide and metyrapone in the management of Cushing 's syndrome , \" Acta Endocrinologica , vol .", "label": "", "metadata": {}, "score": "81.641785"}
{"text": "3844 - 3847 , 2010 .View at Publisher \u00b7 View at Google Scholar .S. J. Neggers , J. J. Kopchick , J. O. L. J\u00f8rgensen , and A. J. Van Der Lely , \" Hypothesis : extra - hepatic acromegaly : a new paradigm ? \" European Journal of Endocrinology , vol .", "label": "", "metadata": {}, "score": "81.647644"}
{"text": "[28 ] reviewed the data of 37 treated CS patients ( 12 with EAS , 5 with Cushing 's disease , the others affected by other causes of CS ) .", "label": "", "metadata": {}, "score": "81.68396"}
{"text": "Incubation in vitro of GRP receptor - expressing rat CA20948 and human PC3 tumour cells with the ( 111)In - labelled analogues resulted in rapid receptor - mediated uptake and internalisation .", "label": "", "metadata": {}, "score": "81.710785"}
{"text": "Thus , the dosage regimen is selected in accordance with a variety of factors including the route of administration and the renal and hepatic function of the patient .", "label": "", "metadata": {}, "score": "81.7374"}
{"text": "Conclusions The GH - receptor antagonist Pegvisomant normalises IGF-1 concentration in up to 97 % of the patients .The dose is titrated to normalize IGF-1 concentration , because GH can not be routinely measured and serve as an indicator for therapeutic efficacy , due to cross - reactivity of the routinely used GH assay with Pegvisomant .", "label": "", "metadata": {}, "score": "81.82005"}
{"text": "However , if GH is normalised by SRL therapy , the drug induced suppression of insulin secretion , directly and via suppression of GLP-1 [ 92 ] , increases lipolysis .", "label": "", "metadata": {}, "score": "81.92152"}
{"text": "1945 - 1955 , 2011 .View at Google Scholar .S. Leiba , R. Weinstein , B. Shindel et al . , \" The protracted effect of o , p'-DDD in Cushing 's disease and its impact on adrenal morphogenesis of young human embryo , \" Annales d'Endocrinologie , vol .", "label": "", "metadata": {}, "score": "81.94803"}
{"text": "Both adenylyl cyclase inhibition and PTP activation are induced by all SST receptor subtypes , while MAPK activity is increased by sst4 , decreased by sst3 and 5 , and modulated in both directions by sst1 and 2 .", "label": "", "metadata": {}, "score": "82.1257"}
{"text": "Adverse events associated with cortisol levels below the normal range were experienced by 13 patients .This was managed by dose reduction without loss of efficacy .", "label": "", "metadata": {}, "score": "82.215576"}
{"text": "Quality of Life The IGF-1 concentration has been shown to be a poor indicator of complete clinical remission .Thus , to assess the clinical efficacy of Pegvisomant therapy Quality of Life ( QoL ) Questionnaires specifically developed for acromegalic patients have been used to monitor clinical efficacy of the medication .", "label": "", "metadata": {}, "score": "82.24315"}
{"text": "5593 - 5602 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .P. J. Jenkins , P. J. Trainer , P. N. Plowman et al . , \" The long term outcome after adrenalectomy and prophylactic pituitary radiotherapy in adrenocorticotropin - dependent Cushing 's syndrome , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "82.30592"}
{"text": "Introduction .Urotensin - II ( U - II ) belongs to a series of regulatory neuropeptides first isolated from the urophysis of the teleost fish Gillichthys mirabilis by Karl Lederis and Howard Bern in the 1960s .", "label": "", "metadata": {}, "score": "82.42816"}
{"text": "0036 ] The active ingredient or a pharmaceutically acceptable salt thereof may also be used in form of a hydrate or include other solvents used for crystallization .", "label": "", "metadata": {}, "score": "82.44861"}
{"text": "217 - 226 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. Rajasoorya , I. M. Holdaway , P. Wrightson , D. J. Scott , and H. K. Ibbertson , \" Determinants of clinical outcome and survival in acromegaly , \" Clinical Endocrinology , vol .", "label": "", "metadata": {}, "score": "82.4554"}
{"text": "Subsequently , with the aim of investigating the role played by the exocyclic region in the receptor interaction , a series of truncated peptides related to hU", "label": "", "metadata": {}, "score": "82.6101"}
{"text": "SST receptors are differentially expressed in discrete or overlapping distribution in multiple target organs , such as central nervous and immune systems , pituitary , thyroid , and adrenal glands , pancreas , gut , and kidney .", "label": "", "metadata": {}, "score": "82.62822"}
{"text": "R53-R73 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .I. Buchmann , M. Henze , S. Engelbrecht et al . , \" Comparison of 68 Ga - DOTATOC PET and 111", "label": "", "metadata": {}, "score": "82.752"}
{"text": "Thyroid Function .Hypothyroidism with the use of SIGNIFOR was reported for seven patients participating in the Phase III study in Cushing 's disease .All seven patients presented with a TSH close to or below the lower limit at study entry which precludes establishing a conclusive relationship between the adverse event and the use of SIGNIFOR .", "label": "", "metadata": {}, "score": "82.76114"}
{"text": "Bradycardia .Bradycardia has been reported with the use of SIGNIFOR [ see Adverse Reactions ( 6 ) ] .Patients with cardiac disease and/or risk factors for bradycardia , such as history of clinically significant bradycardia , high - grade heart block , or concomitant use of drugs associated with bradycardia , should be carefully monitored .", "label": "", "metadata": {}, "score": "82.77681"}
{"text": "were able to show a negative correlation between well - being and the IGF-1 concentration , that is , higher QoL with IGF-1 concentration approaching normal values [ 27 ] .", "label": "", "metadata": {}, "score": "82.80904"}
{"text": "The elevations were not associated with clinical symptoms of hepatic disease .In the clinical development program of SIGNIFOR , there were 4 patients with concurrent elevations in ALT greater than 3 x ULN and bilirubin greater than 2 x ULN : one patient with Cushing 's disease and three healthy volunteers [ see Warnings and Precautions ( 5.4 ) ] .", "label": "", "metadata": {}, "score": "83.04523"}
{"text": "Possibly less Pegvisomant is needed when , due to the effect of SRL , less growth hormone is to compete with in the circulation .In addition , the reduction of insulin in the portal vein during SRL therapy will decrease the number of available GH - receptors and thus increase the efficacy of GH receptor blockade by Pegvisomant [ 178 ] .", "label": "", "metadata": {}, "score": "83.13287"}
{"text": "Moreover , the characterization of cDNA encoding carp pro - U - II has shown that the U - II and somatostatin-14 precursors share a common structure organization since the active peptides are both located at the C - terminal portion of the precursors [ 8 ] .", "label": "", "metadata": {}, "score": "83.17249"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. L. Espinosa - de - los - Monteros , M. Mercado , E. Sosa et al . , \" Changing patterns of insulin - like growth factor - I and glucose - suppressed growth hormone levels after pituitary surgery in patients with acromegaly , \" Journal of Neurosurgery , vol .", "label": "", "metadata": {}, "score": "83.17384"}
{"text": "387 - 391 , 1988 .View at Google Scholar \u00b7 View at Scopus .J. G. M. Klijn , S. W. J. Lamberts , and F. H. De Jong , \" Interrelationships between tumour size , age , plasma growth hormone and incidence of extrasellar extension in acromegalic patients , \" Acta Endocrinologica , vol .", "label": "", "metadata": {}, "score": "83.17903"}
{"text": "4 , pp .465 - 471 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. S. Bates , W. Van't Hoff , J. M. Jones , and R. N. Clayton , \" An audit of outcome of treatment in acromegaly , \" Quarterly Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "83.18547"}
{"text": "2732 - 2740 , 2011 .View at Publisher \u00b7 View at Google Scholar .P. G. Campbell , E. Kenning , D. W. Andrews , S. Yadla , M. Rosen , and J. J. Evans , \" Outcomes after a purely endoscopic transsphenoidal resection of growth hormone - secreting pituitary adenomas , \" Neurosurgical Focus , vol .", "label": "", "metadata": {}, "score": "83.2332"}
{"text": "SIGNIFOR should be clear and colorless .Before you inject your dose , check to make sure that SIGNIFOR is clear and colorless , and does not have any clumps or particles in it .", "label": "", "metadata": {}, "score": "83.292915"}
{"text": "Gefitinib effectively suppressed ACTH secretion and inhibited tumor growth in EGFR - expressing tumors in vivo ( mouse model ) , in support of the in vitro results .", "label": "", "metadata": {}, "score": "83.30257"}
{"text": "65 - 69 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. R. Lila , R. A. Gopal , S. V. Acharya et al . , \" Efficacy of cabergoline in uncured ( persistent or recurrent ) cushing disease after pituitary surgical treatment with or without radiotherapy , \" Endocrine Practice , vol .", "label": "", "metadata": {}, "score": "83.30467"}
{"text": "10 , pp .3411 - 3418 , 1998 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .P. U. Freda , S. L. Wardlaw , and K. D. Post , \" Long - term endocrinological follow - up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly , \" Journal of Neurosurgery , vol .", "label": "", "metadata": {}, "score": "83.33969"}
{"text": "18 , pp .1246 - 1249 , 1990 .View at Google Scholar \u00b7 View at Scopus .I. M. Modlin , S. F. Moss , K. Oberg et al . , \" Gastrointestinal neuroendocrine ( carcinoid ) tumours : current diagnosis and management , \" Medical Journal of Australia , vol .", "label": "", "metadata": {}, "score": "83.34491"}
{"text": "In patients with radiotherapy the relation of GH to IGF-1 is disturbed and can not be relied upon [ 41 ] .A divergence between the concentration of IGF-1 and the GH nadir during OGTT has been observed in both directions , that is , an increased IGF-1 and a normal GH nadir or a normal IGF-1 and insufficient suppression of the GH concentration [ 15 , 42 - 44 ] .", "label": "", "metadata": {}, "score": "83.413055"}
{"text": "Nowadays , combination of tumor debulking , radiotherapy , medical treatment , and chemotherapy , appropriately and timely used , can avoid progression of an otherwise lethal condition .", "label": "", "metadata": {}, "score": "83.45393"}
{"text": "The brachial artery vascular function , which is known to be decreased in active acromegaly , improved in 10 patients treated with 10 - 40 mg / d Pegvisomant for 18 months [ 186 ] .", "label": "", "metadata": {}, "score": "83.4601"}
{"text": "At Month 6 , the percentages of responders for the primary endpoint were 15 % and 26 % in the 0.6 mg b.i.d . and 0.9 mg b.i.d . groups , respectively ( Table 3 ) .", "label": "", "metadata": {}, "score": "83.5602"}
{"text": "Decreases from baseline for blood pressure were observed at Month 6 , including patients who did not receive any antihypertensive medication .However , due to the fact that the study allowed initiation of antihypertensive medication and dose increases in patients already receiving such medications , the individual contribution of SIGNIFOR or of antihypertensive medication adjustments can not be clearly established .", "label": "", "metadata": {}, "score": "83.6173"}
{"text": "5 , pp .293 - 299 , 1993 .View at Google Scholar \u00b7 View at Scopus .S. M. Orme , R. J. Q. Mcnally , R. A. Cartwright , and P. E. Belchetz , \" Mortality and cancer incidence in acromegaly : a retrospective cohort study , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "83.63304"}
{"text": "If hypocortisolism occurs , consider temporary dose reduction or interruption of treatment with SIGNIFOR , as well as temporary , exogenous glucocorticoid replacement therapy .5.2 Hyperglycemia and Diabetes .", "label": "", "metadata": {}, "score": "83.64014"}
{"text": "Specific Populations : .Population PK analyses of SIGNIFOR indicate that race , body weight , age , and gender do not have a clinically relevant influence on PK parameters .", "label": "", "metadata": {}, "score": "83.774"}
{"text": "As a risk to the breastfed child can not be excluded , SIGNIFOR should not be used by the nursing mother .8.4 Pediatric Use . 8.5 Geriatric Use .", "label": "", "metadata": {}, "score": "83.78854"}
{"text": "Nonpeptide Ligands .The use of peptides as drugs in a therapeutic approach is often problematic because of their poor oral and tissue absorption , and their low stability due to the rapid proteolytic cleavage by enzymes .", "label": "", "metadata": {}, "score": "83.83628"}
{"text": "The primary endpoint was met in patients treated with 900 microgram sc twice daily .After six months , the primary efficacy responder rate was 26.3 % ( 95 % confidence interval [ CI ] , 16.6 to 35.9 ) and 14.6 % ( 95 % CI , 7.0 to 22.3 ) , respectively , for the 900 microgram and 600 microgram groups .", "label": "", "metadata": {}, "score": "83.87009"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .N. Hattori , A. Shimatsu , Y. Kato et al . , \" Growth hormone responses to oral glucose loading measured by highly sensitive enzyme immunoassay in normal subjects and patients with glucose intolerance and acromegaly , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "83.914795"}
{"text": "The 2004 WHO classification of pituitary adenomas now includes an \" atypical \" variant , defined as an MIB-1 proliferative index greater than 3 % , excessive p53 immunoreactivity and increased mitotic activity .", "label": "", "metadata": {}, "score": "83.931564"}
{"text": "In vivo rat biodistribution studies with indium-111 labeled MP2286 and MP2288 showed that the primary mode of clearance was renal , and the primary sites of uptake ( % ID / g 24 h p.i . ) were kidneys ( 0.270 and 0.262 , respectively ) and the gastrointestinal tract .", "label": "", "metadata": {}, "score": "83.968636"}
{"text": "No cases of overdosage have been reported in patients with Cushing 's disease receiving SIGNIFOR subcutaneously .Doses up to 2.1 mg b.i.d . have been used in healthy volunteers with adverse reactions of diarrhea being observed at a high frequency .", "label": "", "metadata": {}, "score": "84.1055"}
{"text": "5 , pp .3089 - 3099 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . F. E. Kaiser , D. N. Orth , K. Mukai , and J. H. Oppenheimer , \" A pituitary parasellar tumor with extracranial metastases and high , partially suppressible levels of adrenocorticotropin and related peptides , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "84.12694"}
{"text": "379 - 387 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .P. De , D. A. Rees , N. Davies et al . , \" Transsphenoidal surgery for acromegaly in Wales : results based on stringent criteria of remission , \" Journal of Clinical Endocrinology and Metabolism , vol . 88 , no . 8 , pp .", "label": "", "metadata": {}, "score": "84.18434"}
{"text": "Cytotoxic drugs still represent the main pharmacological approach for treatment of solid cancer although the induction of drug resistance , high toxicity , and poor selectivity often prevent successful outcome .", "label": "", "metadata": {}, "score": "84.33482"}
{"text": "Mitotane ( o , p'-DDD ) .It is a DDD ( dichlorodiphenyldichloroethane ) isomer and a derivative of DDT .A study of 177 patients showed a significant increase in the recurrence - free interval after radical surgery followed by mitotane when compared to surgery alone [ 18 ] .", "label": "", "metadata": {}, "score": "84.568634"}
{"text": "Adverse reactions are ranked by frequency , with the most frequent reactions listed first .Table 1 - Adverse reactions [ n ( % ) ] with an overall frequency of more than 5 % in the combined dose group in the Phase III study in Cushing 's disease patients .", "label": "", "metadata": {}, "score": "84.57787"}
{"text": "We also found receptor - specific accumulation of the 111In - labelled analogue in the transplantable pancreatic tumour CA20948 .The introduction of the DTPA group in this peptide resulted in renal clearance of the radiopharmaceutical , in contrast to the non - DTPA - conjugated compound that is cleared predominantly via the liver . 111In emits Auger and conversion electrons besides gamma radiation , therefore , this radiopharmaceutical is suitable not only for tumour scintigraphy but also has potential for radionuclide therapy of major human cancers as well .", "label": "", "metadata": {}, "score": "84.67447"}
{"text": "nM toward the human receptor , IC 50 value of 1475 nM for rat receptor ) .Despite this , in binding studies using membrane preparations expressing human UT receptor , palosuran interacted competitively with its receptor .", "label": "", "metadata": {}, "score": "84.7083"}
{"text": "Also , post - baseline elevations in PT and PTT were noted in 33 % and 47 % of patients , respectively .The PT and PTT elevations were minimal .", "label": "", "metadata": {}, "score": "84.897766"}
{"text": "In patients with uncontrolled diabetes mellitus intensive anti - diabetic therapy should be optimized prior to treatment with SIGNIFOR .Self - monitoring of blood glucose and/or FPG assessments should be done every week for the first two to three months and periodically thereafter , as clinically appropriate , as well as over the first two to four weeks after any dose increase .", "label": "", "metadata": {}, "score": "84.9239"}
{"text": "The existing treatments can be divided according to the site of action into adrenal acting drugs and in centrally acting drugs ( Table 2 ) .", "label": "", "metadata": {}, "score": "85.0074"}
{"text": "The effect on adipose tissue and its consequences will have to be kept in mind .Liver function tests should be used to monitor therapy .", "label": "", "metadata": {}, "score": "85.02597"}
{"text": "As for urotensin peptides , substitution of natural amino acid residues by unnatural amino acid such as D - stereoisomer , nonproteogenic constrained amino acid or \u03b2 -amino acid has represented strategic chemical approach resulting in the increase of stability and/or affinity for the UT receptor .", "label": "", "metadata": {}, "score": "85.09775"}
{"text": "Salts include acid addition salts with e.g. inorganic acids , polymeric acids or organic acids , for example with hydrochloric acid , acetic acid , lactic acid , aspartic acid , benzoic acid , succinic acid or pamoic acid .", "label": "", "metadata": {}, "score": "85.783844"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Bidlingmaier and P. U. Freda , \" Measurement of human growth hormone by immunoassays : current status , unsolved problems and clinical consequences , \" Growth Hormone and IGF Research , vol .", "label": "", "metadata": {}, "score": "85.78702"}
{"text": "Retinoic Acid .Retinoids are a family of signaling molecules that are related to vitamin A ( retinol ) in terms of their chemical structure .", "label": "", "metadata": {}, "score": "85.81735"}
{"text": "11 , pp .3808 - 3816 , 1998 .View at Google Scholar \u00b7 View at Scopus .K. Laurence , M. Cook David , and H. Hamrahian Amir , \" American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly-2011 update , \" Endocrine Practice , vol .", "label": "", "metadata": {}, "score": "85.94143"}
{"text": "4 , p. E7 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .S. Melmed , R. Sternberg , D. Cook et al . , \" A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "85.96834"}
{"text": "[ 0012 ]In the absence of complete surgical resection , however , tumor recurrence is , over time , common despite conventional or stereotactic radiation and five- and ten - year survival rates are disappointingly low .", "label": "", "metadata": {}, "score": "86.04999"}
{"text": "with uncontrolled or significant cardiac disease including recent myocardial infarction , congestive heart failure , unstable angina or clinically significant bradycardia .on anti - arrhythmic therapy or other substances that are known to lead to QT prolongation .", "label": "", "metadata": {}, "score": "86.05649"}
{"text": "276 , no .17 , pp .14027 - 14036 , 2001 .View at Google Scholar \u00b7 View at Scopus . H. E. Turner , Z. Nagy , K. C. Gatter , M. M. Esiri , A. L. Harris , and J. A. H. Wass , \" Angiogenesis in pituitary adenomas and the normal pituitary gland , \" Journal of Clinical Endocrinology and Metabolism , vol . 85 , no . 3 , pp .", "label": "", "metadata": {}, "score": "86.05834"}
{"text": "QT Prolongation .SIGNIFOR is associated with QT prolongation .In two thorough QT studies with SIGNIFOR , QT prolongation occurred at therapeutic and supra - therapeutic doses .", "label": "", "metadata": {}, "score": "86.14046"}
{"text": "Cure of acromegaly as \" restitutio ad integrum \" is not possible , due to the irreversible bone changes .Thus , complete removal of the tumour , normalisation of the GH secretion and the IGF-1 concentration , as well as preservation of pituitary function , are generally aimed at .", "label": "", "metadata": {}, "score": "86.14409"}
{"text": "In contrast , during Pegvisomant therapy , GH no longer stimulates lipolysis due to the blockade of its receptor , while insulin action is unabated .", "label": "", "metadata": {}, "score": "86.1971"}
{"text": "Do not inject SIGNIFOR into the exact same spot for each injection .Your doctor should show you how to prepare and give your dose of SIGNIFOR before you use it for the first time .", "label": "", "metadata": {}, "score": "86.22518"}
{"text": "4099 - 4103 , 2000 .View at Publisher \u00b7 View at Google Scholar .M. Kurosaki , D. K. L\u00fcdecke , J. Flitsch , and W. Saeger , \" Surgical treatment of clinically nonsecreting pituitary adenomas in elderly patients , \" Neurosurgery , vol .", "label": "", "metadata": {}, "score": "86.2747"}
{"text": "The primary efficacy endpoint was the proportion of patients who achieved normalization of mean 24-hour UFC levels after six months of treatment and did not dose increase during this period .", "label": "", "metadata": {}, "score": "86.320175"}
{"text": "The remaining causes ( 20 % ) are ACTH independent .As soon as the diagnosis is established , the therapeutic goal is the removal of the tumor .", "label": "", "metadata": {}, "score": "86.37636"}
{"text": "They increase with the dose and can be prevented by a slow increase of the dose .Nausea and orthostatic dysregulation can be precluded by taking the dopamine agonist at bedtime .", "label": "", "metadata": {}, "score": "86.39481"}
{"text": "As the results of different assays are not comparable , each assay system needs its own reference value .This is important , since assay systems may change over time causing problems for the interpretation of results during long - term follow - up .", "label": "", "metadata": {}, "score": "86.460236"}
{"text": "Impairment of Fertility .Subcutaneous dosing at 0.1 mg / kg / day before mating and continuing into gestation in rats at exposures less than the human clinical exposure based on body surface area comparisons across species resulted in statistically significant increased implantation loss and decreased viable fetuses , corpora lutea , and implantation sites .", "label": "", "metadata": {}, "score": "86.46712"}
{"text": "475 - 481 , 2000 .View at Google Scholar \u00b7 View at Scopus . A. E. M. Smals , G. F. F. M. Pieters , A. G. H. Smals , and P. W. C. Kloppenborg , \" Sex difference in the relation between sellar volume and basal and GH - releasing hormone stimulated GH in acromegaly , \" Acta Endocrinologica , vol .", "label": "", "metadata": {}, "score": "86.5454"}
{"text": "Firstly percentage reduction is of different significance whether calculated by the largest diameter or by volume reduction .Secondly it has been demonstrated that intra- and interindividual estimation of tumour volume by MRI may vary up to 20 % .", "label": "", "metadata": {}, "score": "86.638626"}
{"text": "Postoperative normalisation of IGF-1 can take some time [ 53 ] ( see above ) .False low values may be due to surgical stress or fasting , as both physiologically reduce the IGF-1 concentration .", "label": "", "metadata": {}, "score": "86.666214"}
{"text": "Signs and symptoms of hyperglycemia may include : . excessive thirst .If you get hyperglycemia while taking SIGNIFOR , your doctor may give you another medicine to take to lower your blood sugar .", "label": "", "metadata": {}, "score": "86.76842"}
{"text": "Reduced exercise capacity , lethargy , or sweating may be nonspecific .Follow - up and long - term observation of the quality of life ( QoL ) using an acromegaly adjusted questionnaire [ 25 , 26 ] can be helpful in assessing the activity of autonomous GH secretion .", "label": "", "metadata": {}, "score": "86.77652"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .S. Ezzat , P. J. Snyder , W. F. Young et al . , \" Octreotide treatment of acromegaly : a randomized , multicenter study , \" Annals of Internal Medicine , vol .", "label": "", "metadata": {}, "score": "86.79581"}
{"text": "11 , pp .924 - 933 , 2009 .View at Publisher \u00b7 View at Google Scholar . A. Luger , U. Feldt - Rasmussen , R. Abs et al . , \" Lessons learned from 15 years of KIMS and 5 years of ACROSTUDY , \" Hormone Research in Paediatrics , vol .", "label": "", "metadata": {}, "score": "86.813774"}
{"text": "In most of these cases surgery will fail to cure the patient .While surgery aims to remove all adenoma tissue , primary medical therapy tries to achieve biochemical remission , prevention of tumour growth , and possibly tumour volume reduction .", "label": "", "metadata": {}, "score": "86.81865"}
{"text": "SIGNIFOR can cause your heart to beat slower , which may cause you to feel weak , dizzy or even faint .People who have , or have had , heart problems are at higher risk for bradycardia . problems with the electrical system of your heart ( QT interval prolongation ) which can put you at risk for abnormal heart beats , dizziness and fainting spells that can be very serious .", "label": "", "metadata": {}, "score": "86.83256"}
{"text": "711 - 718 , 1992 .View at Google Scholar \u00b7 View at Scopus .I. Lancranjan and A. B. Atkinson , \" Results of a European multicentre study with Sandostatin LAR in acromegalic patients , \" Pituitary , vol .", "label": "", "metadata": {}, "score": "86.90108"}
{"text": "5 , pp .709 - 716 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .L. Vilar , L. A. Naves , M. F. Azevedo et al . , \" Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing 's disease , \" Pituitary , vol .", "label": "", "metadata": {}, "score": "86.90872"}
{"text": "Hormonal hypersecretion is efficiently controlled also by sst2/D2R - high - affinity / sst5-low - affinity chimeric molecule BIM-23A760 [ 53 , 77 ] .", "label": "", "metadata": {}, "score": "86.96692"}
{"text": "Unfortunately shortly thereafter , the assay system used ( Nichols IGF-1 assay ) was no longer available .( ii )In patients with poorly controlled diabetes mellitus or malnutrition IGFBP-1 and IGFBP-2 concentrations increase , rendering the determination of IGF-1 difficult [ 40 ] .", "label": "", "metadata": {}, "score": "87.032486"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : Tumours depend on sufficient blood supply for their growth .They are able to promote new blood vessel formation ( neoangiogenesis ) via angiogenic factors .", "label": "", "metadata": {}, "score": "87.054565"}
{"text": "UT receptors .The feature of inversion of the configuration of the Trp residue in position 7 was suggested by the presence of the same modification in both BIM-23127 and SB-710411 .", "label": "", "metadata": {}, "score": "87.09856"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . H. E. Turner , Z. Nagy , K. C. Gatter , M. M. Esiri , A. L. Harris , and J. A. H. Wass , \" Angiogenesis in pituitary adenomas - relationship to endocrine function , treatment and outcome , \" Journal of Endocrinology , vol .", "label": "", "metadata": {}, "score": "87.30745"}
{"text": "As the pharmacological activity of SIGNIFOR mimics that of somatostatin , inhibition of pituitary hormones , other than ACTH , may occur .Monitoring of pituitary function ( e.g. , TSH / free T 4 , GH / IGF-1 ) should occur prior to initiation of therapy with SIGNIFOR and periodically during treatment should be considered as clinically appropriate .", "label": "", "metadata": {}, "score": "87.36726"}
{"text": "4405 - 4410 , 2005 .View at Publisher \u00b7 View at Google Scholar .P. Lundin and F. Pedersen , \" Volume of pituitary macroadenomas : assessment by MRI , \" Journal of Computer Assisted Tomography , vol .", "label": "", "metadata": {}, "score": "87.41195"}
{"text": "If you take too much SIGNIFOR , tell your doctor right away .What are the possible side effects of SIGNIFOR ?SIGNIFOR may cause serious side effects , including : .", "label": "", "metadata": {}, "score": "87.4732"}
{"text": "Drugs that Prolong QT .Co- administration of drugs that prolong the QT interval with SIGNIFOR may have additive effects on the prolongation of the QT interval .", "label": "", "metadata": {}, "score": "87.58581"}
{"text": "Medical Treatments .The therapeutic goal in the treatment of patients with ACTH - dependent Cushing 's syndrome is normalization of plasma ACTH and serum cortisol values , tumor shrinkage and preservation of anterior pituitary function , in cases of pituitary ACTH - secreting tumor .", "label": "", "metadata": {}, "score": "87.72734"}
{"text": "When invasive tumors recur repeatedly despite radical surgery and postoperative radiotherapy , with widespread extrasellar extension , proximity to cranial nerves and critical blood vessels [ 2 ] , combined cytotoxic therapy may be useful .", "label": "", "metadata": {}, "score": "87.73042"}
{"text": "Adrenal - Acting Drugs .Adrenal function must be carefully monitored , as excessive inhibition of steroidogenesis may cause adrenal insufficiency and may require the administration of small doses of glucocorticoids .", "label": "", "metadata": {}, "score": "87.79367"}
{"text": "5 , pp .2271- 2274 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. R. Clemmons , \" Consensus statement on the standardization and evaluation of growth hormone and insulin - like growth factor assays , \" Clinical Chemistry , vol .", "label": "", "metadata": {}, "score": "87.807205"}
{"text": "Excellent effects are reported concerning headache , hyperhidrosis , soft tissue swelling , arthritic pain , and carpal - tunnel syndrome .Side Effects Subcutaneous Octreotide injections can result in reddening of the skin and burning sensations at the injection site .", "label": "", "metadata": {}, "score": "87.84367"}
{"text": "In rare cases an increase of liver function enzymes may occur .Thus control of these parameters is recommended every 6 months .Diffuse alopecia is rare and occurs less often with the subcutaneous than with the slow release preparation and is reversible after discontinuation .", "label": "", "metadata": {}, "score": "87.85661"}
{"text": "Importantly tumour growth during SRL therapy is very rare ( Table 3 ) .However , there are some caveats : ( i ) none of these studies was randomized , ( ii ) in experienced hands the surgical risk is low , even in very old patients [ 137 ] , and finally ( iii ) lifelong SRL treatment is very expensive .", "label": "", "metadata": {}, "score": "87.98374"}
{"text": "This results in the complete remission , especially in cases of benign tumor .Often , however , the tumor may already have metastasized , it may not be resectable , or it may not be identified despite extensive investigation ( occult ) .", "label": "", "metadata": {}, "score": "88.103424"}
{"text": "It is successful in about 70 % of cases ( defined by suppressed plasma cortisol levels and normal 24 h urinary free cortisol ) [ 4 ] .", "label": "", "metadata": {}, "score": "88.23543"}
{"text": "0037 ]The person skilled in the pertinent art is fully enabled to select a relevant test model to prove the hereinbefore and hereinafter indicated therapeutic indications and beneficial effects .", "label": "", "metadata": {}, "score": "88.30304"}
{"text": "2454 - 2462 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .G. Arnaldi , A. Angeli , A. B. Atkinson et al . , \" Diagnosis and complications of Cushing 's syndrome : a consensus statement , \" Journal of Clinical Endocrinology and Metabolism , vol . 88 , no .", "label": "", "metadata": {}, "score": "88.316956"}
{"text": "10 , pp .4592 - 4599 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .L. Curt\u00f2 , M. L. Torre , F. Ferra\u00f9 et al . , \" Temozolomide - induced shrinkage of a pituitary carcinoma causing cushing 's disease - Report of a case and literature review , \" TheScientificWorldJournal , vol .", "label": "", "metadata": {}, "score": "88.325485"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . E. Jouanneau , A. Wierinckx , F. Ducray et al . , \" New targeted therapies in pituitary carcinoma resistant to temozolomide , \" Pituitary , vol .", "label": "", "metadata": {}, "score": "88.33584"}
{"text": "4 , pp .467 - 471 , 2008 .View at Publisher \u00b7 View at Google Scholar . A. F. Muller , J. A. Janssen , L. J. Hofland et al . , \" Blockade of the growth hormone ( GH ) receptor unmasks rapid GH - releasing peptide-6-mediated tissue - specific insulin resistance , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "88.39901"}
{"text": "For more information , ask your doctor or pharmacist .Call your doctor for medical advice about side effects .You may report side effects to FDA at 1 - 800-FDA-1088 .", "label": "", "metadata": {}, "score": "88.451706"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : Neurotensin ( NT ) receptors are overexpressed in exocrine pancreatic cancer and Ewing 's sarcoma .", "label": "", "metadata": {}, "score": "88.47647"}
{"text": "SIGNIFOR can cause serious side effects , including : .Low cortisol levels in your blood ( hypocortisolism ) .Tell your doctor right away if you have any signs and symptoms of hypocortisolism .", "label": "", "metadata": {}, "score": "88.4794"}
{"text": "Side effects of this therapy included hyperglycemia ( 73 % ) and diabetes in 34 % of patients , requiring treatment with glucose lowering medications in 45 % .", "label": "", "metadata": {}, "score": "88.5209"}
{"text": "With your other hand , tap the syringe with your finger to get rid of air bubbles ( See Figure I ) .Step 13 : With 1 hand , gently pinch the skin at the injection site you have chosen and wiped with an alcohol wipe .", "label": "", "metadata": {}, "score": "88.59155"}
{"text": "Primary medical therapy may achieve tumour stabilisation in most patients .Efficacy of primary medical therapy may be comparable to postoperative medical therapy .With long - term therapy a dose reduction may be possible .", "label": "", "metadata": {}, "score": "88.6207"}
{"text": "These symptoms are mostly due to an inhibition of the exocrine pancreas secretion .In rare cases problems persist with steatorrhea and malabsorption .The addition of pancreatic enzymes resolves these problems .", "label": "", "metadata": {}, "score": "88.69234"}
{"text": "4 , pp .1118 - 1124 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. van der Pas , W. W. de Herder , L. Hofland , et al . , \" New developments in medical therapy of Cushing 's syndrome , \" Endocrine - Related Cancer , vol .", "label": "", "metadata": {}, "score": "88.755844"}
{"text": "217 - 224 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .L. J. Woodhouse , A. Mukherjee , S. M. Shalet , and S. Ezzat , \" The influence of growth hormone status on physical impairments , functional limitations , and health - related quality of life in adults , \" Endocrine Reviews , vol .", "label": "", "metadata": {}, "score": "88.78315"}
{"text": "If these active ingredients have , for example , at least one basic center , they can form acid addition salts .Corresponding acid addition salts can also be formed having , if desired , an additionally present basic center .", "label": "", "metadata": {}, "score": "88.7852"}
{"text": "107 - 119 , 1982 .View at Google Scholar \u00b7 View at Scopus .R. Fahlbusch , J. Honegger , and M. Buchfelder , \" Surgical management of acromegaly , \" Endocrinology and Metabolism Clinics of North America , vol .", "label": "", "metadata": {}, "score": "88.84021"}
{"text": "What should I tell my doctor before using SIGNIFOR ?Before you take SIGNIFOR , tell your doctor if you : . have or have had high blood sugar ( hyperglycemia ) . have diabetes . have or have had heart problems . have a history of low levels of potassium or magnesium in your blood . have or have had liver problems . have or have had gallstones . have any other medical conditions . are pregnant or plan to become pregnant .", "label": "", "metadata": {}, "score": "89.00484"}
{"text": "SST receptors are widely expressed throughout the brain : in particular , sst1 and sst2 have a diffuse localization , whereas sst4 and sst5 show a more confined expression in hippocampus and hypothalamus , respectively [ 15 ] .", "label": "", "metadata": {}, "score": "89.11951"}
{"text": "SHP-1 also cause apoptosis by activation of the transcription factor NF- \u03ba B leading to the inhibition of the MAP kinase JNK anti - apoptotic effects .", "label": "", "metadata": {}, "score": "89.226944"}
{"text": "205 - 215 , 1993 .View at Google Scholar \u00b7 View at Scopus .J. A. Gondim , J. P. Almeida , L. A. F. de Albuquerque , E. Gomes , M. Schops , and T. Ferraz , \" Pure endoscopic transsphenoidal surgery for treatment of acromegaly : results of 67 cases treated in a pituitary center , \" Neurosurgical Focus , vol .", "label": "", "metadata": {}, "score": "89.2407"}
{"text": "In pituitary corticotroph tumors expressing EGFR , .p .K .i .p . , a cyclin - dependent kinase inhibitor , is down regulated .", "label": "", "metadata": {}, "score": "89.298805"}
{"text": "Technical Considerations .To establish the effect of surgical therapy several considerations have to be taken in account : .Timing of the Postoperative Evaluation .", "label": "", "metadata": {}, "score": "89.582184"}
{"text": "374 - 378 , 1998 .View at Publisher \u00b7 View at Google Scholar .P. U. Freda , C. M. Reyes , A. T. Nuruzzaman , R. E. Sundeen , A. G. Khandji , and K. D. Post , \" Cabergoline therapy of growth hormone & growth hormone / prolactin secreting pituitary tumors , \" Pituitary , vol .", "label": "", "metadata": {}, "score": "89.675644"}
{"text": "With low morbidity associated with laparoscopic adrenal surgery , this approach has been considered more frequently , and possibly even as main treatment in some individuals with Cushing 's disease , especially when disease is severe or because of patient preference .", "label": "", "metadata": {}, "score": "89.974266"}
{"text": "Side - effects occur less often with the second generation DA .However DA may induce a psychosis and this can occur even after long - time exposure .", "label": "", "metadata": {}, "score": "90.04009"}
{"text": "There may be new information .This information does not take the place of talking to your doctor about your medical condition or your treatment .", "label": "", "metadata": {}, "score": "90.04901"}
{"text": "SIGNIFOR dose reduction or interruption and/or adding a low - dose short - term glucocorticoid may be necessary ( 5.1 ) .Hyperglycemia and Diabetes ( occurs with initiation ) : Intensive glucose monitoring is recommended and may require initiation or adjustment of anti - diabetic treatment per standard of care ( 5.2 ) .", "label": "", "metadata": {}, "score": "90.13002"}
{"text": "Prophylactic , conventional 3-field radiotherapy can be used to reduce the incidence of subsequent Nelson 's and it should always be considered in the management of these patients [ 8 ] .", "label": "", "metadata": {}, "score": "90.21951"}
{"text": "J. A. Jane Jr. , R. M. Starke , M. A. Elzoghby et al . , \" Endoscopic transsphenoidal surgery for acromegaly : remission using modern criteria , complications , and predictors of outcome , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "90.27533"}
{"text": "Conclusions Monotherapy with a dopamine agonists should be considered as first - line treatment in patients with relatively low GH and IGF - I concentrations in view of their low cost and oral intake .", "label": "", "metadata": {}, "score": "90.324234"}
{"text": "Discrepancy between the GH Nadir during OGTT and the IGF-1 Concentration .The observed discrepancy between the GH nadir during an oral glucose load and the IGF-1 concentration is a major problem for the interpretation of biochemical indices of disease activity .", "label": "", "metadata": {}, "score": "90.45228"}
{"text": "CST also is involved in the modulation of inflammatory response , acting as endogenous anti - inflammatory neuropeptide .In the gastrointestinal tract , the mucosal delta - cells are one of the major sources of SST in the gut influencing motility , secretion and absorption [ 25 ] .", "label": "", "metadata": {}, "score": "90.49652"}
{"text": "In the SIGNIFOR 0.6 mg group , mean fasting plasma glucose ( FPG ) levels increased from 98.6 mg / dL at baseline to 125.1 mg / dL at Month 6 .", "label": "", "metadata": {}, "score": "90.51114"}
{"text": "This may explain the slow growth velocity of most pituitary adenomas .Interestingly in somatotropinomas microvessel density was negatively correlated with the patients ' age , possibly explaining the clinical observation of more aggressive somatotroph adenomas in young compared to older adults [ 71 - 73 ] .", "label": "", "metadata": {}, "score": "90.60045"}
{"text": "[ 0011 ] Aggressive surgical resection is the treatment of choice for meningiomas , and when clinically and anatomically feasible , complete removal of tumor offers the best chance of cure .", "label": "", "metadata": {}, "score": "90.729004"}
{"text": "4104 - 4108 , 2001 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .N. A. Tritos and B. M. Biller , \" Advances in medical therapies for Cushing 's syndrome , \" Discovery Medicine , vol .", "label": "", "metadata": {}, "score": "90.777985"}
{"text": "Do not give SIGNIFOR to other people , even if they have the same symptoms that you have .It may harm them .This Medication Guide summarizes the most important information about SIGNIFOR .", "label": "", "metadata": {}, "score": "90.98984"}
{"text": "Options for Medical Therapy .Medical therapy aims to achieve complete remission .Thus criteria already discussed will guide therapeutic decisions .Any deviation will be discussed when appropriate .", "label": "", "metadata": {}, "score": "91.02527"}
{"text": "In the last years several novel therapies have been studied with a view to the potential biochemical control and inhibition of pituitary tumor growth [ 29 ] .", "label": "", "metadata": {}, "score": "91.06314"}
{"text": "Control of hypercortisolemia should be obtained whenever possible , even in rapidly progressive disease , as small cell lung carcinomas , to reduce the associated complications ( generalized infections , hypokalemia , diabetes , hypertension , psychotic reactions , and reduction of quality of life ) .", "label": "", "metadata": {}, "score": "91.07492"}
{"text": "Insulin sensitivity of basal lipolysis and endogenous glucose production were enhanced compared to baseline [ 187 ] .The fasting glucose- and insulin concentration , as well as the homeostasis model assessment index ( HOMA ) , an estimate of insulin resistance , declined during Pegvisomant compared to baseline .", "label": "", "metadata": {}, "score": "91.12715"}
{"text": "PTP \u03b7 dephosphorylates intracellular effectors involved in the control of cell cycle progression , such as the ERK and the PI3K / Akt pathways , causing the upregulation of the cyclin kinase inhibitors .", "label": "", "metadata": {}, "score": "91.15889"}
{"text": "Homo- and/or heterodimerization of all GPCR family , including SST receptors , play(s ) a fundamental role in ligand binding , receptor expression , trafficking and desensitization , and signal transduction [ 46 ] due to distinct biological features of the native monomeric isoforms .", "label": "", "metadata": {}, "score": "91.188446"}
{"text": "4 , p. E5 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .N. J. L. Gittoes , M. C. Sheppard , A. P. Johnson , and P. M. Stewart , \" Outcome of surgery for acromegaly - the experience of a dedicated pituitary surgeon , \" QJM , vol .", "label": "", "metadata": {}, "score": "91.354324"}
{"text": "649 - 653 , 1983 .View at Google Scholar \u00b7 View at Scopus . S. Y. Park , Y. Rhee , J. C. Youn et al . , \" Ectopic Cushing 's syndrome due to concurrent corticotropin - releasing hormone ( CRH ) and adrenocorticotropic hormone ( ACTH ) secreted by malignant gastrinoma , \" Experimental and Clinical Endocrinology and Diabetes , vol .", "label": "", "metadata": {}, "score": "91.57387"}
{"text": "Practical Issues The duration of treatment necessary to induce significant tumour shrinkage is variable .In most responding patients tumour shrinkage can be observed within 3 - 6 months , while some may need SRL therapy up to one year to achieve significant volume reduction .", "label": "", "metadata": {}, "score": "91.62892"}
{"text": "medicines that can affect the electrical system of your heart ( QT prolongation ) .medicines to control your blood pressure ( such as beta - blockers or calcium channel blockers ) .", "label": "", "metadata": {}, "score": "91.72658"}
{"text": "1291 - 1296 , 1996 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . H. Tostivint , I. Lihrmann , C. Bucharles et al . , \" A second somatostatin gene is expressed in the brain of the frog Rana ridibunda , \" Annals of the New York Academy of Sciences , vol .", "label": "", "metadata": {}, "score": "91.856445"}
{"text": "Please refer to this study by its ClinicalTrials.gov identifier : NCT00929669", "label": "", "metadata": {}, "score": "92.03555"}
{"text": "References . H. A. Bern , D. Pearson , B. A. Larson , and R. S. Nishioka , \" Neurohormones from fish tails : the caudal neurosecretory system .", "label": "", "metadata": {}, "score": "92.0435"}
{"text": "Liver Test Elevations : Evaluate liver tests prior to and during treatment ( 5.4 ) .Cholelithiasis : Perform gallbladder ultrasounds before starting treatment and at 6-month intervals ( 5.5 ) .", "label": "", "metadata": {}, "score": "92.28381"}
{"text": "Thus there is an increased risk of chronic gastritis and , with long - term therapy , a decline of the vitamin B12 concentration [ 97 , 98 ] .", "label": "", "metadata": {}, "score": "92.32158"}
{"text": "The mean tumour volume reduction was 19.4 % for the whole cohort , irrespective of whether individually significant shrinkage occurred [ 108 ] .This paper included definitions of tumour shrinkage over a wide range of volume reduction ( from shrinkage of more than 2 mm , or 10 % to 45 % ) .", "label": "", "metadata": {}, "score": "92.432465"}
{"text": "Ideally , management should be commenced in centers with appropriate experience and knowledge and involve a multidisciplinary team , including endocrinologists , neuroradiologists , dedicated neurosurgeons with expertise in pituitary tumor surgery ( or general surgeons in cases of ectopic tumors ) , nuclear medicine physicians and oncologists .", "label": "", "metadata": {}, "score": "92.81944"}
{"text": "Insert the needle into the pinched skin at a 45 degree angle using a quick dart like motion ( See Figure L ) .When your sharps disposal container is almost full , you will need to follow your community guidelines for the right way to dispose of your sharps disposal container .", "label": "", "metadata": {}, "score": "93.02429"}
{"text": "Conclusions Dopamine agonist drugs may be used after incomplete surgery in acromegalic patients .This is mainly recommended in patients with only modestly elevated GH / IGF-1 concentrations .", "label": "", "metadata": {}, "score": "93.30687"}
{"text": "6 , pp .843 - 851 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. H. George , B. W. Scheithauer , K. Kovacs et al . , \" Crooke 's cell adenoma of the pituitary : an aggressive variant of corticotroph adenoma , \" American Journal of Surgical Pathology , vol .", "label": "", "metadata": {}, "score": "93.41913"}
{"text": "A baseline ECG is recommended prior to initiating therapy with SIGNIFOR and monitoring for an effect on the QTc interval is advisable .Hypokalemia and hypomagnesemia must be corrected prior to SIGNIFOR administration and should be monitored periodically during therapy .", "label": "", "metadata": {}, "score": "93.44742"}
{"text": "18 , pp .4936 - 4939 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus Management Strategies for Aggressive Cushing 's Syndrome : From Macroadenomas to Ectopics .", "label": "", "metadata": {}, "score": "93.550575"}
{"text": "95 - 102 , 1994 .View at Google Scholar \u00b7 View at Scopus .B. Swearingen , F. G. Barker , L. Katznelson et al . , \" Long - term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "93.557526"}
{"text": "49 - 53 , 1989 .View at Google Scholar \u00b7 View at Scopus .J. P. Luton , J. A. Mahoudeau , P. Bouchard , et al . , \" Treatment of Cushing 's disease by O , p'DDD .", "label": "", "metadata": {}, "score": "93.60901"}
{"text": "125 - 130 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . S. S. Praw and A. P. Heaney , \" Medical treatment of Cushing 's disease : overview and recent findings , \" International Journal of General Medicine , vol .", "label": "", "metadata": {}, "score": "93.64269"}
{"text": "In the Phase III trial , 5 % of patients had an ALT or AST level greater than 3 times the upper limit of normal ( ULN ) .", "label": "", "metadata": {}, "score": "93.961586"}
{"text": "General information about the safe and effective use of SIGNIFOR .Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide .", "label": "", "metadata": {}, "score": "94.09171"}
{"text": "It has been long considered that U - II was exclusively produced by the fish urophysis [ 1 ] .However , the identification of U - II from the brain of a frog [ 2 , 3 ] has shown that the cDNA encoding prepro - U - II exists in several species of vertebrates .", "label": "", "metadata": {}, "score": "94.12926"}
{"text": "Management of persistent or recurrent CS is a challenge and medical therapy plays a critical role in the control of hypercortisolemia and associated symptoms .Unfortunately , this approach is not always successful .", "label": "", "metadata": {}, "score": "94.147095"}
{"text": "Tumour shrinkage occurred in 13 of 21 patients , with a mass reduction by more than half in 5 GH-/PRL co - secreting adenomas [ 148 ] .", "label": "", "metadata": {}, "score": "94.20447"}
{"text": "Good uptake was found in the receptor - positive HT29 tumour and high uptake was present in the kidneys .Co- injection of excess unlabelled NT significantly reduced tumour uptake , showing that tumour uptake is a receptor - mediated process .", "label": "", "metadata": {}, "score": "94.4572"}
{"text": "Cholestatic liver dysfunction , with a histological diagnosis of drug - related liver toxicity , developed in a patient with Gilbert syndrome and resolved after treatment was stopped [ 194 ] .", "label": "", "metadata": {}, "score": "94.59407"}
{"text": "Depending on the individual situation ( obesity , metabolic syndrome , age )SRL can nevertheless induce diabetes mellitus .Patients with pre - existing diabetes mellitus may have an increased or reduced need of insulin treatment , and thus a tight control of blood sugar is mandatory in this group when SRL is initiated .", "label": "", "metadata": {}, "score": "94.6653"}
{"text": "Figure 1 - Mean ( \u00b1SE ) Urinary Free Cortisol ( nmol/24h ) at time points up to Month 6 by randomized dose group .The reference line is the upper limit of normal for UFC , which is 145 nmol/24hour ; + /-Standard errors are displayed .", "label": "", "metadata": {}, "score": "94.72145"}
{"text": "Adipose tissue , the kidneys , and skeletal muscle seem to need less Pegvisomant to reduce GH actions compared to the liver where more Pegvisomant is required in order to reduce IGF-1 production [ 173 ] .", "label": "", "metadata": {}, "score": "94.76097"}
{"text": "In a further meta - analysis Freda confirmed their earlier results [ 80 ] and added follow - up information .The response rate increased over time [ 46 ] .", "label": "", "metadata": {}, "score": "94.781494"}
{"text": "View at Google Scholar \u00b7 View at Scopus .G. A. Kaltsas , P. Nomikos , G. Kontogeorgos , M. Buchfelder , and A. B. Grossman , \" Clinical review : diagnosis and management of pituitary carcinomas , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "94.87477"}
{"text": "Combination therapy rather than Pegvisomant monotherapy is preferred due to its higher cost - effectiveness .With these therapeutic strategies up to 95 % of the patients will achieve complete remission ( Figure 1 ) .", "label": "", "metadata": {}, "score": "94.88582"}
{"text": "On this there is very little information .Our own investigation showed no positive effect of presurgical SRL treatment on the conservation of pituitary function [ 126 ] .", "label": "", "metadata": {}, "score": "95.24834"}
{"text": "Hyperglycemia and Diabetes .Hyperglycemia - related terms were reported frequently in the Phase III trial .For all patients , these terms included : hyperglycemia ( 40 % ) , diabetes mellitus ( 18 % ) , increased HbA1c ( 11 % ) , and type 2 diabetes mellitus ( 9 % ) .", "label": "", "metadata": {}, "score": "95.35028"}
{"text": "Tumour volume reduction is generally less in tumour remnants or after irradiation .In those patients tumour shrinkage has been reported in 27 % , while shrinkage occurred in up to 52 % in therapy - na\u00efve patients [ 117 ] .", "label": "", "metadata": {}, "score": "95.596115"}
{"text": "Read the \" Instructions for Use \" at the end of this Medication Guide for information about the right way to use SIGNIFOR .Use SIGNIFOR exactly as your doctor tells you to .", "label": "", "metadata": {}, "score": "95.604935"}
{"text": "19 - 25 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. L. Derr , S. J. Cameron , and S. H. Golden , \" Pre - analytic considerations for the proper assessment of hormones of the hypothalamic - pituitary axis in epidemiological research , \" European Journal of Epidemiology , vol .", "label": "", "metadata": {}, "score": "95.830826"}
{"text": "If ALT is abnormal at baseline and elevations of ALT of 3 - 5 times the baseline values are observed on treatment , repeat the test within a week or sooner if exceeding 5 times ULN .", "label": "", "metadata": {}, "score": "95.9174"}
{"text": "12 , pp .4712 - 4721 , 2011 .View at Publisher \u00b7 View at Google Scholar Medical Therapy of Acromegaly .Interdisziplin\u00e4res Stoffwechsel - Centrum , Charit\u00e9 - Universit\u00e4tsmedizin Berlin , Campus Virchow - Klinikum , 13353 Berlin , Germany .", "label": "", "metadata": {}, "score": "95.95747"}
{"text": "Dose reduction by 0.3 mg decrements per injection is suggested .2.3 Dosage in Patients with Hepatic Impairment .For patients with moderate hepatic impairment ( Child - Pugh B ) , the recommended initial dosage is 0.3 mg twice a day and the maximum dosage is 0.6 mg twice a day .", "label": "", "metadata": {}, "score": "96.14357"}
{"text": "If you get hypocortisolism while taking SIGNIFOR , your doctor may change your dose or ask you to stop taking it .High blood sugar ( hyperglycemia ) .", "label": "", "metadata": {}, "score": "96.29586"}
{"text": "The recommended dosage range of SIGNIFOR is 0.3 to 0.9 mg by subcutaneous injection twice a day .The recommended initial dose is either 0.6 mg or 0.9 mg twice a day .", "label": "", "metadata": {}, "score": "96.43445"}
{"text": "Monitoring of liver tests should be done after 1 to 2 weeks on treatment , then monthly for 3 months , and every 6 months thereafter .", "label": "", "metadata": {}, "score": "96.4617"}
{"text": "Other reported clinical experience has not identified differences in responses between the elderly and younger patients . 8.6 Hepatic Impairment .Dose adjustment is not required in patients with mild impaired hepatic function ( Child - Pugh A ) , but is required for patients with moderately impaired hepatic function ( Child - Pugh B ) [ see Dosage and Administration ( 2.3 ) and Clinical Pharmacology ( 12.3)].", "label": "", "metadata": {}, "score": "96.524445"}
{"text": "2010;92(suppl1):120 - 124 .Lindholm , J. Incidence and Late Prognosis of Cushing 's Syndrome : A Population - Based Study .The Journal of Clinical Endocrinology & Metabolism .", "label": "", "metadata": {}, "score": "96.776764"}
{"text": "Cholelithiasis has been frequently reported in clinical studies with SIGNIFOR [ see Adverse Reactions ( 6 ) ] .Ultrasonic examination of the gallbladder before , and at 6- to 12-month intervals during SIGNIFOR therapy is recommended .", "label": "", "metadata": {}, "score": "96.85611"}
{"text": "Transsphenoidal surgery of a pituitary adenoma achieves complete remission in about 60 % of the patients .Surgical results correlate with tumour volume , especially so with supra- and parasellar adenomas , and with the preoperative GH concentration [ 1 , 3 , 10 , 37 , 52 , 104 - 107 ] .", "label": "", "metadata": {}, "score": "97.17118"}
{"text": "Mechanism of Tumour Shrinkage The mechanism of tumour shrinkage is still not fully understood .SRL are not cytotoxic .Tumour shrinkage is probably in part due to an inhibition of the GH synthesis and subsequent volume reduction of the intracellular organelles involved in hormone production and intracellular transport .", "label": "", "metadata": {}, "score": "97.43418"}
{"text": "Side effects are dose - dependent , with the most common being hypertension , edema , increased acne and hirsutism in women due to its ability to inhibit the synthesis of aldosterone , resulting in an accumulation of its precursors with mineralocorticoid and weak androgen activity .", "label": "", "metadata": {}, "score": "97.48045"}
{"text": "6 , pp .666 - 671 , 2012 .View at Google Scholar Sign up to receive free email alerts when patent applications with chosen keywords are published SIGN UP .", "label": "", "metadata": {}, "score": "97.58444"}
{"text": "The median exposure to the treatment was 10.4 months ( 0.03 - 37.8 ) with 68 % of patients having at least six - months exposure .", "label": "", "metadata": {}, "score": "97.95122"}
{"text": "Untreated acromegalic patients have a decreased fat mass due to the lipolytic effect of GH .Increased lipolysis causes insulin resistance and deterioration of glucose tolerance .", "label": "", "metadata": {}, "score": "98.0956"}
{"text": "Patient having a pathology or medical history susceptible to interfere with the realization of the study or results evaluation according to the judgment of the investigator or the study monitor .", "label": "", "metadata": {}, "score": "98.18308"}
{"text": "fatigue . diabetes mellitus . injection site reactions . common cold . hair loss .weakness . fluid retention .Tell your doctor if you have any side effect that bothers you or that does not go away .", "label": "", "metadata": {}, "score": "98.271454"}
{"text": "Hypocortisolism .Cases of hypocortisolism were reported in the Phase III study in Cushing 's disease patients [ see Adverse Reactions ( 6 ) and Clinical Studies ( 14 ) ] .", "label": "", "metadata": {}, "score": "98.34487"}
{"text": "Pituitary irradiation achieves eucortisolism in 50 - 60 % of cases , albeit after 3 - 5 years [ 4 ] , and patients can develop pituitary insufficiency , brain vascular morbidity or secondary neoplasms .", "label": "", "metadata": {}, "score": "98.409645"}
{"text": "Phosphorylated receptors are then internalized into clathrin - coated vesicles and directed to endosomes , where they are dephosphorylated by specific serine / threonine phosphatases .", "label": "", "metadata": {}, "score": "98.57652"}
{"text": "Dopamine ( DA ) is a catecholamine hormone with a wide range of functions .DA receptors have been found in a variety of organs ( pituitary , adrenals , brain , kidney , gastrointestinal tract , cardiovascular system ) , and possibly exert an inhibitory effect when activated .", "label": "", "metadata": {}, "score": "98.850296"}
{"text": "To view content sources and attributions , please refer to our editorial policy .The principal morbidity following axillary node dissection within the scope of breast cancer surgery is the post - operative development of lymphocele .", "label": "", "metadata": {}, "score": "99.087585"}
{"text": "Terms & Privacy .Connect .Subscribe to receive email notifications whenever new articles are published .This material is provided for educational purposes only and is not intended for medical advice , diagnosis or treatment .", "label": "", "metadata": {}, "score": "99.173775"}
{"text": "With weekly intake , steady state is achieved after approximately 4 weeks .With a dose of 1.75 mg / week to 2.75 mg / week the GH concentration declined to below 2 \u03bc g / L in 46 % of the patients and the IGF-1 concentration was reduced to below 300 \u03bc g / L in 39 % [ 150 ] .", "label": "", "metadata": {}, "score": "99.225006"}
{"text": "GH reduces the insulin sensitivity .The reduction of the GH concentration by SRL thus improves insulin sensitivity and hence the drug - induced inhibition of insulin secretion can be without negative effects on glucose tolerance .", "label": "", "metadata": {}, "score": "99.26108"}
{"text": "Do not inject SIGNIFOR into skin that is red or irritated .The recommended injection sites for SIGNIFOR are the top of your thigh or stomach area ( abdomen ) .", "label": "", "metadata": {}, "score": "99.40654"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .L. Boero , M. Manavela , K. Danilowicz et al . , \" Comparison of two immunoassays in the determination of IGF - I levels and its correlation with oral glucose tolerance test ( OGTT ) and with clinical symptoms in acromegalic patients , \" Pituitary .", "label": "", "metadata": {}, "score": "99.699486"}
{"text": "Urinary excretion of radioactivity was significantly lower than after 111In - octreotide , averaging 64 % after 24 h.The uptake after 24 h , expressed as a percentage of the injected dose of 177Lu - octreotate , was comparable to that after 111In - octreotide for kidneys , spleen and liver , but was three- to fourfold higher for four of five tumours .", "label": "", "metadata": {}, "score": "100.01209"}
{"text": "The median reduction in UFC after six months was 47.9 % for both groups .The median reduction in UFC after 12 months was 62.4 % ( 900 microgram ) and 67.6 % ( 600 microgram ) .", "label": "", "metadata": {}, "score": "100.03761"}
{"text": "Maximum urinary free cortisol reduction is typically seen by two months of treatment [ see Clinical Studies ( 14 ) ] .For patients who are started on 0.6 mg twice a day , a dosage increase to 0.9 mg twice a day may be considered based on the response to the treatment , as long as the 0.6 mg dosage is well tolerated by the patient .", "label": "", "metadata": {}, "score": "100.31161"}
{"text": "Management of Cushing 's Syndrome .Management of patients with CS requires a major effort to understand the etiology and to control hypercortisolemia as soon as the diagnosis is established .", "label": "", "metadata": {}, "score": "100.38544"}
{"text": "Tell your doctor about all the medicines you take , including prescription and non - prescription medicines , vitamins , and herbal supplements .Taking SIGNIFOR with certain other medicines can affect each other and cause side effects .", "label": "", "metadata": {}, "score": "100.833954"}
{"text": "It is not known if SIGNIFOR passes into your breast milk .You and your doctor should decide if you will take SIGNIFOR or breastfeed .", "label": "", "metadata": {}, "score": "101.04799"}
{"text": "Your doctor should do blood tests to monitor your liver tests while you use SIGNIFOR . gallstones ( cholelithiasis ) .Your doctor should do an ultrasound to check for gallstones before you start using SIGNIFOR and while you use it . high blood sugar .", "label": "", "metadata": {}, "score": "101.17348"}
{"text": "To learn more about this study , you or your doctor may contact the study research staff using the Contacts provided below .For general information , see Learn About Clinical Studies .", "label": "", "metadata": {}, "score": "101.72762"}
{"text": "16 , pp . 2940- 2944 , 2002 .View at Publisher \u00b7 View at Google Scholar .137 , no .4 , pp .", "label": "", "metadata": {}, "score": "101.866646"}
{"text": "Primary medical therapy is defined as any medical therapy instead of surgery .Possible indications for primary medical therapy are ( i ) patient 's preference , ( ii ) comorbidities that pose an anaesthetical or surgical risk , and ( iii ) possibly very old age [ 133 ] .", "label": "", "metadata": {}, "score": "102.02741"}
{"text": "About Novartis .Located in East Hanover , New Jersey , Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG , which provides innovative healthcare solutions that address the evolving needs of patients and societies .", "label": "", "metadata": {}, "score": "102.164024"}
{"text": "Urotensin - II Ligands : An Overview from Peptide to Nonpeptide Structures . 1 Department of Pharmacy , University of Naples Federico II , 80131 Naples , Italy 2 Department of Biochemistry , Biophysics and General Pathology , Second University of Naples , 80138 Naples , Italy .", "label": "", "metadata": {}, "score": "102.24167"}
{"text": "Concomitant disease that could prolong QT or increase exposure to the study medication including dehydration , renal or hepatic impairment .Concomitant medication known to increase the QT interval .", "label": "", "metadata": {}, "score": "102.30064"}
{"text": "Lipohypertrophy In the German Acrostudy 12 out of 371 patients reported some degree of lipohypertrophy [ 193 ] .An impressive form of lipohypertrophy has been illustrated by Buyuktas et al . in one patient [ 196 ] .", "label": "", "metadata": {}, "score": "102.567184"}
{"text": "4 , pp .266 - 271 , 1995 .View at Google Scholar \u00b7 View at Scopus .S. W. J. Lamberts and J. C. Birkenhaeger , \" Bromocriptine in Nelson 's syndrome and Cushing 's disease , \" Lancet , vol .", "label": "", "metadata": {}, "score": "103.20521"}
{"text": "On average , as UFC levels were reduced , clinical manifestations of Cushing 's disease improved including reduction of blood pressure , total cholesterol , weight and body mass index(1 ) .", "label": "", "metadata": {}, "score": "103.56596"}
{"text": "Adrenalectomy necessarily requires steroid replacement therapy for the rest of the patient 's life , as with primary adrenocortical insufficiency .There is also a significant risk of developing Nelson 's syndrome , which occurs in 5 - 10 % of the patients , likely a subset with an aggressive phenotype , after adrenalectomy for Cushing 's syndrome [ 4 , 6 ] .", "label": "", "metadata": {}, "score": "103.58553"}
{"text": "The first line and most common treatment approach for Cushing 's disease is surgical removal of the tumor(2 ) .Cushing 's disease is a rare but serious disease that affects approximately one to two patients per million per year(6 ) .", "label": "", "metadata": {}, "score": "103.6765"}
{"text": "167 , no . 2 , pp .137 - 143 , 2012 .View at Google Scholar .83 , no .10 , pp .", "label": "", "metadata": {}, "score": "103.694016"}
{"text": "Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this .Do not recycle your used sharps disposal container .", "label": "", "metadata": {}, "score": "103.734924"}
{"text": "Brain Tumors .Glioblastoma multiforme ( GBM ) , the most aggressive primary brain cancer , expresses multiple SST receptors [ 214 ] , being sst1 and sst2 the most frequent in both glioma tissues and cell lines [ 133 , 215 ] .", "label": "", "metadata": {}, "score": "104.40611"}
{"text": "What is SIGNIFOR ?SIGNIFOR is a prescription medicine used to treat Cushing 's disease in adults who can not have surgery or have failed surgery .", "label": "", "metadata": {}, "score": "104.480934"}
{"text": "Ask your doctor for a list of these medicines , if you are not sure .Know the medicines you take .Keep a list of them to show to your doctor and pharmacist when you get a new medicine .", "label": "", "metadata": {}, "score": "104.58002"}
{"text": "Novartis is the only global company with leading positions in these areas .In 2011 , the Group 's continuing operations achieved net sales of USD 58.6 billion , while approximately USD 9.6 billion ( USD 9.2 billion excluding impairment and amortization charges ) was invested in R&D throughout the Group .", "label": "", "metadata": {}, "score": "104.95456"}
{"text": "With your other hand , tap the top of the SIGNIFOR ampule with your finger to make sure there is no liquid in the top of the ampule when you open it ( See Figure D ) .", "label": "", "metadata": {}, "score": "106.102615"}
{"text": "Section of Pharmacology , Department of Internal Medicine and Center of Excellence for Biomedical Research ( CEBR ) , University of Genova , Viale Benedetto XV , 2 16132 Genova , Italy .", "label": "", "metadata": {}, "score": "106.31578"}
{"text": "Generally GH concentrations are lower in older , obese , or male compared to younger , lean , or female subjects and patients [ 13 ] .", "label": "", "metadata": {}, "score": "106.84206"}
{"text": "Talk with your doctor and family members or friends about deciding to join a study .To learn more about this study , you or your doctor may contact the study research staff using the Contacts provided below .", "label": "", "metadata": {}, "score": "108.11493"}
{"text": "Apoptosis may occur via extrinsic ( activated by the receptors of the TNF \u03b1 -related apoptosis - inducing ligand ) , and Fas ligand or intrinsic ( mitochondrial ) pathways .", "label": "", "metadata": {}, "score": "108.17981"}
{"text": "775 - 779 , 1998 .View at Publisher \u00b7 View at Google Scholar .84 , no .6 , pp . 1986 - 1991 , 1999 .", "label": "", "metadata": {}, "score": "108.49139"}
{"text": "11 Suppl , pp .21 - 27 , 2005 .View at Google Scholar .153 , no . 1 , pp .135 - 141 , 2005 .", "label": "", "metadata": {}, "score": "108.4932"}
{"text": "6 , pp .881 - 893 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .166 , no . 2 , pp .", "label": "", "metadata": {}, "score": "108.88106"}
{"text": "About Cushing 's disease .Cushing 's syndrome is an endocrine disorder caused by excessive cortisol , a vital hormone that regulates metabolism , maintains cardiovascular function and helps the body respond to stress(2 ) .", "label": "", "metadata": {}, "score": "109.08566"}
{"text": "Hepatic Impairment .In a clinical study in subjects with impaired hepatic function ( Child - Pugh A , B and C ) , subjects with moderate and severe hepatic impairment ( Child - Pugh B and C ) showed significantly higher exposures than subjects with normal hepatic function .", "label": "", "metadata": {}, "score": "109.326515"}
{"text": "15 , no .12 , pp . 2300- 2302 , 2001 .View at Google Scholar \u00b7 View at Scopus .97 , no .", "label": "", "metadata": {}, "score": "109.38417"}
{"text": "Store SIGNIFOR at 68 \u00b0 F to 77 \u00b0 F ( 20 \u00b0 C to 25 \u00b0 C ) .Keep SIGNIFOR out of the light .", "label": "", "metadata": {}, "score": "109.79518"}
{"text": "Cushing 's disease may present with weight gain , central obesity , moon face , severe fatigue and weakness , striae ( purple stretch marks ) , buffalo hump , depression and anxiety(2 ) .", "label": "", "metadata": {}, "score": "109.81039"}
{"text": "In all of these cases , total bilirubin elevations were seen either concomitantly or preceding the transaminase elevation .The patient with Cushing 's disease developed jaundice .", "label": "", "metadata": {}, "score": "109.910255"}
{"text": "The median value of the baseline 24-hour UFC for all patients was 565 nmol/24 hours ( normal range 30 to 145 nmol/24 hours ) .", "label": "", "metadata": {}, "score": "109.94448"}
{"text": "Mean and median percentage changes in UFC from baseline are presented in Table 3 .Table 3- 24-Hour Urinary Free Cortisol ( UFC )", "label": "", "metadata": {}, "score": "110.082825"}
{"text": "5 , pp .701 - 705 , 2002 .View at Google Scholar \u00b7 View at Scopus .166 , no . 2 , pp .", "label": "", "metadata": {}, "score": "110.21887"}
{"text": "Cushing 's syndrome ( CS ) is a rare but severe clinical condition caused by cortisol excess of various etiologies .It is associated with significant morbidity and mortality and leads to metabolic , cardiovascular , infectious , psychiatric , and gonadal complications ( Table 1 ) .", "label": "", "metadata": {}, "score": "110.71152"}
{"text": "4398 - 4405 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .26 , no .5B , pp .", "label": "", "metadata": {}, "score": "110.91794"}
{"text": "4465 - 4473 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .89 , no . 2 , pp .", "label": "", "metadata": {}, "score": "111.22562"}
{"text": "518 - 523 , 1997 .View at Publisher \u00b7 View at Google Scholar .116 , no . 2 , pp .287 - 292 , 1987 .", "label": "", "metadata": {}, "score": "111.45381"}
{"text": "5389 , pp .737 - 740 , 1998 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .149 , no . 9 , pp .", "label": "", "metadata": {}, "score": "111.726456"}
{"text": "4 , pp .393 - 401 , 1994 .View at Google Scholar \u00b7 View at Scopus .45 , no . 9 , pp .", "label": "", "metadata": {}, "score": "111.91958"}
{"text": "5 , pp .694 - 701 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .123 , no .", "label": "", "metadata": {}, "score": "112.18321"}
{"text": "6 , pp .742 - 747 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . 7 , no . 3 , pp .", "label": "", "metadata": {}, "score": "112.626434"}
{"text": "The definitive treatment of CS consists in surgical resection of the tumor secreting ACTH .When the source of the excessive secretion is the pituitary gland , the standard approach is to perform an endoscopic endonasal trans - sphenoidal exploration , with excision of the tumor , if found .", "label": "", "metadata": {}, "score": "112.80037"}
{"text": "476 - 482 , 2007 .View at Publisher \u00b7 View at Google Scholar .154 , no . 3 , pp .467 - 477 , 2006 .", "label": "", "metadata": {}, "score": "113.03714"}
{"text": "4 , pp .325 - 329 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . 86 , no . 1 , pp .", "label": "", "metadata": {}, "score": "113.11572"}
{"text": "4 , pp .489 - 495 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . 94 , no .", "label": "", "metadata": {}, "score": "113.76218"}
{"text": "4405 - 4410 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . 86 , no . 7 , pp .", "label": "", "metadata": {}, "score": "114.04522"}
{"text": "137 , no . 8 , pp .3461 - 3468 , 1996 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "114.21617"}
{"text": "6 , pp .1035 - 1042 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .140 , no .", "label": "", "metadata": {}, "score": "114.72072"}
{"text": "A total of 162 patients were enrolled in this study .The majority of patients were female ( 78 % ) and had persistent or recurrent Cushing 's disease despite pituitary surgery ( 83 % ) with a mean age of 40 years .", "label": "", "metadata": {}, "score": "114.721146"}
{"text": "In a large survey comprising 307 patients an increase in pituitary volume was reported in 18 ( 5.9 % ) of the patients [ 191 ] .", "label": "", "metadata": {}, "score": "114.76358"}
{"text": "83 - 86 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .147 , no . 1 , pp .", "label": "", "metadata": {}, "score": "114.78114"}
{"text": "103 - 110 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .90 , no .6 , pp .", "label": "", "metadata": {}, "score": "114.795685"}
{"text": "Pituitary microadenomas have a typically indolent growth rate , and clinically significant invasion and malignant transformation remain uncommon .These can cause symptoms due to mass effect before any full endocrine manifestations .", "label": "", "metadata": {}, "score": "114.802475"}
{"text": "4 , pp .579 - 584 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .145 , no . 1 , pp .", "label": "", "metadata": {}, "score": "114.83368"}
{"text": "3348 - 3356 , 2008 .View at Publisher \u00b7 View at Google Scholar .86 , no .4 , pp .1716 - 1723 , 2001 .", "label": "", "metadata": {}, "score": "115.09662"}
{"text": "10 , no .12 , pp .1688 - 1696 , 1996 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "116.374084"}
{"text": "133 - 138 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .95 , no .5 , pp .", "label": "", "metadata": {}, "score": "116.4046"}
{"text": "17 , pp .2416 - 2423 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .30 , no .", "label": "", "metadata": {}, "score": "116.475006"}
{"text": "89 - 100 , 1996 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . 300 , no . 1 , pp .", "label": "", "metadata": {}, "score": "116.48137"}
{"text": "173 - 190 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .45 , no .23 , pp .", "label": "", "metadata": {}, "score": "116.748215"}
{"text": "Cushing 's disease is a debilitating endocrine disorder caused by excess cortisol in the body due to the presence of a non - cancerous pituitary tumor .", "label": "", "metadata": {}, "score": "116.783554"}
{"text": "19 , no . 1 , pp .255 - 267 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "117.56108"}
{"text": "281 , no .28 , pp .19156 - 19171 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "117.649574"}
{"text": "90 , no . 8 , pp .4963 - 4969 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "117.74886"}
{"text": "Academic Editor : A. L. Barkan .Copyright \u00a9 2012 U. Pl\u00f6ckinger .This is an open access article distributed under the Creative Commons Attribution License , which permits unrestricted use , distribution , and reproduction in any medium , provided the original work is properly cited .", "label": "", "metadata": {}, "score": "117.797455"}
{"text": "117 - 120 , 1994 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .11 , no . 8 , pp . 1062 - 1069 , 1997 .", "label": "", "metadata": {}, "score": "117.81534"}
{"text": "274 , no .21 , pp .15186 - 15193 , 1999 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "117.83881"}
{"text": "305 - 310 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .90 , no .12 , pp .", "label": "", "metadata": {}, "score": "117.98779"}
{"text": "278 , no .23 , pp .20574 - 20581 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "118.58597"}
{"text": "5 , pp .869 - 872 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .95 , no .", "label": "", "metadata": {}, "score": "118.79366"}
{"text": "14 , no . 9 , pp .3911 - 3928 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "119.07617"}
{"text": "94 , no . 2 , pp .523 - 527 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "119.49578"}
{"text": "64 , no . 3 , pp .245 - 249 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "119.521805"}
{"text": "481 , no . 3 , pp .271 - 276 , 2000 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "119.75047"}
{"text": "771 - 776 , 1990 .View at Google Scholar \u00b7 View at Scopus .93 , no .4 , pp .1254 - 1262 , 2008 .", "label": "", "metadata": {}, "score": "120.00632"}
{"text": "66 , no .5 , pp .837 - 844 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "120.0193"}
{"text": "397 - 408 , 2000 .View at Google Scholar \u00b7 View at Scopus .12 , no . 13 , pp .2011- 2015 , 2006 .", "label": "", "metadata": {}, "score": "120.40766"}
{"text": "87 , no . 1 , pp .12 - 21 , 2001 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "120.48075"}
{"text": "245 - 249 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .83 , no .12 , pp .", "label": "", "metadata": {}, "score": "120.627594"}
{"text": "92 - 94 , 1997 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .91 , no .6 , pp .", "label": "", "metadata": {}, "score": "120.94524"}
{"text": "379 - 383 , 2003 .View at Google Scholar \u00b7 View at Scopus .121 , no . 2 , pp .185 - 190 , 1989 .", "label": "", "metadata": {}, "score": "121.19647"}
{"text": "80 - 91 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . 86 , no . 2 , pp .", "label": "", "metadata": {}, "score": "121.221466"}
{"text": "153 , no . 1 , pp .67 - 71 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "121.409515"}
{"text": "1813 , no .6 , pp .1172 - 1189 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . U.", "label": "", "metadata": {}, "score": "121.46757"}
{"text": "Pituitary carcinomas , defined as primary tumors with intra- or extracranial metastases , are rare , encountered in less than 1 % of all hypophyseal tumors .", "label": "", "metadata": {}, "score": "121.48505"}
{"text": "70 , no . 2 , pp .666 - 674 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "122.050476"}
{"text": "1649 - 1654 , 1999 .View at Google Scholar \u00b7 View at Scopus .87 , no . 2 , pp .915 - 926 , 2002 .", "label": "", "metadata": {}, "score": "122.12749"}
{"text": "Received 27 April 2012 ; Accepted 13 June 2012 .Copyright \u00a9 2012 Carlotta Pozza et al .This is an open access article distributed under the Creative Commons Attribution License , which permits unrestricted use , distribution , and reproduction in any medium , provided the original work is properly cited .", "label": "", "metadata": {}, "score": "122.161896"}
{"text": "Copyright \u00a9 2013 Francesco Merlino et al .This is an open access article distributed under the Creative Commons Attribution License , which permits unrestricted use , distribution , and reproduction in any medium , provided the original work is properly cited .", "label": "", "metadata": {}, "score": "123.23021"}
{"text": "Academic Editor : Hubert Vaudry .Copyright \u00a9 2013 Federica Barbieri et al .This is an open access article distributed under the Creative Commons Attribution License , which permits unrestricted use , distribution , and reproduction in any medium , provided the original work is properly cited .", "label": "", "metadata": {}, "score": "123.96825"}
{"text": "287 - 292 , 2002 .View at Google Scholar \u00b7 View at Scopus . 13 , no . 1 , pp .18 - 28 , 2010 .", "label": "", "metadata": {}, "score": "124.87145"}
{"text": "89 , no . 2 , pp .153 - 161 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "125.14202"}
{"text": "742.e1 - 753 .e1 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .27 , no .28 , pp .", "label": "", "metadata": {}, "score": "125.98831"}
{"text": "276 - 285 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . 311 , no . 1 , pp .", "label": "", "metadata": {}, "score": "126.038086"}
{"text": "45 , no .10 , pp .1788 - 1797 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "126.43215"}
{"text": "34 , no .10 , pp .1617 - 1626 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "126.84232"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .62 , no . 3 , pp .282 - 288 , 2005 .", "label": "", "metadata": {}, "score": "130.93848"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .158 , no . 3 , pp .295 - 303 , 2008 .", "label": "", "metadata": {}, "score": "132.11485"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .30 , no .4 , pp .408 - 414 , 2012 .", "label": "", "metadata": {}, "score": "132.42636"}
{"text": "View at Google Scholar \u00b7 View at Scopus .92 , no .5 , pp .1580 - 1584 , 1995 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "143.9779"}
